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ABSTRACT 
 
GENE EXPRESSION PROFILING OF HEDGEHOG PATHWAY GENES IN 
EPITHELIAL CANCERS 
 
ÖZLEM AKILLI ÖZTÜRK 
M. Sc. in Molecular Biology and Genetics 
Supervisor: Assoc. Prof. Işık G. Yuluğ 
September 2006, 127 Pages 
 
The Hedgehog (Hh) signaling pathway has been investigated in many cancer types 
and shown to have important effects, but not effectively studied in breast, colon and 
liver cancers. In this study, gene expression profile of BCL2, SHH, SMO, IHH, 
PTCH1, GLI1, GLI2 and GLI3 were analyzed in 15 breast, 14 colon, and 15 
hepatocellular carcinoma (HCC) cell lines and 29 primary breast tumor samples and 
three matched normal tissue sample pools by quantitative real-time RT-PCR. Breast 
cell lines have different levels of target gene expression in the Hh pathway, such that 
this pathway is activated only in some of the breast carcinoma cell lines possibly 
through a ligand-independent pathway. In all the breast cancer cell lines studied, 
PTCH1, SMO, GLI3 and BCl2 had high expression.  Expression profiles of the target 
genes predicted the estrogen receptor status correctly in 93% of the breast cell lines 
studied. In HCC cell lines, Hh pathway gene expression profile differentiates the 
poorly differentiated HCC cell lines from well differentiated ones in Discriminant 
Function Analysis (DFA) perfectly. High SMO and IHH expressions have been 
found to be markers for aberrant Hh pathway activity in the well differentiated HCC 
cell lines. In colon cancer cell lines deregulated expression profile among the genes 
were observed. In primary breast tumor samples, there was a very strong prediction 
for ER status of the samples with the expression of the genes included in this study.  
 
This is the first comprehensive study that shows the transcriptional gene expression 
profiles of the main target genes of the Hh pathway in cancer cell lines and breast 
cancer tissue samples  
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ÖZET 
EPİTEL KANSERLERDE HEDGEHOG YOLAĞI GENLERİNİN GEN İFADE 
PROFİLİ 
ÖZLEM AKILLI ÖZTÜRK 
Master Tezi, Moleküler Biyoloji ve Genetik Bölümü 
Doç. Dr. Işık G.Yuluğ 
Eylül 2006, 127 Sayfa 
 
Hedgehog (Hh) sinyal yolu birçok kanser tipinde incelenmiş ve önemli etkileri 
olduğu gösterilmiştir ama meme, kolon ve karaciğer kanserlerinde kapsamlı olarak 
çalışılmamıştır. Bu çalışmada BCL2, SHH, SMO, IHH, PTCH1, GLI1, GLI2 ve GLI3 
gen ifadesi profili 15 meme, 14 kolon ve 15 hepatoselüler karsinom (HSK) hücre 
hattında, 29 primer meme tümörü örneğinde ve 3 eşleştirilmiş normal doku örneği 
havuzunda nicel gerçek zamanlı RT-PCR ile analiz edilmiştir. Meme hücresi 
hatlarının Hh yolundaki hedef gen ifadesi düzeyi farklıdır ve bu yol sadece 
bazı meme karsinomu hücre hatlarında muhtemelen liganddan bağımsız bir yolla 
aktive edilir. Çalışılan tüm meme kanseri hatlarında PTCH1, SMO, GLI3 ve BCL2 
ifadesi yüksek bulunmuştur.  Hedef genlerin ifade profilleri çalışılan meme hücresi 
hatlarının %93’ünde estrojen reseptörü durumunu doğru tahmin etmiştir. HSK hücre 
hatlarında Hh yolu gen ifadesi profili iyi farklılaşmamış HSK hücre hatlarını iyi 
farklılaşmış olanlardan Ayırdedici Fonksiyon Analizi (DFA) kullanıldığında 
kusursuz olarak ayırmıştır. Yüksek SMO ve IHH ifadelerinin iyi farklılaşmış HSK 
hücre hatlarında normal dışı Hh yolu aktivitesi için belirteçler olduğu bulunmuştur. 
Kolon kanseri hücre hatlarında bazı genler için düzenlemesi bozulmuş ifade profili 
gözlenmiştir. Primer meme tümörü örneklerinde örneklerin ER durumunun 
öngörülmesi ile bu çalışmaya dahil edilen genlerin ifadesi arasında çok kuvvetli bir 
ilişki bulunmuştur. 
Bu çalışma kanser hücre hatları ve meme kanseri doku örneklerinde Hh yolunun ana 
hedef genlerinin transkripsiyonel gen ifadesi profillerini gösteren ilk kapsamlı 
çalışmadır. 
  
v 
 
 
 
 
                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 to efulim, to dost, and to my family….. 
 
 
  
vi 
ACKNOWLEDGEMENTS 
 
First of all,  I would like to thank Assoc. Prof. Işık G. YULUĞ for her valuable 
supervision during my study. She supported me both theoretically and morally 
during my studies in MBG Department of Bilkent University.   
 
I would like to thank Asst. Prof. Özlen Konu for her instructive comments in 
statistical analysis, and supporting me during graduate life at Bilkent. 
 
I would like to thank deeply to Bâlâ for sharing her experience and knowledge 
regarding Real-Time RT-PCR and her valuable friendship.  
 
I would like to thank Murat and İsmail for sharing their valuable senior project study 
with me, and for helping me in primer design. 
 
I would like to express my special thanks to the Scientific and Technical Research 
Council of Turkey and the Turkish Association for Cancer Research and Control, 
Terry Fox Programme for their financial support. 
 
I would like to thank deeply to my friends, Fatma, Bahar, and Aslı for sharing their 
valuable time, and encouraging me and I wish them best luck and happiness in their 
lives. I also would like to thank all members of the MBG Department of Bilkent 
University. 
 
I would like to thank deeply to efulim, and to dost for their support in every step of 
my life. 
 
Of  course, my deepest gratitudes go to my family, who have been far away from me 
for 7 years, but I always felt that they were near me. I thank them for their love and 
support. 
  
vii 
TABLE OF CONTENTS 
           
SIGNATURE PAGE         ii 
ABSTRACT         iii 
ÖZET           iv 
ACKNOWLEDGEMENTS        vi 
TABLE OF CONTENTS       vii 
LIST OF FIGURES        xii 
LIST OF TABLE                 xiv 
ABBREVIATIONS        xv 
 
CHAPTER 1. INTRODUCTION              1 
 
 
1.1.  EPITHELIAL CANCERS       1 
1.1.1. BREAST CANCER       2 
1.1.1.1. Pathology of Breast Cancer      3 
1.1.1.1.1. Ductal Carcinoma In Situ      4 
1.1.1.1.2. Lobular Carcinoma In Situ     4 
1.1.1.1.3. Infiltrating Ductal Carcinoma     5 
1.1.1.1.4. Infiltrating Lobular Carcinoma     6 
1.1.1.1.5. Invasion and Metastasis      6 
1.1.1.2. Genetics of Breast Cancer      7 
1.1.1.3. Signaling Pathways in Breast Cancer     9 
1.1.2. HEPATOCELLULAR CARCINOMA     10 
1.1.2.1. Pathology of Hepatocellular Carcinoma    10 
1.1.2.2. Genetics of Hepatocellular Carcinoma     11 
1.1.2.3. Signaling Pathways in Hepatocellular Carcinoma   13 
 
  
viii
1.1.3. COLORECTAL CANCER      13 
  1.1.3.1. Genetics of Colorectal Cancer      13 
  1.1.3.2. Signaling Pathways in Colorectal Cancer    15 
 
1.2. HEDGEHOG SIGNALING PATHWAY     17 
      1.2.1.  Hedgehog Signaling Pathway and the Genes    17 
1.2.2. Hedgehog Signaling in Development     21 
1.2.3. Hedgehog Signaling in Mammary Gland Development   24 
1.2.4. Hedgehog Signaling and Cancer      26 
1.2.5. Hedgehog Signaling and Breast Cancer     30 
 
1.3.  MEASUREMENT OF GENE EXPRESSION WITH  
        QUANTITATIVE REAL TIME RT-PCR     31 
1.3.1. Detection Chemistries       33 
1.3.2. Quantification Strategies       34 
1.3.3. Normalization        36 
1.3.4. Melt Curve Analysis       36 
 
1.4.  AIM AND STRATEGY       37 
 
CHAPTER 2. MATERIALS AND METHODS    39 
 
      2.1.   TISSUE CULTURE       39 
2.1.1.  Cryopreservation of Cell Lines     41 
2.1.2. Cell Line Culturing       41 
2.1.3. Subculturing the Cells      42 
2.1.4. Preparation of Cell Pellets      42 
2.1.5. Tumor Samples       42 
 
2.2. RNA ISOLATION        44 
 
  
ix 
2.3. cDNA PREPARATION       44 
 
2.4. OLIGONUCLEOTIDES       45 
 
2.5. REVERSE TRANSCRIPTION POLYMERASE  
CHAIN REACTION (RT-PCR)       46 
 
2.6. QUANTITATIVE REAL TIME RT-PCR     46 
 
2.7. AGAROSE GEL ELECTROPHORESIS     48 
 
2.8. SOLUTIONS AND BUFFERS      49 
 
2.9. STATISTICAL ANALYSIS       49 
2.9.1. Cluster Analysis       50 
2.9.2. Pearson Correlation       50 
2.9.3. Multidimensional Scaling (MDS)     50 
2.9.4. Discriminant Function Analysis     51 
2.9.5. Mann Whitney Test       51 
 
CHAPTER 3. RESULTS       52 
 
3.1. RNA INTEGRITY        52 
 
3.2. FIRST STRAND cDNA SYNTHESIS     52 
 
3.3. MELT CURVE ANALYSIS       53 
 
3.4. STANDARD CURVES AND AMPLIFICATION EFFICIENCIES 55 
 
3.5. QUANTITATIVE REAL TIME RT-PCR     60 
  
x 
 
3.6. BREAST CARCINOMA CELL LINES     62 
3.6.1. Expression Status of the Hh Pathway Target Genes   63 
3.6.2. Hierarchical Cluster Analysis      64 
3.6.3. Pearson Correlation Analysis      65 
3.6.4. Multidimensional Scaling (MDS)     66 
3.6.5. Discriminant Function Analysis     68 
 
3.7. HEPATOCELLULAR CARCINOMA CELL LINES   69 
3.7.1. Expression Status of the Hh Pathway Target Genes   70 
3.7.2. Hierarchical Cluster Analysis      71 
3.7.3. Pearson Correlation Analysis      72 
3.7.4. Multidimensional Scaling (MDS)     73 
3.7.5. Discriminant Function Analysis     75 
 
3.8.COLON CARCINOMA CELL LINES     76 
3.8.1. Expression Status of the Hh Pathway Target Genes   76 
3.8.2. Hierarchical Cluster Analysis      77 
3.8.3. Pearson Correlation Analysis      78 
3.8.4. Multidimensional Scaling (MDS)     79 
 
3.9. PRIMARY BREAST TUMOR SAMPLES     81 
3.9.1. Expression Status of the Hh Pathway Target Genes   82 
3.9.2. Hierarchical Cluster Analysis      83 
3.9.3. Pearson Correlation Analysis      83 
3.9.4. Multidimensional Scaling (MDS)     84 
3.9.5. Discriminant Function Analysis     86 
3.9.6. Mann Whitney Test       87 
 
CHAPTER 4. DISCUSSION AND FUTURE PERSPECTIVES     88 
 
  
xi 
 
4.1 EXPRESSION ANALYSIS IN BREAST CARCINOMA CELL LINES   89
   
4.2 EXPRESSION ANALYSIS IN HEPATOCELLULAR  
      CARCINOMA CELL LINES      93 
 
4.3 EXPRESSION ANALYSIS IN COLON CARCINOMA CELL LINES      96 
 
4.4 EXPRESSION ANALYSIS IN PRIMARY BREAST  
      TUMOR SAMPLES        99 
 
CHAPTER 5. FUTURE PERSPECTIVES           105 
 
REFERENCES                109 
 
APPENDICES                123 
 
APPENDIX A Quantitative Real Time RT-PCR Ct Values  
for Breast Carcinoma Cell Lines             123 
 
APPENDIX B  Quantitative Real Time RT-PCR Ct Values  
for Hepatocellular Carcinoma Cell Lines            124 
 
APPENDIX C  Quantitative Real Time RT-PCR Ct Values  
for Colon Carcinoma Cell Lines                        125 
 
APPENDIX D  Quantitative Real Time RT-PCR Ct Values  
for Primary Breast Tumor Samples             126 
 
 
  
xii 
 
 
LIST OF FIGURES 
 
Figure 1.1  Anatomy of the breast        2 
Figure 1.2 Major hepatocarcinogenesis pathways defined by genetics 
  alterations with clinical parameters     12 
Figure 1.3 Adeno-carcinoma sequence for colorectal cancer   15 
Figure 1.4 Schematic representation of a colon crypt and proposed model 
  for polyp formation       16 
Figure 1.5  Hedgehog Signaling Pathway      18 
Figure 1.6  Synthesis of Hedgehog ligands in the signaling cells  19 
Figure 1.7  Upstream regulation of the Gli transcription factors and their  
individual and combined roles in regulating Hh target  
gene expression        20 
Figure 1.8  Hedgehog network model in virgin mice duct and  
alveolar development in pregnancy and lactation   25  
Figure 1.9  Amplification Curve       32  
Figure 2.1  pUC Mix Marker, 8       48 
Figure 3.1  GAPDH amplified cDNA samples     53 
Figure 3.2  Melt curve graph       54 
Figure 3.3  Amplification efficiency graphs of the gene specific primers 56 
Figure 3.4  q-rt-RT-PCR amplification graph and the melt curve  61 
Figure 3.5  Selected q-rt-RT-PCR agarose gel electrophoresis photograph 62 
Figure 3.6 Expression profile of the Hedgehog pathway target genes  
in human breast carcinoma cell lines     64 
Figure 3.7  Two-dimensional Cluster Analysis of genes in human  
breast carcinoma cell lines      65 
Figure 3.8  Gene-based MDS Analysis for breast carcinoma cell lines  67 
Figure 3.9  Cell-line based MDS Analysis for breast carcinoma cell lines 68 
Figure 3.10  Expression profile of the Hedgehog pathway target genes  
in human HCC cell lines      71 
  
xiii
Figure 3.11  Two-dimensional Cluster Analysis of genes in human  
HCC cell lines        72 
Figure 3.12  Gene-based MDS Analysis for HCC cell lines   74 
Figure 3.13  Cell-line based MDS Analysis for HCC cell lines   74 
Figure 3.14  Expression profile of the Hedgehog pathway target genes  
in human colon carcinoma cell lines     77 
Figure 3.15  Two-dimensional Cluster Analysis of genes in human  
colon carcinoma cell lines      78 
Figure 3.16  Gene-based MDS Analysis for colon cancer cell lines  80 
Figure 3.17  Cell-line based MDS Analysis for colon cancer cell lines  80 
Figure 3.18  Expression profile of the Hedgehog pathway target genes  
in primary breast tumor samples     82 
Figure 3.19  Two-dimensional Cluster Analysis of genes in  
primary breast tumor tissues      83 
Figure 3.20  Gene-based MDS Analysis for primary breast tumor tissues  85 
Figure 3.21  Cell-line based MDS Analysis for primary breast tumor tissues 85 
 
  
xiv 
LIST OF TABLES 
 
Table 1.1  Genes involved in breast carcinogenesis     9 
Table 1.2  Vertebrate Hedgehog Functions      23 
Table 1.3  Animal models of Hedgehog-dependent tumors    27 
Table 1.4  Mutations in the PTCH1 gene      28 
Table 1.5  Hedgehog-dependent primary human tumors    29 
Table 2.1  Breast carcinoma cell line information    40 
Table 2.2  Hepatocellular carcinoma cell line information   40 
Table 2.3  Colon carcinoma cell line information    41 
Table 2.4  Primary breast tumor sample information    43 
Table 2.5  Oligonucleotide sequences      45 
Table 2.6  Breast normal sample pool information    47 
Table 3.1  Amplification efficiencies of the gene specific primers   60 
Table 3.2  Fold expression values of the Hh pathway genes in breast  
carcinoma cell lines       63 
Table 3.3  Pearson Correlation for human breast carcinoma cell lines  66 
Table 3.4  DFA of human breast carcinoma cell lines based on ER status         69 
Table 3.5  Fold expression values of the Hh pathway genes in HCC cell lines 70 
Table 3.6  Pearson Correlation for human HCC cell lines   73 
Table 3.7  DFA of human HCC cell lines based on their differentiation status  75 
Table 3.8  Fold expression values of Hh pathway genes in colon  
                        carcinoma cell lines       76 
Table 3.9  Pearson Correlation for human colon carcinoma cell lines  79 
Table 3.10  Fold expression values of the Hh pathway genes in primary  
                        breast tumor samples       81 
Table 3.11  Pearson Correlation for primary breast tumor tissues  84 
Table 3.12  DFA of primary breast tumor tissues based on their ER status 86 
Table 3.13  DFA of primary breast tumor tissues based on their grade status 87 
Table 3.14  Mann-Whitney test for primary breast tumor tissues  
based on their ER status      87 
  
xv 
 
ABBREVIATIONS 
 
ACTB    Actin, beta  
APC    Adenomatosis Polyposis Coli 
A.T.    Annealing Temperature 
bp    Base Pairs 
BCC                                        Basal Cell Carcinoma 
BCL2    B-cell CLL/lymphoma 2 
BFB                                        Bromophenol Blue 
BRCA                                     Breast Cancer  
BMP    Bone Morphogenetic Protein 
BWS    Beckwith-Wiedemann Syndrome 
cDNA    Complementary DNA  
CHEK    CHK checkpoint homolog (S. pompe)  
Ci    Cubitus Interruptus 
CNS    Central Nervous System  
COS2    Kinesin-related protein Costal 2 
CP    Crossing Point 
Ct                                            Cycle Threshold 
ddH2O                                     Double distilled water 
DCIS    Ductal Carcinoma In Situ  
DEPC    Diethylpyrocarbonate  
DFA    Discriminant Function Analysis 
DHH    Desert Hedgehog (Drosophila) 
DISP    Dispatched (Drosophila) 
DMEM   Dulbecco’s Modified Eagle’s Medium  
DMSO    Dimethyl Sulfoxide 
DNA    Deoxyribonucleic Acid 
dNTP    Deoxyribonucleotide triphosphate 
dsDNA   double-stranded DNA 
E    Embryonic day 
  
xvi 
EDTA    Diaminoethane Tetra-acetic Acid  
EGF    Epidermal Growth Factor  
ERBB2 v-erb-b2 Erythroblastic Leukemia Viral Oncogene 
homolog 2, neuro/glioblastoma derived oncogene 
homolog (avian) 
ER    Estrogen Receptor 
EtBr    Ethidium Bromide 
EXT    Exostoses Protein Family 
FAM    6-carboxyfluorescein 
FAP    Familial Adenomatous Polyposis 
FBS    Fetal Bovine Serum 
FGF    Fibroblast Growth Factor  
FRET    Fluorescent Resonance Energy Transfer 
Fu    Serine/Threonine Kinase Fused 
GAPDH   Glyceraldehyde-3-Phosphate Dehydrogenase 
GLI1    Glioma-Associated Oncogene homolog 1 
GLI2    Gli-Kruppel Family Member GLI2 
GLI3    Gli-Kruppel Family Member GLI3 
HCC    Hepatocellular Carcinoma 
HBS    Hepes Buffered Saline 
HBV    Hepatis B Virus 
HCV    Hepatis C Virus 
HER2    ERBB2 
HGF    Hepatocyte Growth Factor 
Hh    Hedgehog 
HIP1    Hedgehog Interacting Protein 1 
HMBS    Hydroxymethylbilane Synthase 
HNF    Hepatic Nuclear Factor 
HNPCC   Hereditary Nonpolyposis Colorectal Cancer 
HPE    Holoprosencephaly 
HPRT    Hypoxanthine Guanine Phosphoribosyl Transferase 
  
xvii 
HSPG    Heparin Sulfate Proteoglycan 
IDC    Infiltrating Ductal Carcinoma 
IHH    Indian Hedgehog homolog (Drosophila) 
IGF    Insulin-like Growth Factor  
ILC    Infiltrating Lobular Carcinoma 
LA    Lobulo-Alveolar 
LCIS    Lobular Carcinoma In Situ 
LOF    Loss of Function 
LOH    Loss of Heterozygosity 
MDS    Multidimensional Scaling 
MIN    Microsatellite Instability 
MMP    Matrix Metallopeptidase 
MMR    Mismatch Repair 
µg    Microgram 
mg    Miligram  
min    Minute    
µl    Microliter 
ml    Mililiter 
µm     Micrometer 
mm    Milimeter 
µM     Micromolar 
mM    Milimolar  
MPF    Mitosis Promoting Factor  
mRNA    Messenger RNA 
MYC    Myelocytomatosis Viral Oncogene homolog (avian) 
NBCCS   Naevoid Basal Cell Carcinoma Syndrome 
NOS    No Special Type 
Oligo(dT)   Oligodeoxythymidylic acid 
P21/CIP1   Cyclin-dependent Kinase Inhibitor 1A 
PBS    Phosphate Buffered Saline 
PCR    Polymerase Chain Reaction 
  
xviii 
Pg    Progesterone 
pmol    Picomole 
PR    Progesterone Receptor 
Prl    Prolactin 
PTCH    Patched homolog (Drosophila) 
PTEN    Phosphatase and Tensin homolog 
PTHrP    Parathyroid Hormone-Related Protein 
q-rt-RT-PCR   Quantitative real time RT-PCR 
RB1    Retinoblastoma 1 
RFU    Relative Fluorescence Unit 
Rpm    Revolutions Per Minute 
RT PCR   Reverse Transcription PCR 
RTK    Receptor Tyrosine Kinase 
SCLC    Small Cell Lung Cancer 
SDHA Succinate Dehydrogenase Complex, Subunit A,
 
flavoprotein (Fp) 
Sec    Second 
SHH    Sonic Hedgehog homolog (Drosophila) 
SMO    Smoothened homolog (Drosophila) 
SUFU    Suppressor of Fused homolog (Drosophila) 
TAE    Tris-Acetate-EDTA buffer 
TBP    TATA Box Binding Protein 
TDLU    Terminal Duct Lobular Unit 
TGF-β    Transforming Growth Factor-β  
Tm    Melting Temperature 
TP53    Tumor protein p53 
Tris    Tris (Hydroxymethyl)- Methylamine 
TTV    Tout-Velu 
UV    Ultraviolet 
VEGF    Vascular Endothelial Growth Factor 
v/v    volume/volume 
  
xix 
w/v    weight/volume 
Wnt    Wingless 
XC    Xylene Cyanol 
YO    Oxazole Yellow 
ZPA    Zone of Polarizing Activity  
 1 
CHAPTER 1 
 
 
INTRODUCTION 
 
Cancer is abnormal proliferation of the cells that loss control over the cell growth. 
Cancers that arise from epithelial surfaces are called carcinoma. If the surface is 
glandular type of surface then it is called adenocarcinoma. Carcinomas and 
adenocarcinomas are the most common types of the cancer. They include breast, 
lung, prostate, intestinal, skin, ovary, kidney, and liver. Cancer develops as a result 
of loss of control over the mechanisms regulating the normal organ functioning. 
Signaling pathways are one side of these mechanisms. Hedgehog signaling pathway 
is one of the developmentally most important pathways with a role in many cancer 
types. It is important to identify the role of Hedgehog signaling in epithelial cancer 
progression. Studies up to now have shown that Hh pathway induce cell proliferation 
in carcinomas.  In the future, studying the global gene expression of different types 
of tumors will allow the identification of expression profiles unique for the epithelial 
cancers, their stage, and grade, leading to the finding of new targets for the treatment 
of these cancers.  
 
1.1. EPITHELIAL CANCERS 
 
Carcinoma is the general name given to epithelial cancers. Carcinomas invade 
surrounding tissues and organs, and may spread to lymph nodes and distal sites of the 
body. When the carcinoma is not invasive it is called Carcinoma in situ. Carcinomas 
may have the name of the organ of the origin (pancreas, breast) or the putative cell of 
the origin (hepatocellular carcinoma).  
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1.1.1. Breast Cancer 
 
A woman's breast is made up of glands that make breast milk (lobules), ducts (small 
tubes that connect lobules to the nipple), fatty and connective tissue, blood vessels, 
and lymph vessels (Figure1.1). 
 
 
 
Figure 1.1: Anatomy of the breast. Woman breast is formed by ducts, lobules, fatty 
and connective tissues [http://www.cancer.org].  
 
Breast cancer is one of the major cancer types women suffer from in the Unites 
States and Western Europe. After lung cancer, it is the second leading cause of 
cancer death in women. Nearly 212,920 women in the United States will be found to 
have invasive breast cancer in 2006 and about 40,970 of them will die from the 
disease. Right now there are slightly over 2 million women living in the United 
States who have been treated for breast cancer.  
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The chance of a woman having invasive breast cancer some time during her life is 
about 1 in 8. The chance of dying from breast cancer is about 1 in 33. Breast cancer 
death rates are going down. This decline is probably due to earlier diagnosis and 
improved treatment of the disease. 
 
Risk factors for breast cancer are age, genetic background, reproductive history, 
radiation, socio-economic status, place of residence, and ethnicity [Medina, 2005; 
http://www.cancer.org]. Reproductive history has an important impact on the onset 
of breast cancer. Early menarche, late menopause, and late age of first pregnancy 
increase the risk of getting breast cancer [Medina, 2005].  
 
It is thought that breast cancer is a heterogeneous group of diseases with each 
subtype having its own stable phenotype maintained during tumor progression rather 
than a single disease with a single tumorigenesis pathway [Mallon et al., 2000; 
Polyak, 2006]. The most important determinants of these subtypes found are estrogen 
receptor (ER) and progesterone receptor (PR) status of tumor cells, the amplification 
and overexpression of the HER2 oncogene, and histologic grade. Considering these 
features, breast tumors are divided into luminal A, B, and C, HER2 (+), and basal 
subtypes. Tumor subtypes may reflect the cell of origin of the tumor with ER (-) and 
ER (+) tumors initiating from the earliest progenitors and more committed transit 
amplifying cells (cells with more limited proliferative capacity), respectively. In 
accordance with the proposed existence of subtype specific tumor progression 
pathways, it is increasingly evident that risk factors are also different for each tumor 
type [http://www.cancer.org].  
 
1.1.1.1. Pathology of Breast Cancer 
 
Most breast lumps, areas of thickening, are benign; that is, they are not cancer. 
Benign breast tumors are abnormal growths, but they do not spread outside of the 
breast and they are not life-threatening. Some benign breast lumps can increase a 
woman's risk of getting breast cancer.  Lumps are formed by fibrocystic changes in 
most cases. These changes include stromal fibrosis, cyst formation, and adenosis. 
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Adenomas are also common benign lesions characterized by well-circumscribed 
benign epithelial elements with a variable amount of stroma. 
 
Epithelial hyperplasia may be one of the initiating steps of breast carcinoma. 
Atypical hyperplasia is an epithelial proliferation in which some features of ductal 
carcinoma are seen in epithelial tissues [Beckmann et al., 1997; Mallon et al., 2000].  
 
1.1.1.1.1. Ductal Carcinoma in Situ (DCIS) 
 
It is the most common type of noninvasive breast cancer. Nearly all women with 
cancer at this stage can be cured. DCIS is a morphologically identifiable, preinvasive 
malignant proliferation of the breast epithelial cells [Mallon et al., 2000; 
http://www.cancer.org]. The abnormal cells are contained within the mammary 
epithelial structures. No invasion of the basement membrane and no infiltration of 
the breast stroma are apparent. With a true in situ carcinoma, malignant epithelial 
cells do not have access to the lymphatic or vascular channels present within the 
breast stroma. Classifications are performed according to the degree of nuclear 
pleomorphism (often graded on a scale of 1–3), the presence or absence of necrosis, 
and the mitotic activity. The most characteristic feature of DCIS is that the cells 
composing the intraluminal proliferation are morphologically similar to each other, 
but have nuclear abnormalities associated with malignancy.  
 
1.1.1.1.2. Lobular Carcinoma in Situ (LCIS) 
 
LCIS is a neoplastic proliferation of epithelial cells in the terminal duct lobular unit 
with specific morphological features and therapeutic implications [Beckmann et al., 
1997; Mallon et al., 2000]. LCIS is a proliferation of neoplastic, epithelial cells 
which expand the individual acini of the lobular units involving more than 50% of 
the acini in a lobular unit. Both LCIS and DCIS are observed more in premenopausal 
women, suggesting that these lesions regress after menopause and that they are 
hormone dependent. This idea is supported by the ER positivity of these lesions.  
 
 5 
1.1.1.1.3. Infiltrating Ductal Carcinoma (IDC) 
 
IDC is the most common type of breast cancer. It accounts for about 80% of invasive 
breast cancers [http://www.cancer.org]. If a tumor does not show the morphological 
features of a special type of invasive carcinoma or the characteristics of invasive 
lobular carcinoma, it is an IDC. Therefore, it is also called carcinoma of no special 
type (NOS) [Mallon et al., 2000]. This group of tumors is morphologically 
heterogeneous. IDC tumors have very variable growth patterns and stromal 
responses. They are often hard and fibrous. The pattern of infiltration of the edge of 
the tumor is variable. In some instances these tumors have a well-circumscribed 
pushing margin which abuts on and distorts the surrounding normal stroma, resulting 
in a smooth, rounded interface between the tumor and the surrounding tissue. In 
these instances there is often an associated dense lymphatic infiltrate at the margin. 
In other cases, the tumor infiltrates the surrounding tissue diffusely enveloping 
preexisting normal structures in its path, resulting in an irregular infiltrative margin. 
 
The stage is determined by spread of the tumor to the body. However, grade is 
determined by how the tumor cells appear under the microscope, growth rate of the 
tumor cells, and the tendency of tumor to spread other parts of the body. There are 
four stages of breast cancer [http://www.cancer.gov]. If the tumor size is less than 2 
centimeters and there is no metastasis, it is a stage I tumor. As it progresses to stage 
IV, tumor size and metastasis levels increase. In stage IIIB and IV, the metastasis 
spreads to other parts of the body rather than lymph nodes. As the stage increases, 
the severity of the disease increases, as well. It is possible to separate IDC into three 
grades based on the degree of tubule formation, nuclear pleomorphism, and mitotic 
activity. Each of the three parameters is given a score of 1–3 and the individual 
scores are then added together. A score of 3–5 indicates Grade 1, 6–7 indicates 
Grade 2, and 8–9 indicates Grade 3. The first parameter, tubule formation, is 
assessed on the basis of percentage of the tumor showing distinct tubules: a score of 
1 is assigned if 75% or more, a score of 2 if 10–75%, and a score of 3 if less than 
10%. Nuclear pleomorphism is the second component. If the nuclei are small, with 
regular outlines, uniform chromatin, and little variation in size, they are assigned a 
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score of 1. The cytoplasm of the tumor cells may also show considerable variation, 
with some cells having little cytoplasm and others having abundant cytoplasm that 
can be eosinophilic and granular, or foamy and basophilic, or midway between the 
two. The third parameter is an assessment of the proliferation rate determined by 
counting the number of mitoses in 10 high-power fields at the periphery of the tumor. 
The method is standardized for each microscope objective and the tumor scored on a 
scale of 1–3.  
 
1.1.1.1.3. Infiltrating Lobular Carcinoma (ILC) 
 
ILC is the second most common type of invasive breast carcinoma and accounts for 
approximately 10% of all invasive breast malignancies [Mallon et al., 2000; 
http://www.cancer.org]. The cellular morphology of the tumor and the pattern of 
infiltration are very important in diagnosis. The tumor cells of lobular carcinoma are 
found in association with foci of typical LCIS and infiltrate in a very characteristic 
way with one cell behind the other in a defined pattern called the Indian filing 
pattern. They often form concentric rings around blood vessels and lobules 
producing a targetoid pattern. In classical lobular carcinoma, the tumor cells are 
relatively small. They have regular rounded nuclei with dense, evenly staining 
chromatin. Nucleoli are not prominent. ILC has a higher incidence of multicentricity 
and bilaterality than IDC and a slightly better overall survival rate than tumors in the 
NOS category. There are also several other less common types of breast cancer 
including tubular, mucinous, medullary, papillary, invasive cribriform, and secretory 
carcinoma.  
 
1.1.1.1.4. Invasion and Metastasis 
 
Breast carcinoma metastasizes more widely and more frequently than other 
malignant tumors [Mallon et al., 2000]. When this occurs, 95% of the patients so 
affected die of metastatic disease. Breast carcinoma metastasizes to distant sites by 
way of the angiolymphatic system. The first lymph nodes to be seeded with tumor 
cells are the axillary nodes, followed by the supraclavicular nodes and the mammary 
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nodes. Distant sites of metastases include the opposite breast, skeletal system, lungs 
and pleurae, liver, ovaries, adrenal glands, and central nervous system including the 
leptomeninges and eyes.  Lymphovascular channel invasion is used as a pathological 
prognostic indicator. 
 
1.1.1.2. Genetics of Breast Cancer 
 
Cancer is a genetic disease and breast cancer has all the hallmarks of multistep 
genetic disease. Progression of breast cancer occurs through the accumulation of 
various genetic alterations [Beckmann et al., 1997] (Table 1.1). A normal epithelial 
cell develops into a premalignant atypical cell and after clonal expansion becomes a 
premalignant lesion called carcinoma in situ. As cells detach from the basement 
membrane and invade the stroma, the carcinoma becomes invasive [Kenemans et al., 
2004]. Gain of function genetic events develop in oncogenes by DNA mutations, 
rearrangements or amplifications, and loss-of-function mutations in tumor suppressor 
genes are important molecular events. Mutations in tumors suppressor genes mostly 
occur in inherited cancers while mutations of oncogenes are mostly observed in 
sporadic cancer development. 
 
Hereditary breast cancer forms nearly half of familial breast cancer cases [Kenemans 
et al., 2004]. Most inherited cases of breast cancer have been associated with two 
genes: BRCA1, which stands for BReast CAncer gene one, and BRCA2, or BReast 
CAncer gene two [Futreal et al., 1994; Miki et al., 1994; Shattuck et al., 1995; 
Wooster et al., 1994; Wooster et al., 1995]. The function of these genes is to keep 
breast cells growing normally and to prevent any cancer cell growth. But when these 
genes contain abnormalities, or mutations, they are associated with an increased 
breast cancer risk. Abnormal BRCA1 and BRCA2 genes may account for up to 2-3% 
of all breast cancers. Women diagnosed with breast cancer that have an abnormal 
BRCA1 or BRCA2 gene often have a family history of breast cancer, ovarian cancer, 
or both. Mutations in the cell cycle check point kinase gene (CHEK2) are observed in 
approximately 5% of all familial breast cancer cases [Kenemans et al., 2004]. 
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However, it is also important to remember that most women with breast cancer have 
no family history of the disease.  
 
Only 4-10% of breast cancers have a germ line mutation that predispose to breast 
cancer [Lerebours et al., 2002]. The remaining part is somatic breast cancers 
resulting from the genetic alterations. 70% of breast cancers are aneuploid, with 
DNA amplifications in oncogenes or chromosomal deletions in tumor suppressor 
genes. The consistently mutated tumor suppressor gene in sporadic breast cancer is 
TP53 with point mutations in approximately 22-34% of the cases. TP53 mutations 
are observed mostly in ductal carcinoma [Beckmann et al., 1997]. Point mutations 
are the common form of mutation for the TP53 leading to proteins defective for 
sequence-specific DNA binding and activation of target genes. TP53 mutation is a 
rare event in the progress of breast cancer, and it is rarely observed in hereditary 
breast cancer [Kenemans et al., 2004]. MYC is also altered in the breast cancer. It is 
amplified and thus overexpressed in approximately 15-20% of breast tumors. MYC 
may be involved in the early stages of cancer progression since it is a key 
transcription factor having role in cell growth, differentiation, and apoptosis 
[Lerebours et al., 2002]. In addition, down regulation of the expression of the RB1 
tumor suppressor gene is frequent in breast cancer. Deletions of the chromosomal 
region containing the RB1 gene, 13q14.1, are found in 25-35% of breast cancers 
[Lerebours et al., 2002]. Although BRCA1 and BRCA2 mutations are rare in sporadic 
breast cancers, the down regulation of BRCA1 expression by hyper-methylation is 
observed [Lerebours et al., 2002]. The respective locus at 17q22 is frequently deleted 
in sporadic breast cancers. P21 has a role in the regulation of DNA methylation. In 
the normal cells it prevents DNA methylation. In the cancer cells it loses its control 
and the level of DNA methylation decreases overall, although at some major genes 
there is dense methylation [Salisbury, 2001]. P21 itself is under epigenetic control in 
the breast cancer by histone deacetylation. Beside these, there are many genes that 
are deregulated in breast cancer. Microarray technology will allow more progress in 
the understanding of the genetics of breast cancer. 
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Table 1.1: Genes involved in breast carcinogenesis [Kenemans et al., 2004] 
 
 
1.1.1.3. Signaling Pathways in Breast Cancer 
 
There is a hypothesis about the cellular origin of cancer in which stem cells are 
thought to be responsible for cancer progression, since they are quiescent over long 
periods of time, and could accumulate mutations, and thus when stimulated to 
proliferate enrich abnormal cell growth [Li et al., 2005; Liu et al., 2005; Woodward 
et al., 2005]. Normal stem cells and cancer stem cells share some properties that 
prove this hypothesis, in which self-renewal, the ability to differentiate, active 
telomerase and anti-apoptotic pathways, anchorage independence and, ability to 
migrate and form metastasis are important ones. Mammary gland stem cells function 
in tissue remodeling during cycles of pregnancy, which make them good candidate 
for the transfer of the mutations to the remodeled tissues. Understanding the 
signaling pathways involved in the self-renewal of both normal and cancer stem cells 
is important for anti-cancer therapies [Woodward et al., 2005]. There are several key 
signaling pathways governing this process in stem cells. These are Wnt/β-catenin, 
Hedgehog (Hh), transforming growth factor (TGF)-β, PTEN and Bmi signaling 
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pathways. Deregulation of these pathways is shown to cause mammary tumors in 
transgenic mice [Li et al., 2005; Liu et al., 2005]. 
 
1.1.2. Hepatocellular Carcinoma 
The liver plays a central role in the metabolism of an organism. In this organ, several 
highly-specialized cell types interact by taking over complex and life-essential 
metabolic functions such as glucose and protein metabolism. Since the liver is made 
up of different types of cells, different types of tumors can form in the liver 
[http://www.cancer.org]. Some of these are cancerous and some are benign, and they 
treated differently. While there are other types of liver cancers, the most common 
form in adults is called hepatocellular carcinoma (HCC). It begins in the hepatocytes, 
the main type of liver cell. About 3 out of 4 primary liver cancers are HCC. 
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in 
some areas of the world with an extremely poor prognosis. The major etiologic risk 
factors for HCC development include toxins (alcohol, aflatoxin B1), androgens and 
estrogens, hepatitis B virus (HBV) and hepatitis C virus (HCV) infection as well as 
various inherited metabolic disorders, such as alpha-1-antitrypsin deficiency and 
hemochromatosis [Blum, 2005]. 
18,510 new cases of primary liver cancer and bile duct cancer are estimated to be 
diagnosed in the United States during 2006. It is about twice as common in men as in 
women. About 16,200 people will die of liver cancer in the United States during 
2006. This cancer is many times more common in developing countries in Africa, 
and East Asia than in the United States. In many of these countries it is the most 
common type of cancer [http://www.cancer.org].  
 
1.1.2.1. Pathology of Hepatocellular Carcinoma 
 
Hepatocellular carcinoma is heterogeneous both phenotypically and genetically. 
Assessment of the differentiation grade of hepatocellular carcinomas (HCCs) is 
important for evaluation of the pathological diagnosis, prognosis and therapeutic 
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treatment [Ishiyama et al., 2003]. Early well-differentiated tumors are highly 
proliferative and become less differentiated when they reach 1-1.5 cm. At this stage, 
HCC cells start to acquire the abilities of angiogenesis, tissue invasion and 
metastasis. Later on, they become undifferentiated and are able to invade vessels and 
form extra-hepatic metastases [Bruix et. al., 2004]. This dedifferentiation process is 
associated with a progressive accumulation of genomic changes including 
chromosomal gains and losses, as well as p53 mutations [Thorgeirsson et al., 2002]. 
The comprehensive expression of HNF-3β, HNF-4α, HNF-1α, and C/EBPα 
corresponds well with differentiated functions and morphology of HCC. Expressions 
of HNF-4α and HNF-1α among these four transcription factors showed synchronism 
and had a close relationship with HCC differentiation. HNF-4α and HNF-1α are 
useful markers to evaluate differentiation of HCC [Ishiyama et al., 2003]. 
 
Malignant transformation occurs through a pathway of increased liver cell turnover, 
induced by chronic liver injury and regeneration in a context of inflammation, 
immune response, and oxidative DNA damage which cause mutations of various 
genes and a genetic instability [Blum, 2005]. 
 
1.1.2.2. Genetics of Hepatocellular Carcinoma 
 
Numerous genetic alterations are accumulated during the progression of HCC. There 
are mainly two types of genetic alterations of which the first one is genetic 
alterations specific of hepatocellular tumor risk factors as shown in Figure 1.2 
[Laurent-Puig et al., 2006]. It includes integration of hepatitis B virus (HBV) DNA, 
R249S TP53 mutation in aflatoxin B1-exposed patients, KRAS mutations related to 
vinyl chloride exposure, hepatocyte nuclear factor 1a, HNF1a, mutations associated 
to hepatocellular adenomas and adenomatosis polyposis coli, APC, germline 
mutations predisposing to hepatoblastomas. The second type of genetic alterations 
are etiological nonspecific, it includes recurrent gains and losses of chromosomes, 
alteration of TP53 gene, activation of WNT/β-catenin pathway through CTNNB1/β-
catenin and axis inhibition protein, AXIN, mutations, inactivation of retinoblastoma 
and insulin-like growth factor 2 receptor, IGF2R, pathways through inactivation of 
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RB1, P16 and IGF2R. Based on the presence or the absence of chromosomal 
instability two pathways of hepatocarcinogenesis have been found as shown in 
Figure 1.2. Hepatitis B virus and poorly differentiated tumors are related to 
chromosome instable tumors associated with frequent TP53 mutations, whereas non-
HBV and well-differentiated tumors are related to chromosomal stable samples that 
are frequently β-catenin activated. 
 
 
 
Figure 1.2:  Major hepatocarcinogenesis pathways defined by genetic 
alterations with clinical parameters. Lines joining boxes indicate significant 
correlations [Laurent-Puig et al., 2006]. 
 
Beckwith–Wiedemann syndrome (BWS) or in the familial adenomatous polyposis 
(FAP) are two cancer predispositions leading to hereditary HCC [Laurent-Puig et al., 
2006]. FAP is owing to APC germline mutation. Nuclear/cytoplasmic accumulation 
of the β-catenin is observed in most hepatoblastomas and sequence analysis of the β-
catenin N-terminal domain has revealed interstitial deletions or missense mutations 
in the GSK3β phosphorylation motif in 48–67% of sporadic hepatoblastoma tumors. 
Activation of the WNT/β-catenin pathway may be related to axis inhibition protein 2, 
AXIN2, mutations in other familial cases.  
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1.1.2.3. Signaling Pathways in  Hepatocellular Carcinoma 
 
Dysregulation of growth factors, receptors and their downstream signaling pathway 
components represent a central pro-tumorigenic principle in human 
hepatocarcinogenesis. Especially the insulin-like growth factor/IGF-1 receptor 
(IGF/IGF-1R), hepatocyte growth factor (HGF/MET), wingless (Wnt/β-
catenin/FZD), transforming growth factor alpha/epidermal growth factor receptor 
(TGFα/EGFR) and Transforming Growth Factor β (TGF-β/TGF-β Receptor) 
pathways contribute to proliferation, anti-apoptosis and invasive behavior of tumor 
cells. 
 
1.1.3. Colorectal Cancer 
 
Colorectal cancer is the third most common cancer found in men and women in this 
United States other than skin cancer [http://www.cancer.org]. It is estimated that 
there will be about 106,680 new cases of colon cancer and 41,930 new cases of rectal 
cancer in 2006 in the United States. Combined, they will cause about 55,170 deaths.  
 
The death rate from colorectal cancer has been decreasing for the past 15 years. One 
reason is that there are fewer cases. Thanks to colorectal cancer screening, polyps 
can be found and removed before they turn into cancer [http://www.cancer.org].  
 
1.1.3.1. Genetics of Colorectal Cancer 
 
Hereditary nonpolyposis colorectal cancer (HNPCC) and familial adenomatous 
polyposis (FAP) are inherited cancer syndromes that account for approximately five 
percent of all colon cancers [http://www.cancer.org].  In HNPCC, families typically 
have at least three members with a history of colorectal cancer, and patients 
commonly develop cancers at an early age.  Patients with FAP also have a strong 
family history of colon cancer and develop multiple polyps at a young age, some of 
which ultimately turn malignant if preventive measures are not taken.  FAP is caused 
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by mutations in the APC gene, whereas HNPCC is caused by muttaions in several 
genes, including MSH2, MLH1, PMS1, PMS2, MSH6, TGFBR2, and MLH3 
[http://www.cancer.org].  
 
Due to the accumulation of mutations in a number of oncogenes and tumor 
suppressor genes transformation of colorectal epithelial cells into the cancer cells 
occur as shown in Figure 1.3 [Wang et al., 2006].  Approximately 15% of sporadic 
colorectal cancers are caused by somatic inactivation of mismatch repair (MMR) 
genes, which leads to a microsatellite instability (MIN) phenotype. Interestingly, a 
much higher incidence (~85%) of MIN has been found in colorectal cancer patients 
with HNPCC tumors. The predominant mechanism responsible for the inactivation 
of MMR in these tumors is epigenetic silencing through promoter methylation with 
the additional involvement of somatic mutations [Wang et al., 2006].  
 
The tumor suppressor APC was first identified by genetic analysis in patients with 
FAP. Adenomatous polyposis coli, which is encoded by the FAP locus on 
chromosome 5, is mutated in most sporadic forms of colon cancer as well. This 
invariably leads to hyperproliferation of colon crypt cells and to the formation of 
polyps. K-ras is the well known oncogene functioning in 47-50% of colorectal 
cancers. When mutated it stimulates the Wnt signaling through suppression of GSK-
3β [Wang et al., 2006]. Matrix metalloproteinases have an important role in colon 
cancer progression. Increased levels of MMP-1, -2, -3, -7, -9, and -13 are found in 
the colon cancer samples as compared to normal mucosa. MMP may function in the 
tumor progression not only through ECM degradation but also through liberating 
growth factors and/or cytokines, suppressing the immune response, and modulating 
the angiogenesis. In addition, MMP-7 may have a role in EGF receptor activation in 
colon cancer cells. 
 
 
 
 15
 
 
Figure 1.3: The adenoma-carcinoma sequence for colorectal cancer. A mutation 
in APC or β-catenin results in the activation of the Wnt signaling pathway, triggering 
tumor formation. Subsequent progression towards malignancy is accompanied by 
sequential mutations in k-RAS, deletion of chromosome 18q affecting genes 
encoding SMAD2 and SMAD4, p53, and genes involved in tumor invasiveness such 
as E-cadherin. Tumor suppressor proteins are represented above the adenoma-
carcinoma sequence, whereas oncogenes are depicted below. Increasing levels of 
nuclear β-catenin accompany tumor progression [Giles et al., 2003]. 
 
1.1.3.2. Signaling Pathways in Colorectal Cancer 
 
Stem cells residing in the crypt base of the colon have been thought to be responsible 
for colon cancer progression since they are the cells providing the balance between 
asymmetrical cell division and cell proliferation which can be disrupted by several 
genetic and/or epigenetic alterations (Figure 1.4) [Wang et al., 2006]. Activating 
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mutations of the Wnt pathway causes 90% of the colorectal cancer [Giles et al., 
2003] 
 
 
Figure 1.4: Schematic representation of a colon crypt and proposed model for 
polyp formation. At the bottom third of the crypt, the progenitor proliferating cells 
accumulate nuclear β-catenin. Consequently, they express β-catenin/TCF target 
genes. An uncharacterized source of WNT factors likely resides in the mesenchymal 
cells surrounding the bottom of the crypt, depicted in red. As the cells reach the mid-
crypt region, β-catenin/TCF activity is downregulated and this results in cell cycle 
arrest and differentiation. Cells undergoing mutation in APC or β-catenin become 
independent of the physiological signals controlling β-catenin/TCF activity. As a 
consequence, they continue to behave as crypt progenitor cells in the surface 
epithelium giving rise to aberrant crypt foci [Giles et al., 2003]. 
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1.2. HEDGEHOG SIGNALING PATHWAY 
 
Hedgehogs (Hh) comprise a family of secreted signaling molecules that direct 
numerous developmental and patterning events in mammalian tissues [Ingham et al., 
2001; Taipale et al., 2001]. Both the distribution of Hh molecules and the cellular 
response to Hh are tightly regulated. Research over the past years has shed light on 
the complex Hh signaling pathway.  
 
1.2.1. Hedgehog Signaling Pathway and the Genes 
 
The Hh protein family includes Sonic (SHH), Indian (IHH), and Desert (DHH) 
hedgehogs [Ingham et al., 2001]. The Hh signaling pathway starts with expression of 
one of these proteins (Figure 1.5). SHH is the predominant signaling molecule in 
lung, brain and limb development and is the most extensively studied Hh protein in 
vertebrates. The receptor that SHH binds is called patched (PTCH). PTCH is a 12- 
pass transmembrane protein. In quiescent cells PTCH catalytically acts on 
Smoothened (SMO) to inhibit it. In this form a cytoplasmic complex made up from 
atypical kinesin costal2, Ser/Thr kinase fused, and suppressor of fused (SUFU) 
favors the repressor form of the GLI transcription factors. Binding of SHH to PTCH 
inactivates it so that SMO is relieved and COS2/FU/SUFU cannot process the GLI 
transcription factor family of proteins. SUFU has a role in subcellular localization of 
GLI proteins. Mutations of SUFU results in a truncated form which is unable to 
transport GLI proteins, leading to constitutively active Hh pathway [Wetmore, 2003]. 
Processed GLI proteins result in N-terminal truncated activator and C-terminal 
truncated repressor fragments [Magliano et al., 2003]. Active GLI transcription 
factor family proteins translocate to nucleus, bind to Hh target gene promoters and 
induce their expression [Watkins et al., 2004]. In vertebrates there are three GLI 
transcription factor family proteins. Glioma-associated oncogene (GLI1) is an onco-
protein and positive regulator of the pathway. It is target of itself in the Hh signaling 
and thought not to be regulated by processing. GLI-Kruppel family member Gli2 
(GLI2) and GLI-Kruppel family member Gli3 (GLI3) contain potent repressor 
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domains and behave both as activators and repressors [Toftgard, 2000]. GLI1 is 
thought to be the main transcription factor activating the pathway in both 
development and disease. GLI2 has a role in ectopic expression of the pathway 
[Wetmore, 2003]. 
 
 
Figure 1.5: Hedgehog Signaling Pathway. [Biljsma et al., 2004] 
 
The active SHH signaling peptide is formed by an autoprocessing reaction that 
converts a 45 kDa precursor into a 20 kDa signaling peptide that is doubly lipid 
modified, with palmitate and cholesterol residues at the N and C termini, respectively 
(Figure 1.6). The 25kDa C-terminal part has the autoproteolytic activity, and the N-
terminal domain has the signaling activity. Transport of the ligand requires 
transmembrane protein Dispatched (DISP) [Ma et al., 2002], which is a 12-pass 
transmembrane protein with sequence similarity to PTCH. DISP makes Hh ligand 
available for long range signaling by releasing it from the plasma membrane [Cohen, 
2003]. The movement of processed ligand to the responding cell occurs by help of 
tout-velu (TTV) protein. It belongs to the EXT protein family functioning in heparin 
sulfate proteoglycan (HSPG) biosynthesis. HSPG may function in the carriage of 
ligand to the PTCH receptor or moving of it from cell to cell [Cohen, 2003].  
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SHH is the most broadly expressed hedgehog gene and responsible for the major 
effects on the development of the brain, spinal cord, axial skeleton, and limbs. IHH is 
found to be functioning in regulation of cartilage differentiation in the long bones. 
DHH is expressed mainly in developing germ line and Schwann cells of the 
peripheral nervous system [Bale, 2003]. 
 
 
Figure 1.6: Synthesis of Hedgehog ligand in the signaling cells [Watkins et al., 
2004]. Hedgehog signaling protein is formed by autoprocessing reaction in which Hh 
precursor protein is converted to dual lipid modified active protein. 
 
Gli transcription factor family is composed of three GLI proteins in vertebrates 
(GLI1, GLI2, and GLI3). These proteins have several regions with sequence 
homology, including a centrally located DNA-binding domain with five C2-H2 zinc 
fingers and a C-terminal transcription activation domain [Ruiz i Altaba, 1999]. These 
proteins have distinct activities and are not functionally equivalent. Nevertheless, 
their partial redundancy and often overlapping domains of expression has made it 
difficult to define precisely their individual features and functions.  
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GLI3 is the transcription factor that most resembles the Ci transcription factor of 
Drosophila. Like Ci, it is proteolytically cleaved to form a repressor form in the 
absence of the ligand. Hh stimulation prevents the cleavage; the repressor effect of 
GLI3 is relieved [Ruiz i Altaba, 1999], and contributes to target gene activation at 
least by a direct derepression and possibly by direct transcriptional activation. Hh 
ligand binding is thought to induce activation of GLI2 mediated transcriptional 
activity. GLI1 is primary target of the pathway and its expression is regulated by 
both GLI2 and GLI3. In the absence of GLI2 and GLI3, it can mediate the target 
gene activation, however in the absence of GLI2 and GLI3 there is no GLI1 
expression in the cell [Lipinski et al., 2006] (Figure 1.7). 
  
 
 
Figure 1.7: Upstream regulation of the Gli transcription factors and their 
individual and combined roles in regulating Hh target gene expression [Lipinski 
et al., 2006].  In the absence of the signal, Gli3 functions as a repressor of the Hh 
signaling pathway. When there is signaling, repression of Gli3 is relieved, and 
activator form of the Gli2 becomes active and induces target gene activation.  
 
Several antagonists of Hh signaling have been determined that regulate the Hh 
pathway during development of certain organs. The most important one of these is 
hedgehog interacting protein 1 (HIP1). It is also a target gene of the pathway, and 
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functions in feedback inhibition [Toftgard, 2000]. HIP1 binds to all Hh ligands with 
high affinity and sequesters them in the target cell membrane, thus preventing the 
signaling. HIP1 modulates the Hh signaling in vertabrates. Its binding to the ligand 
attenuates the signal, and allows differential responses to be generated [Chuang et 
al., 1999]. Ectopic expression of HIP prevents the Hh signaling [Kayed et al., 2005].   
 
1.2.2. Hedgehog Signaling in Development 
 
Cell-cell signaling is a crucial aspect of development and yet just five signal 
transduction pathways mediate the early development of most animals. These 
intercellular signaling pathways consist of the Wnt, TGF-β, Notch, RTK (receptor 
tyrosine kinase) and Hedgehog pathways. The most common target of signaling in 
development is transcription. Different pathways activate or repress different genes 
at distinct times and places in the embryo. Signaling pathways have important roles 
in determining embryonic patterning and cell fate decisions. Analysis of Drosophila 
development has been vital in elucidating the components and functions of these 
signaling pathways. Research in vertebrates revealed that vertebrates not only have 
the same signaling components as Drosophila, but also often the developmental roles 
of these signaling components are similar to those in Drosophila. Hedgehog 
signaling was first identified in Drosophila embryo development with a role in 
segmental patterning. 
 
The three mammalian Hh genes are broadly expressed throughout embryonic 
development with Shh showing the widest range of expression [Bitgood et al., 1995]. 
Hedgehog signaling pathway has many crucial functions in the growth, patterning, 
and morphogenesis of many regions in the vertebrates and insects as shown in Table 
1.2. It can act both as a morphogen to induce different cell fates and as a mitogen to 
regulate cell proliferation. Signaling can be short- and long-range, direct and indirect, 
and importantly, concentration-dependent, evoking distinct molecular responses at 
discrete concentration thresholds. It functions in the segmental patterning in the fruit 
fly embryo, digit patterning in the chick limb bud, and left-right asymmetry of 
vertebrate embryos. In addition it is crucial in the maintenance of tissue patterns in 
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adults [Bijlsma et al., 2004; Harfe et al., 2004]. Hh signaling functions in limb and 
forebrain development by regulating organ size and cell proliferation [Watkins et al., 
2004].  Shh is involved in development of CNS [Dahmane et.al, 2001]. Shh acts as a 
morphogen throughout the dorso-ventral axis of the embryo along the ventral neural 
tube and induces expression of homeobox genes [Ruizi i Altaba et al., 2004]. It is 
required for differentiation of floor plate cells and ventral neurons in the early neural 
tube. In addition Hh signaling regulates stem cell fate in the cerebellum [Dahmane et 
al., 2001; Ruizi i Altaba et al., 2004; Watkins et al., 2004]. In the limb, Shh is 
expressed from the cells found in the zone of polarizing activity (ZPA) and specifies 
the digit identity in the anterior-posterior axis. If the temporal gradient of Shh 
changes, digit identity also changes [Chuang et al., 2000; Harfe et al., 2004].  
 
In studies of mouse embryo it has been shown that Hh signaling is required for 
foregut development. Experiments performed in both wild-type and Shh-/- mutant 
mice embryos show that Shh-/- mutant embryos have abnormal foregut and lung 
development. These results show that Shh is required for normal development of 
oesophagus and trachea and mutations of SHH and/or its signaling components may 
contribute to foregut defects in humans [Litingtung et al., 1998].  
 
Shh and Ihh mutant mice embryos show defects in gastrointestinal organogenesis 
[Ramalho-Santos et al., 2000]. Hh signaling is important for anterior-posterior 
patterning, radial patterning, and epithelial stem cell differentiation and proliferation 
in gastrointestinal development. Radial axis patterning in the developing intestine is 
governed by the ratio of lamina propria and submucosa to smooth muscle and enteric 
neuronal cell neurons which is determined by Shh and Ihh expression [Watkins et al., 
2004]. In the developing mouse pancreas, increased Hh signaling prevents the 
organogenesis [Kawahira et al., 2003]. Hh signaling regulates organ size, 
morphogenesis, and function of the pancreas.  
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Table 1.2: Vertebrate Hedgehog Functions [Ingham et al., 2001].  
Tissue/cell type/organ Ligand Nature of role  
Angiogenesis/vasculogenesis Ihh Stimulates endothelial cell production in yolk sac 
  Shh Induces angiogenesis 
Blood cells Shh 
Proliferation of stem cells, modulation 
hematopoietic and thymocyte differentiation 
Bone and cartilage Shh 
Induction of early chondrogenic factors in somite 
proliferation/survival axial chondrogenic precursors 
  Ihh 
Coordination of proliferation/ differentiation in 
endochondral skeleton 
Cerebellum Shh 
Proliferation of granule cell precursors, 
differentiation of Bergmann glia 
Eye 
Shh (Ihh, Dhh, 
twhh) 
Stimulates and inhibits retinal neurogenesis 
astrocyte proliferation in optical nerve, retinal 
precursor proliferation 
  Shh and/or twhh Induction of proximal fates in the eye fields 
Gut Shh 
Separation of trachea and esophagus, A-P patterning 
gut tube 
  Ihh and/or Shh  
Proliferation and inhibition of mesenchyme 
differentiation, radial patterning of gut tube 
Gonads/external genitalia Dhh 
Peritubular cell development, maturation of testes, 
Sertoli Leydig cell interactions, male germ line 
development, masculinization 
Hair/feather Shh 
Follice/feather morphogenesis, polarity of feather,  
Telogen to anogen switch in hair follicle 
Heart Shh or Ihh  Cardiac morphogenesis 
Lateral Asymmetry Shh, Shh or Ihh  Regulation of L/R asymmetry (left pathway) 
Limbs Shh A-P patterning of skeleton, outgrowth of limb-bud 
Lung Shh 
Branching epithelium, proliferation/ survival of 
mesenchyme 
Muscle Shh 
Induction/proliferation/survival of epaxial muscle 
precursors, fiber-type identity, regulation of smooth 
muscle differentiation 
Neural Crest Shh 
Survival of cranial neural crest, cranial facial 
morphogenesis, proliferation/ differentiation of 
sympathetic cells 
Neurons Shh 
Induction of specific ventral neural cell types, 
proliferation/survival/death neural precursors 
Olfactory Shh Olfactory pathway formation 
Oligodendrocytes Shh Proliferation/differentiation/survival of precursors 
Pancreas Shh 
Inhibition of pancreatic anlagen formation, 
insulin production  
Specification of pancreas anlagen (in fish) 
Peripheral nerves Dhh Formation of peripheral nerve sheath 
Pituitary Shh 
Inhibits transdifferentiation to lens, proliferation/cell 
type determination 
Prostate Shh Growth and ductal morphogenesis 
Tooth Shh Growth, polarity and morphogenesis 
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1.2.3. Hedgehog Signaling in the Mammary Gland Development 
 
In mouse mammary gland development, both Shh and Ihh can be detected in the 
mammary epithelium in E12. After placode formation, Ptch1 expression can be 
observed in both ectodermal and mesenchymal tissues. Gli1 expression cannot be 
observed in early development. Only after E13.5 it is expression is detectable in the 
epithelium. Gli2 and Gli3 expressions can be seen after placode formation at E11.5-
E12.5 in epithelial tissues [Lewis et al., 2004; Michno et al., 2003]. Gli3 is shown to 
be important for mammary placode formation although detectable expression is seen 
only after placode formation. In ductal development, Ptch1 and Gli2 genes have been 
shown to be important [Lewis et al., 2004].  
 
During the pregnancy and lactation periods Ptch is highly expressed. 
Haploinsufficiency of Ptch1 causes severe histological defects in ductal structure, 
and small morphological changes in terminal end buds in virgin mice [Lewis et al., 
2004; Michno et al., 2003]. Gli2 is thought to be the main Hh signaling transcription 
factor in the mammary gland development. Gli2 null phenotype mice had misshapen 
ducts showing hyperplasia similar to human micropapillary ductal hyperplasia. 
While it is expressed in the stroma during mammary gland development, it is 
expressed in both stroma and epithelial tissues during pregnancy and lactation 
[Gallego et al., 2002]. Single gene loss of function mutation studies in mice for Shh, 
Ihh, Gli1, and Gli3 showed that these genes are not required for ductal development 
individually. Shh and Ihh may have redundancy in ductal development in virgin 
mice. Indeed, high expression of Ihh is observed in the Shh deficient mice. Loss of 
Shh expression does not have any effect on the expression profile of cyclin D1, a 
target of the pathway [Michno et al., 2003].  
 
The working model for the role of Hh signaling in ductal development is that in the 
ducts of the virgin mice Ptch1 inhibits the Smo in the presence of low levels of Ihh in 
the epithelium [Lewis et al., 2004] (Figure 1.8). Thus, Gli2 cannot be expressed in 
that part of the mammary gland. However, in the stroma Ptch activates the pathway, 
and Gli2 acts as a transcriptional activator. Ptch1 can bind to Hh ligand and sequester 
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ligand away from the cells to prevent respond to stimulus. Loss of Ptch1 allows Hh 
ligand to signal to the stroma which is not exposed to high levels of ligand. In the 
absence of the Hh ligand Ptch1 can initiate apoptosis. If loss of Ptch1 occurs, it may 
lead to a failure in the apoptotic program, and cells accumulate in the duct. 
 
        
 
Figure 1.8: Hedgehog network model in virgin mice duct and alveolar 
development in pregnancy and lactation. Hypothesized functional relationships 
among network components are shown for both the stroma and the epithelium 
[Lewis et al., 2004]. 
 
There is also a revised model for ductal development in which ductal development is 
ligand independent [Lewis et al., 2004]. Pcth1 is expressed in both epithelium and 
stroma to prevent signaling in the presence of low level of ligand expression by Smo 
inhibition, sequestration of the ligand, and induction of apoptosis, or combination of 
these. In this case Gli2 activity should be regulated by other pathways like Wnt. If 
this is the case, then Gli2 should act as a transcriptional repressor. 
 
Ihh expression seems to be hormonally regulated because expression increases 
dramatically in the pregnancy, and becomes maximal during the lactation 
[Walterhouse et al., 2003]. Expressional regulation of Shh is not clear yet [Lewis et 
al., 2004]. That is why Ihh is the primary active Hh ligand in mammary 
development. All three Hh ligand expression are observed in postnatal mice 
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mammary gland by RT-PCR, whereas in the in situ hybridization experiments only 
Ihh expression is detected, which proves the importance of the Ihh in the mammary 
development [Michno et al., 2003]. In the alveolar epithelium Ptch1 mRNA 
expression increases with the pregnancy, but stays same in the stroma. Gli2 
expression becomes both stromal and epithelial in the pregnancy and lactation. 
Increased expression of Ihh in the pregnancy may inhibit the Ptch1 and activate the 
downstream pathway. As a result Gli2 expression may be induced in the epithelium 
and acts as transcriptional activator for the target genes. 
 
Effects of Hh signaling on the proliferation and differentiation of the mammary 
mesenchyme have not been described. 
 
1.2.4. Hedgehog Signaling and Cancer 
 
Distinct tissues require specific levels of Hh signaling for proper functioning. Any 
increase or decrease in the signaling activity results in severe defects. Although Hh 
signaling is one developmental pathway, it is expressed in some mature cell types 
and its deregulation leads to tumor progression in these tissues.  
 
Table 1.3, Table 1.4 and Table 1.5 shows the Hh pathway with relation to cancer. 
The importance of hedgehog signaling in carcinogenesis has been demonstrated by 
the fact that many of the genes involving Hh signaling are known oncogenes, 
including SMO, SHH, GLI1, and GLI2, or that PTCH1 can function as a tumor 
suppressor. Mutations in these genes causes to the development of many common 
cancers, which are shown to be dependent on activated Hh signaling. These 
mutations both include inactivating mutations in the PTCH and activating mutations 
in SHH and SMO.  
 
GLI1 is first identified as an amplified gene in malignant glioma cells. 
Overexpression of the Gli1 in mouse skin results in rapid and spontaneous 
development of basal cell carcinoma (BCC), cylindromas, and trichoblastomas 
[Toftgard, 2000]. These tumors show increased expression of Ptch1 and Sufu. 
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Individuals with naevoid basal cell carcinoma syndrome (NBCCS) have an inherited 
mutation in one of the PTCH1 alleles. Cancer develops by inactivation of the 
remaining allele. In nearly 40% of sporadic BCC, a PTCH1 mutation is detected.  
Most of the mutations lead to premature protein production [Wicking et al., 2001]. In 
animal models, any activating mutation of the pathway is sufficient for the 
development of BCC. Ectopic expression of Shh, Gli1, or Gli2 results in lesions 
similar to human BCC [Wetmore, 2003]. 
 
Table 1.3: Animal models of Hedgehog-dependent tumors [Magliano et al., 2003] 
Animal model Phenotype Species 
Shh overexpression in the skin 
K14 promoter 
BCC Mouse 
Ptch inactivation Medulloblastoma and other 
tumors 
Mouse 
Smo-M2 overexpression in the 
skin K5 promoter 
BCC Mouse 
Gli1 overexpression in the skin BCC, trichoepithelioma Mouse 
Gli2 overexpression in the skin BCC Mouse 
Gli2 overexpression in the skin Skin tumors with BCC-like 
characteristics 
Xenopus 
Gli1 overexpression in the 
brain 
Hyperproliferation of 
progenitor cells 
Xenopus 
 
Human patients with Gorlin’s syndrome have inherited mutations in PTCH gene 
(Table 1.4). Patients suffering from Gorlin’s syndrome develop BCC and sporadic 
medulloblastomas [Ruizi i Altaba et al., 2004]. PTCH mutations are also observed in 
desmoplastic sporadic medulloblastoma. Most of these mutations are loss of 
heterozygosity (LOH) [Toftgard, 2000]. There are additional mutated genes of the 
Hh pathway playing a role in development of medulloblastoma, in which mutations 
of SUFU is important. In 9% of sporadic human medulloblastomas truncating 
mutations of SUFU are observed. There is upregulation of GLI1 and GLI2 mRNA 
level in medulloblastomas showing the active pathway in these tumors.  
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Table 1.4: Mutations in the PTCH1 gene [Hahn et al., 1996] 
Sample Type Inheritance Exon Type of Mutation Designation 
NBCCS Familial 8 Premature stop C1081T 
NBCCS Familial 6 37 bp deletion del 804-840 
NBCCS Familial 8 Premature stop G1148A 
NBCCS Familial 13 2 bp insertion 2047insC 
NBCCS Sporadic 13 1 bp insertion 2000insC 
NBCCS Sporadic 15 1 bp deletion 2583delC 
BCC Sporadic 8 Premature stop CC1081TT 
BCC Sporadic 16 14 bp deletion del2704-2717 
 
Sporadic and inherited mutations of human SHH gene cause holoprosencephaly 
(HPE), a severe midline defect including cleft lip and palate, single maxillary incisor, 
impaired CNS septation, and phenotypes ranging from hypotelorism to a single 
cyclopic eye.  
 
In normal conditions in the mature cell types, Hh signaling regulates cell 
proliferation through expressional regulation of cyclin D and cyclin E [Magliano et 
al., 2003]. Myc transcription factors are transcriptional targets of the Hh signaling 
and they are important inducers of cell proliferation. Berman et.al.  (2002) showed 
that expression of c-MYC, l-MYC, and n-MYC is decreased in medulloblastomas by 
cyclopamine treatment. Furthermore, PTCH regulates the activity of cyclin B, a part 
of mitosis-promoting-factor (MPF), by interacting in the cytoplasm, hence 
preventing the nuclear localization of the activated complex [Barnes et al., 2001; 
Magliano et al., 2003]. In response to SHH stimulation PTCH relieves the cyclin B, 
and the cell enters mitosis. Dysregulation of Hh signaling results in uncontrolled cell 
proliferation in these cells. 
 
Several foregut-derived tumors require ligand-dependent activation of the pathway 
(Table 1.5). In cancers of lung, esophagus, stomach, and pancreas SHH and IHH are 
expressed from the tumor cells and taken by the same cells as well [Watkins et al., 
2004; Berman et.al, 2002].  
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Table 1.5: Hedgehog-dependent primary human tumors  
Gene Tissue  Expression Method % of sample References 
SHH Pancreas upregulated In situ, IHC 70% in 20 
Thayer et al., 
2003 
PTCH1, 
GLI1 Stomach upregulated In situ 64% in 99 Ma et al., 2005 
PTCH1 Prostate upregulated IHC 
70% in 22 
high score Sheng et al., 2004 
GLI1 Lung (SCLC) upregulated IHC 65% in 40 
Vestergaard et 
al., 2006 
SHH Colon upregulated q-rt-RT-PCR 
82% in 57 (t-
n) 
Manzo et al., 
2006 
GLI1 Breast upregulated IHC 100% in 52 Kubo et al., 2004 
SHH Colon upregulated RT-PCR 
86% in 44 (t-
n) 
Douard et al., 
2006 
GLI1 Skin upregulated q-rt-RT-PCR 47% in 68 Hatta et al., 2005 
SHH Pituitary adenoma downregulated IHC 100% in 55 Vila et al., 2005 
SHH Liver upregulated In situ 60% in 115 
Huang et al., 
2006 
PTCH1 Liver upregulated In situ 56% in 115 
Huang et al., 
2006 
GLI1 Liver upregulated In situ 70% in 115 
Huang et al., 
2006 
PTCH1 Pancreas upregulated RT-PCR, IHC 71% in 28 Shao et al., 2006 
SMO Pancreas upregulated RT-PCR, IHC 54% in 28 Shao et al., 2006 
IHH Pancreas upregulated q-rt-RT-PCR 100% in 31 
Kayed et al., 
2004 
PTCH1 Skin upregulated q-rt-RT-PCR 100% in 27 
Bonifas et al., 
2001 
GLI1 Skin upregulated q-rt-RT-PCR 100% in 12 
Bonifas et al., 
2001 
 
Despite the liver’s requirement for Hh signaling during embryogenesis, mature 
hepatocytes lack Hh pathway activity [Sicklick et al., 2006]. Expression of SHH was 
detectable in about 60% of 115 cases of hepatocellular carcinoma (HCC) examined. 
Furhermore, Hh target genes PTCH1 and GLI1 were expressed in over 50% of the 
tumors, concluding that the Hh pathway is frequently activated in HCCs [Huang et 
al., 2006]. Overexpression of the SMO, as well as an increase in the stoichiometric 
ratio of SMO to PTCH1 mRNA levels, correlated with tumor size. Overexpression 
and/or tumorigenic activation of the SMO mediate c-MYC overexpression which 
plays a critical role in HCC progress and makes SMO a good prognostic factor in 
HCC tumorigenesis [Sicklick et al., 2006]. Quantitative real-time RT-PCR also 
revealed the decreased expression of HIP1 and increased expression of GLI1 and 
SMO in HCC samples compared with nontumor liver tissues [Patil et al., 2006]. 
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Hh signaling is also required for the maintenance of the tumor. Transformed cells 
require Hh activity for survival and growth. Cyclopamine treatment induces 
apoptosis and loss of proliferation in the cancer cells. Cyclopamine is a natural 
steroidal alkaloid that induces Hh blockage without interfering with the generation or 
processing of the ligand [Cooper et al., 1998; Incardona et al., 1998]. It directly 
binds to the heptahelical bundle of the Smo protein [Watkins et al., 2004]. 
 
1.2.5. Hedgehog Signaling and Breast Cancer 
 
Several signaling pathways function in the regulation of mammary stem cells such as 
Wnt, Notch, Hedgehog, and TGF-β. Dysregulation of these pathways in the 
mammary gland induce mammary tumors in transgenic mice [Li et al., 2005].  
 
Similarities between hedgehog mutation-induced ductal dysplasias and human breast 
pathologies suggest a role for altered hedgehog signaling in the development of 
mammary cancer [Lewis et al., 2004]. There is also evidence that altered hedgehog 
signaling has a direct role in the neoplastic progression of the mammary gland. One 
study showed PTCH1 mutation in two of seven human breast cancers [Xie et al., 
1997]. Recently, a polymorphism in the 3’end of the PTCH1 coding region 
(C3944T;Pro1315→Leu) has been linked to increased breast cancer risk associated 
with oral contraceptive use [Chang-Claude et al., 2003]. Evidence for a role in breast 
cancer also comes from published genetic studies in mice showing hyperplastic 
defects in the mammary gland of ∆Ptch1 + and ∆Gli1 mutants [Lewis et al., 2004]. 
When compared to adjacent tissues breast cancer samples have higher intensity GLI1 
staining in immunohistochemistry experiments. Cyclopamine is able to inhibit the 
growth of mammary carcinoma cells in vitro [Kubo et al., 2004]. 
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1.3. MEASUREMENTS OF GENE EXPRESSION WITH 
QUANTITATIVE REAL TIME RT-PCR 
 
Many applications in medicine or research require detection of the number of 
specific targets in the specimen [Mocellin et al., 2003]. Northern blotting, RNase 
protection assays, and polymerase chain reaction (PCR)-based methods are applied 
to quantify mRNA amount. The most sensitive one of these methods is PCR based 
ones with its combination with reverse transcription (RT) [Fronhoffs et al., 2002]. 
Since it requires a minute amount of mRNA it is more advantageous to perform PCR 
rather than other methods.  
 
PCR is the method to detect as little as a single copy of a particular sequence of DNA 
and RNA. In theory there is a quantitative relationship between the amount of 
starting sequence and amount of PCR product at a given cycle. This is not the case in 
practice since the PCR product increases in every cycle. Reverse transcription PCR 
(RT-PCR) is a kind of PCR used to detect expression level of a gene at mRNA level 
[Pfaffl, 2001]. Gene expressional differences between tissues, disease states, and 
treatments can be revealed by using quantitative RT-PCR [Pfaffl, 2001; Bustin et al., 
2004a].  
 
Quantitative real-time RT-PCR (q-rt-RT-PCR) is one of the methods that is 
developed for quantitative measurement of the gene expression levels [Pfaffl, 2001; 
Mocellin et al., 2003]. It has many advantages over the traditional RT-PCR 
[Fronhoffs et al., 2002; Wong et al., 2005]. Firstly it is simple, has a wide dynamic 
range of quantitation and allows high throughput screening at one time. Secondly, it 
is reproducible, accurate, specific, and sensitive. It can detect as few as 10 initial 
template copies [Fronhoffs et al., 2002]. Besides, gene expression differences as 
small as 23% between samples can be detected by q-rt-RT-PCR [Wong et al., 2005]. 
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In a PCR reaction there are four major phases: the linear ground phase, early 
exponential phase, log-linear (exponential) phase, and plateau phase [Wong et al., 
2005]. In the linear ground phase PCR just begins and fluorescence does not exceed 
background. Calculation of baseline fluorescence is performed at that phase (Figure 
1.9). In early exponential phase fluorescence exceeds the background and Ct value is 
measured. The Ct value is used as measurement unit in the real-time RT-PCR. It is 
the cycle number at which fluorescence reaches a threshold value of ten times the 
standard deviation of baseline fluorescence emission [Mocellin et al., 2003; Wong et 
al., 2005]. The Ct value is inversely proportional to the amount of starting material. 
The threshold value is the point at which a reaction reaches a fluorescent intensity 
above background. It should be in the linear part of the reaction. The program 
automatically determines the Ct value of the sample. In the third phase, the PCR 
reaction reaches its optimal amplification period in which PCR doubling in each 
cycle is ideal. In the plateau phase reaction components become rate limiting agents. 
 
 
Figure 1.9: Amplification Curve: When fluorescent signal reaches to detectable 
level it is displayed as an amplification curve. The point at which the amplification 
curve reaches to the threshold level is called the Ct value 
[http://www.appliedbiosystems.com] 
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There are several considerations when designing primers for q-rt-RT-PCR. The 
optimal PCR product length is approximately 100 to 200bp for SYBR Green. The 
forward and the reverse primer should have similar melting temperatures within 
0.5oC of each other. The primers should have low or no self complementarities in 
order to avoid the formation of primer dimers. Primers that span introns or cross 
intron/exon boundaries are advantageous because they allow the distinction of cDNA 
from genomic DNA contaminations.  
  
1.3.1. Detection Chemistries 
 
There are specific and non-specific detection chemistries used in real-time RT-PCR. 
In non-specific method, DNA intercalating dyes are used. Probes and molecular 
beacons are the molecules used in the specific chemistry. In the specific chemistry, 
fluorescent resonance energy transfer (FRET) or similar interactions between the 
donor and quencher molecules form the basis of detection system [Bustin et al., 
2004a].  
 
The most simple detection method in real-time RT-PCR requires a dye that emits 
fluorescent light when intercalated into double-stranded DNA (dsDNA) but not to 
single-stranded DNA. The intensity of the fluorescence signal is proportional to the 
amount of all double-stranded DNA present in the reaction [Wong et al., 2005]. In 
the first experiments ethidium bromide and YO-PRO-1 were used as intercalating 
dyes. However, by ethidium bromide it is not possible to distinguish between the 
amounts of the ssDNA and the dsDNA. Currently, SYBR Green I is the most 
frequently used one. SYBR Green I is a binding dye for ds DNA. It binds to the 
minor groove of the ds DNA and increases the fluorescence over a hundred fold. 
SYBR Green I is preferred to other methods in most cancer studies due to the usage 
of high number of genes and sample input. It is more precise, and produces more 
linear decay plot than the TaqMan detection system [Bustin et al., 2004b]. Since 
these intercalating dyes can bind to every ds-DNA this technique can be used in 
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different gene assays [Wong et al., 2005]. In addition they are cheaper because of the 
lack of probe associated cost [Bustin et al., 2004a]. 
 
1.3.2. Quantification Strategies 
 
The quantification strategy is the most important part of the real-time RT-PCR. It 
depends on the target sequence, expected amount of the mRNA, and degree of 
accuracy required [Pfaffl, 2001]. 
 
Two strategies can be performed in real-time RT-PCR: absolute and relative 
quantitative real-time RT-PCR [Pfaffl, 2001]. Absolute quantification relates the 
PCR signal to input copy number using a calibration curve, while relative 
quantification measures the relative change in mRNA expression levels. The 
reliability of an absolute real-time RT-PCR assay depends on the condition of 
‘identical’ amplification efficiencies for both the native target and the calibration 
curve in RT reaction and in the following kinetic PCR. Therefore, it should be used 
in the analysis where the determination of exact copy number is necessary. In most 
analyses it is enough to determine the relative change in the expression of the gene. 
In these cases, relative quantification is easier to perform than absolute quantification 
since there is no need for a calibration curve. It is based on the expression levels of a 
target gene versus a housekeeping gene (reference gene). The units used to express 
relative quantities are irrelevant and the relative quantities can be compared across 
multiple real-time RT-PCR experiments.  
 
Relative quantification determines the changes in steady-state mRNA levels of a 
gene across multiple samples and expresses it relative to the levels of an internal 
control RNA [Pfaffl, 2001]. This reference gene is often a housekeeping gene and 
can be co-amplified in the same tube in a multiplex assay or can be amplified in a 
separate tube [Huggett et al., 2005]. Therefore, relative quantification does not 
require standards with known concentrations and the reference can be any transcript, 
as long as its sequence is known. To calculate the expression of a target gene in 
relation to an adequate reference gene various mathematical models are established. 
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Calculations are based on the comparison of the distinct cycle determined by various 
methods, e.g. crossing points (CP) and threshold values (Ct) at a constant level of 
fluorescence; or CP acquisition according to established mathematic algorithm. To 
date, several mathematical models that calculate the relative expression ratio have 
been developed. Relative quantification models without efficiency correction are 
available (equations 1.1, 1.2). 
 
Equation 1.1:     R=2-[∆Ctsample-∆Ctcontrol] 
 
                                             Equation 1.2:      R= 2-∆∆Ct 
 
In equation 1.2, the first ∆Ct is for the target gene and the second ∆Ct is for the 
housekeeping gene.  
 
With kinetic PCR efficiency correction, the relative expression ratio of a target gene 
is calculated based on its real time PCR efficiency (E) and the difference between Ct 
(CP) values of the unknown sample versus the control sample. By dividing 
expression ratio of the target gene to the reference gene relative quantification is 
performed [Pfaffl, 2001]. 
 
Equation 1.3:  R= [(E target) ∆Cttarget (control-sample)] / [(E reference) ∆Ctreference (control-sample)] 
 
For a standard curve with ½ serial dilutions: 
 
Equation 1.4: Exponential amplification = 2(-1/slope) 
Equation 1.5: Efficiency = [2(-1/slope)]-1 
 
Since there is no need for an external calibration curve, hence artificial nucleic acids, 
relative expression studies are rapid and sensitive methods. They are adequate for 
most studies of physiological expression changes with minimal error rate [Pfaffl, 
2001].  
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1.3.3. Normalization 
 
Housekeeping genes are expressed in all nucleated cells and required for cell survival 
[Thellin et al., 1999]. Thus, accurate normalization of quantitative RT-PCR data 
requires knowledge of which housekeeping gene or genes are expressed at equal or 
similar levels within a group of samples [Vandesompele et al., 2002]. Many 
techniques developed for mRNA quantification use housekeeping genes as internal 
standards. Beta actin (ACTB) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) have been historically considered to be adequate housekeepers for 
normalization of gene expression.  However, studies show that their expression may 
be regulated as well between different tissues [Bereta et al., 1995; Chang et al., 
1998]. This is partly explained by their participation to other functions in different 
cell types [Singh et al., 1993; Ishitani et al., 1996]. GAPDH has been found to be 
regulated by biphosphonates in breast cancer cell lines [Valenti et al., 2006]. The 
researcher should find the most suitable reference gene for his/her experimental 
setup. For this purpose, several excel based programs have been developed [Huggett 
et al., 2005]. The program, geNorm, finds the best reference gene by using the 
geometric mean of the reference gene expression of sample cDNAs. The software is 
free and can be downloaded from http://medgen.ugent.be/~jvdesomp/genorm/. 
BestKeeper and Norm-Finder are other software developed for the same purpose 
[Huggett et al., 2005]. They also use the geometric mean of the expressions. In 
addition, Norm-Finder ranks the potential reference genes by how much they differ 
between the samples. It is available at http://www.mdl.dk.  
 
1.3.4. Melt Curve Analysis 
 
In real-time PCR, the melting point of the PCR product is determined by raising the 
temperature by a fraction of a degree and measuring the changes in fluorescence 
[Ririe et al., 1997]. Plotting the fluorescence as a function of temperature during the 
thermal cycler heats up to dissociation temperature gives the melting curve. The 
software plots the rate of change of the relative fluorescence units (RFU) with time 
(T) (-d (RFU)/dT) on the Y-axis versus the temperature on the X-axis, and this will 
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peak at the melting temperature (Tm) [http://pathmicro.med.sc.edu/pcr/realtime-
home.htm]. The melting point of a DNA sample depends on its base composition and 
length. Therefore all PCR products for a particular primer pair should have the same 
melting point. If there are different melting points that means there is contamination, 
mispriming, and primer-dimer artifacts. In real-time PCR reactions performed with 
SYBR green specificity is provided by drawing the melting curve.  
 
1.4. AIM AND STRATEGY 
 
Signaling pathways having role in development cross talks each other and 
deregulation in one pathway affects the others. For this reason it is important to study 
developmentally important signaling pathways in cancer since deregulation of these 
pathways is crucial for cancer development. One pathway that is important in 
regulating patterning, proliferation, survival and growth in the embryo and adults is 
the Sonic Hedgehog (Shh)-Gli signaling pathway. Uncontrolled activation of this 
pathway results in cancer development. 
 
We aimed to identify the expression profile of the genes that play major roles in the 
Hedgehog signaling pathway in epithelial cancers; breast, colon, and hepatocellular 
carcinoma by using real time quantitative-reverse-transcriptase PCR technique. 
 
The strategy was as follows: 
 
• Seven genes that play major roles in the Hh pathway (SHH, IHH, SMO, 
PTCH1, GLI1, GLI2 and GLI3), and a downstream target of Hh pathway 
which has an important role in cancer progression, BCL2, and four house 
keeping genes, GAPDH, ACTB, TBP, and SDHA, were selected for the gene 
expression analysis. 
• Fifteen breast, 14 colon, and 15 hepatocellular carcinoma (HCC) cell lines 
and 29 primary breast tumor samples and three matched normal tissue sample 
pools were used in this study. 
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• The total RNAs were isolated from each sample and used for OligodT 
primed-cDNA synthesis.  
• The gene specific primers were designed for q-rt-RT-PCR analysis. 
• Primer amplification efficiencies were determined for each primer pair. 
• Melt curve analysis of each gene were performed with q-rt-RT-PCR by using 
Bio-Rad icycler machine for each sample. 
• Quantification of mRNA expression values of each gene was calculated by 
using efficiency corrected relative quantification method. 
• Geometrical mean of ACTB, SDHA, and TBP1 reference gene expression 
values were used for normalization of the breast tissue samples and GADPH 
expression values were used for normalization of  the cell lines. 
• Multivariate statistical methods such as Cluster, Discriminant Function 
Analysis, and Multidimensional Scaling were used to analyze the data. 
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CHAPTER 2 
 
 
MATERIALS & METHODS 
 
 
2.1. TISSUE CULTURE 
 
Breast carcinoma, hepatocellular carcinoma (HCC), and colon carcinoma cell lines 
used in this thesis are shown in Table 2.1, Table 2.2, and Table 2.3 respectively. All 
cell lines were grown in 150 mm culture dishes as monolayer. Cells were grown in 
Dulbecco’s Modified Eagle Medium (DMEM) supplied with 10% FBS and 50mg/ml 
penicillin/streptomycin. 
 
HME1 (Clontech, California, USA), a normal epithelial cell line immortalized with 
hTERT expression, was used as normal control for breast cancer cell lines. The 
growth medium of HME1 was different from others and prepared with equal 
amounts of HAM’S F-12 Medium and DMEM supplemented with 10% FBS, 
100U/ml penicillin, 100µg/ml streptomycin, 2mM L-glutamine, 0.1mM non-
essential amino acids, 10mM HEPES Buffer, 3.5ng/ml insuline, 0.1mg/ml EGF, and 
0.5µg/ml hydrocortisone.  
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Table 2.1: Breast carcinoma cell line information 
 
Breast Cancer 
Cell Lines 
ATCC 
Number Cancer Type ER Statusa 
MDA MB 157 HTB 24 Medulallary carcinoma N 
MDA MB 231 HTB 26 Adenocarcinoma N 
MDA MB 361 HTB 27 Adenocarcinoma P 
MDA MB 453 HTB 131 Metastatic carcinoma N 
MDA MB 468 HTB 132 Adenocarcinoma N 
BT 474 HTB 20 Ductal carcinoma P 
BT 20 HTB 19 Carcinoma P 
MCF 7 HTB 22 Adenocarcinoma P 
MCF 12A CRL 10782 Non-tumorigenic epithelial cell line  P 
HCC 1937 CRL 2336 Primary ductal carcinoma N 
CAMA 1 HTB 21 Adenocarcinoma P 
SK BR 3 HTB 30 Adenocarcinoma N 
ZR 75.1 CRL 1500 Ductal carcinoma P 
T47D HTB 133 Ductal carcinoma P 
HBL100 HTB 124 Tumorigenic epithelial cell line N 
Htert- HME 1 CRL 4010 Epithelial; immortalized with hTERT N 
 
aER: Estrogen receptor 
 
 
Table 2.2: Hepatocellullar carcinoma cell line information 
 
HCC Cell Lines ATCC Number Differentiation Status 
SNU182 CRL-2235 Poor 
SNU387 CRL-2237 Poor 
SNU398 CRL-2233 Poor 
SNU423 CRL-2238 Poor 
SNU449 CRL-2234 Poor 
SNU475 CRL-2236 Poor 
HEP3B HB 8064 Well 
HEP3B TR  M. Ozturk Well 
HEP40  M. Ozturk Well 
HEPG2 HB 8065 Well 
SKHEP1 HTB52 Poor 
HUH7  JCRB database Well 
PLC/PRL/5 CRL-8024 Well 
FOCUS  M. Ozturk Poor 
MAHLAVU  M. Ozturk Poor 
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Table 2.3: Colon carcinoma cell line information 
 
Colon Cancer Cell Lines ATCC Number 
SW620 CCL-227 
SW480 CCL-228 
SW48 CCL-231 
HCT8 CCL-244 
HCT15 CCL-225 
HT29 HTB-38 
TC71  R. Hamelin 
T7  R. Hamelin 
LOVO CCL-229 
LS411 CRL-2159 
COLO205 CCL-222 
CO115  R. Hamelin 
W05  R. Hamelin 
KM12  R. Hamelin 
 
All cell lines were cultured at a 37oC incubator with an atmosphere of 5% CO2 in air 
(Heto-Holten, Surrey, UK). All applications were performed under sterile laminair 
hoods (Heto-Holten, Surrey, UK) in cell culture facility. All media and solutions 
used for tissue culture were kept at 4oC and preheated to 37oC before use.  
 
2.1.1. Cryopreservation of cell lines 
 
Exponentially growing cells were harvested by trypsinization and neutralized by 
adding fresh growth medium. The cells were counted and precipitated at 1500 rpm 
for 5 minutes. The cells were resuspended with freezing medium at a concentration 
of 4x106 cells/ml/vial. Freezing medium was made up 90% FBS and 10% DMSO 
and stored in the cryotubes. Cryotubes were incubated at -20oC for 1 hour, at -80oC 
overnight and transferred to the liquid nitrogen tank for long term storage. 
 
2.1.2. Cell Line Culturing 
 
The frozen stocks of the cell lines were kept in a liquid nitrogen tank for long term 
storage. The cells were thawed quickly at 37oC and mixed with 5 µl growth medium 
and centrifuged at 1500 rpm for 5 minutes at room temperature. Supernatant was 
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removed and the cells were resuspended with fresh complete growth medium. Cells 
were grown in the 10 mm cell culture plates in the incubator. 
 
2.1.3. Subculturing the cells 
 
The cells were grown at a confluence of approximately 80%. The old medium was 
aspirated and the cells were washed with 1X PBS two times. 2µL Trypsin/EDTA 
solution was added and the cells were left for incubation for 3 to 4 min. When cells 
were detached from the surface of the plate, trypsin was inactivated by adding fresh 
growth medium. Cells were then transferred into the new plates.  
 
2.1.4. Preparation of cell pellets 
  
The cell pellets were collected to freeze down and stored for mRNA or protein 
preparation. When cells were 70-80% confluent, medium was aspired and cells were 
washed with ice cold 1X PBS once. Then 3ml of cold 1X PBS was added and cells 
were collected by using a scrapper. Then cells were centrifuged at 1500 rpm for 5 
minutes at 4oC and supernatant was removed. Cell pellet were stored at -80oC for 
further experiments.  
 
2.1.5. Tumor Samples 
 
The primary breast tumor and matched normal tissue samples were obtained from 
Ankara Numune Education and Research Hospital. The tissue samples were 
collected freshly after surgical operation and then snap frozen in liquid nitrogen. 
Tissue specimens were stored at -80oC. Then the frozen tissues were used for further 
experiments. The pathological analysis of primary breast tumor samples is given in 
the Table 2.4.   
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Table 2.4: Primary breast tumor sample information 
 
Name 
Cancer 
Type bLN Grade Stage Age 
eER 
status 
fPR 
status 
ErbB2 
status gTumor % 
MFT14 aIDC cP   4 40 P P   90 
MFT16 IDC dN 2 2A 39 P P N 100 
MFT21 IDC P 3 4 60 N N N 90 
MFT25 IDC P 3 3A 51 P P N 100 
MFT40 IDC P 3 4 48       100 
MFT41 IDC P 2 2B 28 N P P 100 
MFT49 IDC P 2 2A 43 P P P 100 
MFT78 IDC P 2   69 P P P 60 
MFT79 IDC P 3 2A 24 N N P 90 
MFT90 IDC P 2 2B 32 P P P 100 
MFT94 IDC N 3 2A 37 N N N 100 
MFT95 IDC P 3   54 P P N 80 
MFT97 IDC P 2 3B 43       80 
MFT113 IDC P 1 3B 63 P N P 100 
MFT115 IDC N 3 2A         80 
MFT116 IDC P 1 1 74 N N P 90 
MFT117 IDC   2 4   N N P 90 
MFT120 IDC N 2 2B 50       100 
MFT124 IDC P 1 2A 57 P N P 90 
MFT125 IDC P 3 2A 30 N N P 100 
MFT127 IDC P 2 2A   N N   50 
MFT129 IDC P 2 2A 58 N N N 80 
MFT131 IDC P 2 2B 53 N P P 90 
MFT132 IDC N 3 2B 68 N N P 100 
MFT149 IDC P 3 2B 56       95 
MFT154 IDC P 3 3B 32 N N P 95 
MFT155 IDC N 3 1 54       95 
MFT173 IDC P 3 3B 60 P P N 90 
MFT174 IDC P 1 2B 44 N N P 90 
 
aIDC: Infiltrating ductal carcinoma; bLN: lymph node; cP: positive; dN: negative; eER: estrogen 
receptor; fPR: progesterone receptor; gTumor %: tumor percentage in pathological sections 
 
The tissue sections were cut by using a cryostat and 5µm sections were transferred 
on to the slides. The slides were stained with hematoxylin for 2 minutes washed 
under the tap water and rinsed with acid alcohol (1%) respectively. Then the slides 
were gently washed with 1% ammonia water (v/v) and rinsed under the tap water and 
stained with Eosin for one minute followed by tap water rinses. The slides were 
immersed in 70%, 90% and 100% ethanol respectively and air-dried. As a last step 
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the slides were rinsed in xylene and mounted with coverslips with mounting medium. 
The samples were sent to a pathologist for the evaluation of the tumor percentage in 
the tissue sections. The tumor samples with high tumor percentage and no tumor 
cells in the normal counterparts were chosen for further analysis. 
 
2.2. RNA ISOLATION  
 
Before RNA isolation all the solutions and materials were treated with DEPC in 
order to avoid RNase contamination and hence degradation of RNA. Total RNA of 
tumor tissues was isolated with TRI reagent (AppliChem, Germany). Tissues were 
lysed in 1ml TRI reagent and passed through a 21-gauge needle several times. After 
5 min incubation at room temperature, 0.2ml chloroform was added per ml of TRI 
reagent. Tubes were shaken vigorously by hand for 15 seconds and incubated at 
room temperature for 2-3 min. After incubation the mixture was centrifuged at 
12000xg for 15 min at 4oC and then aqueous phase was collected into a new tube. 
0.5ml isopropanol was added per 1ml of TRI reagent. The mixture was incubated at 
room temperature for 10 min and then centrifuged at 12000xg for 10 min at 4oC to 
recover RNA. The supernatant was removed and pellet was washed with 75% 
ethanol twice. Mixture was centrifuged at 7500xg for 5 min at 4oC and pellet was air-
dried. Dried pellet was dissolved in ddH2O and to remove contaminating DNA RNA 
isolation was repeated by use of NucleoSpin RNA II kit (Macherey & Nagel, 
Germany). The total RNA isolation of cell line pellets was performed directly by use 
of NucleoSpin RNA II kit. Isolated RNAs were stored at -80oC. The concentrations 
of RNA samples were measured by ND-1000 Spectrophotometer (Nanodrop 
Technologies, Inc., Wilmington, USA). 
 
2.3. cDNA PREPARATION 
 
The cDNA samples were synthesized from the total RNA samples with the 
RevertAid First Strand cDNA Synthesis Kit (MBI Fermentas, Ontario, Canada) 
according to manufacturer’s protocol. All cDNAs were made from 1 µg of RNA and 
stored at -20oC. 
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2.4. OLIGONUCLEOTIDES 
 
The gene specific primers used in RT-PCR and real-time RT-PCR were designed by 
Primer 3 program [http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi] and 
purchased from Iontek Inc. (Bursa, Turkey). The forward and reverse primers were 
designed to intron/exon boundaries wherever it was possible, otherwise designed to 
take an intronic sequence between them. The primer sequences are given in Table 
2.5.  
 
Table 2.5: Oligonucleotide sequences 
 
Gene Accession Number Sequence (5’ to 3’) Size (bp)a 
GLI1-F NM_002181 CACCGAGGGCCCACTCTTTT-3' 154  
GLI1-R   TCGCGAGTTGATGAAAGCTA-3'   
GLI2-F NM_005270 CCCACTCCAACGAGAAACCC-3' 96  
GLI2-R   GGACCGTTTTCACATGCTTCC-3'   
GLI3-F NM_000168 CAGCAAGTGGCTCCTATGGT 116  
GLI3-R   TTGTCGGCTTAGGATCTGCT   
SHH-F NM_000193 GTGGCCGAGAAGACCCTA 177  
SHH-R   CAAAGCGTTCAACTTGTCCTTA   
IHH-F NM_002181 TCACCACATCAGACCGCGAC 127  
IHH-R   GAGTGCTCGGACTTGACGGA   
PTCH1-F NM_000264 CTCACGTCCATCAGCAATGT 147  
PTCH1-R   CATGCTGAGAATTGCAGGAA   
SMO-F NM_005631 CTGCACGAATGAGGTGCAGA 149  
SMO-R   GCTCAGCCTCTGTGAAGAGC   
BCL2-F NM_000657 ACTGAGTACCTGAACCGGCA  123 
BCL2-R   CTTCAGAGACAGCCAGGAGA   
GAPDH-F NM_002046 GGCTGAGAACGGGAAGCTTGTCAT 150  
GAPDH-R   CAGCCTTCTCCATGGTGGTGAAGA   
TBP-F NM_003194 TGCACAGGAGCCAAGAGTGAA 132  
TBP-R   CACATCACAGCTCCCCACCA   
ATCB-F NM_001101 CCAACCGCGAGAAGATGACC 124  
ACTB-R   GGAGTCCATCACGATGCCAG   
SDHA1-F NM_004168 TGGGAACAAGAGGGCATCTG 86  
SDHA1-R   CCACCACTGCATCAAATTCATG   
 
abp: base pair
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2.5. REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-
PCR) 
 
Primers designed for the real-time RT-PCR were first checked with PCR to 
determine their optimal working conditions. Polymerase Chain Reaction (PCR) was 
performed to amplify the desired DNA fragments from cDNAs using the thermal 
cycler TechGene (Techne Inc., New Jersey, USA). A reaction mixture of 2.5ml 10X 
reaction buffer, 1.5ml MgCl2 (25mM), 0.5ml dNTP (10µM), 1ml of each primer (10 
pmol), and 0.5ml Taq DNA polymerase (5u/µL) was prepared per 1ml cDNA.   
 
Initial denaturation 95.0oC  5 min 
Denaturation          95.0oC  30 sec 
Annealing              A.T.      30 sec  30 cycles 
Extension              72.0oC   30 sec  
Final extension     72.0oC   5 min 
 
A.T. is the annealing temperature at which the primer pair binds to its specific gene.  
 
2.6. QUANTITATIVE REAL TIME RT-PCR 
 
Amplification efficiency for each primer was tested by using standard two-fold 
dilution series of the breast cancer cell line cDNAs. The general approach is to 
choose a cell line that shows the highest expression level for a particular gene to 
determine the amplification efficiency. The expression of the genes varies between 
the cell lines. For each gene a different cell line was used for amplification efficiency 
analysis. The real-time RT-PCR reactions were carried out in iCycler (Bio-Rad, 
California, USA). After the amplification steps, a melting curve analysis was by 
performed raising the temperature by 0.5oC and measuring the change in 
fluorescence. Starting temperature was 55oC and ending temperature was 94oC. Each 
PCR reaction was made in duplicates from the same reaction mixture.  
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Six candidate reference genes which belong to different functional classes were 
chosen for stability analysis, which are ACTB, SDHA, TBP, HPRT, GAPDH, and 
HMBS. 30 tumor and matched normal tissues were analyzed by geNorm and Norm-
Finder software tools to find out most stably expressed housekeeping genes for 
breast tumor samples studied. ACTB, SDHA, and TBP were the housekeeping genes 
with most stable expression pattern in primary breast tumor samples. 
 
Analysis of relative expressions were performed by use of the comparative Ct 
method. For the cell lines, GAPDH was used as reference gene. For the breast cancer 
tumor samples, geometric mean of the expression values of ACTB, TATA-binding 
protein (TBP), and succinate dehydrogenase complex subunit A (SDHA) were used 
as reference gene. For the colon and hepatocellular carcinoma cell lines, geometric 
average of expression level of these cell lines were used as the control sample. 
hTERT cell line was used in the breast cancer cell lines, and the geometric mean of 
three normal sample pools was used in the breast tumor samples as the control 
sample.  
 
Table 2.6: Breast normal sample pool information  
 
Pool Name Normal braest samples 
MFN P1 MFN21, MFN41, MFN 49 
MFN P2 MFN95, MFN113, MFN116 
MFN P3 MFN120, MFN125, MFN129 
 
The real-time RT-PCR reaction mixture was made up of 6.25µl SYBR Green mix 
(Bio-Rad, California, USA), 0.5µl of each primer (10 pmol), and 4.25µl ddH2O. 
12.5µl mineral oil was added to cover top of the mixture to prevent evaporation.  
 
Initial denaturation   94.0oC  3 min 
Denaturation            94.0oC  30 sec 
Annealing                A.T.      30 sec 50 cycles 
Extension                 72.0oC  30 sec 
 
 48
2.7. AGAROSE GEL ELECTROPHORESIS 
 
PCR products were fractionated by horizontal gel electrophoresis in 2% (w/v) 
agarose gel by using 1xTAE buffer. Agarose was completely dissolved in 1xTAE 
electrophoresis buffer in the desired percentages. Ethidium bromide solution was 
added to final concentration of 30ng/ml for visualization. 2 µl 6X DNA loading dye 
was added to 10 µl of quantitative real time RT-PCR (q-rt-RT-PCR) products and 12 
µl of normal PCR products and total volume was loaded to each well and run at 100 
V for 30 minutes. Puc8 marker (MBI Fermentas, Ontario, Canada) was used as DNA 
size marker. Transilluminator (Bio-Rad, California, USA) was used to visualize the 
DNA bands under ultraviolet light (long wave, 340 nm). MultiAnalyst (Bio-Rad, 
California, USA) software was used to take photographs of the gels. 
 
 
 
 
Figure 2.1: pUC Mix Marker, 8 
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2.8. SOLUTIONS AND BUFFERS 
 
PBS 
Stock solution (10XPBS) was prepared by dissolving 80g NaCl, 2g KCl, 11.5g 
Na2HPO4.7H2O, and 2g KH2PO4 in 1lt ddH2O. Working solution (1XPBS) was 
prepared by dilution of 10XPBS to 1X with ddH2O. pH of the working solution was 
adjusted to 7.4. 
 
TAE 
Stock solution (50XTAE) was prepared by addition of 121g Tris-base, 18,6g EDTA, 
and 28.55ml glacial acetic acid to 500ml ddH2O. pH of the stock solution was 
adjusted to 8.5. Working solution (1XTAE) was prepared by dilution of 50XTAE to 
1X with ddH2O.  
 
DEPC-Treated Water 
1ml DEPC was added to 1lt ddH2O and stirred under hood overnight. DEPC was 
inactivated by autoclaving. 
 
6X Agarose Gel Loading Dye 
A mixture of 0.009g bromophenol blue (BFB), 0.009g xylene cyanol (XC), 2.8ml 
ddH2O, 1.2 ml 0.5M EDTA was prepared. The total volume was brought to 15ml by 
addition of glycerol. 
 
2.9. STATISTICAL ANALYSIS 
 
Multivariate statistical methods such as Cluster, Discriminant Function Analysis, and 
Multidimensional Scaling provide a reduction of variables and an objective 
classification of samples. 
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2.9.1. Cluster Analysis  
 
Cluster Analysis makes grouping of the objects according to degree of association 
between the objects. If the degree of association is high between the two objects, 
they are put in the same group, and if the association is low, they do not belong the 
same group. Hierarchical cluster analysis was chosen for clustering. In the 
hierarchical cluster, each case has a separate cluster at the beginning, and then 
clusters are combined according to their degree of association. This hierarchical 
clustering process can be represented as a tree, or dendrogram. Average linkage 
method of hierarchical cluster was chosen for clustering. It is based on the average 
distance between the objects. The clustering method represents the relationships of 
genes as a tree structure by connecting genes using their similarity scores based on 
the Pearson correlation coefficient. Both gene and sample based cluster analysis was 
performed. Cluster analysis and imaging were carried out by Eisen Lab Cluster 
Version 2.11 and Treeview Version 1.60 softwares 
[http://rana.lbl.gov/EisenSoftware.htm]. 
 
2.9.2. Pearson Correlation 
 
Pearson correlation reflects the degree of linear relationship between the two 
variables. It ranges from +1 to -1. +1 reflects the perfect positive linear relationship 
and -1 represents the negative linear relationship between the two variables. Pearson 
correlation was carried out in Minitab. The cut off p value used in the Pearson 
correlation test is 0.05.  
 
2.9.3. Multidimensional Scaling (MDS) 
 
Multidimensional Scaling refers to a family of models where the structure in a set of 
data is represented in a map based on the relationships between a set of points in a 
space [http://www.stat.psu.edu/~chiaro/BioinfoII/mds_sph.pdf]. MDS can be used on 
a variety of data, using different models and allowing different assumptions about the 
level of measurement. It makes it easier for the researcher to analyze data by 
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providing more user friendly summary of the analysis. There are two important 
things to consider in MDS. First the axes are meaningless, and the second the 
orientation of picture is arbitrary. There are two parameters of an MDS analysis: 
clusters and dimensions. Clusters are formed by the objects that are grouped together 
and the dimensions order the objects in the map along a continues line. This line may 
be from left to right and from down to up. 
 
MDS requires an input of matrix showing the proximity between the interested 
variables. A matrix of Pearson correlation between the interested variables was used 
as input in our analysis. It is a useful tool to analyze similarities and dissimilarities 
between the interested variables. MDS is carried out in Matlab© for both the 
proximities between the samples and between the target genes. MDS function library 
for Matlab© was downloaded from Assoc. Prof. Rich Strauss’s web site 
http://www.biol.ttu.edu/Strauss/Matlab/matlab.htm.  
 
2.9.4. Discriminant Function Analysis 
 
Discriminant function analysis shows how independent variables contribute to the 
categorical dependent variable. All variables were assumed to have the same 
covariance matrix, thus, linear discriminant analysis was performed. Discriminant 
analysis was performed in Minitab  for several clinical properties of the samples 
used in the analysis.  
 
2.9.5. Mann Whitney Test 
 
The Mann Whitney test is used to identify if the two populations are different from 
each other. In the two-tailed test, null hypothesis is that median of the two 
populations are equal. If the p value is less than the chosen α level there is sufficient 
evidence to reject null hypothesis. The Mann Whitney test was performed in 
Minitab for ER status of primary breast tumor samples used in this study with a 
95% confidence interval for each gene. 
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CHAPTER 3 
 
 
RESULTS 
 
We aimed to identify the expression profile of the genes that play major roles in the 
Hedgehog signaling pathway in epithelial cancers, primarily in breast cancer. It is 
important to detect the expressional levels of the Hh signaling elements to explain 
this pathway’s role in tumor development. 
 
The expression levels of the genes can be determined by determining the protein or 
mRNA levels of the genes. In this study the mRNA expression levels of the genes 
were determined with q-rt-RT-PCR, which is the most sensitive method to determine 
the expression level of the genes. 
 
3.1. RNA INTEGRITY 
 
The integrity of the purified total RNA from the tissue samples and the cell lines 
were checked by using ND-1000 Spectrophotometer. The λ260/λ280 ratio of the RNAs 
was between 1.8-2.0. This range shows the high quality of isolated total RNAs. The 
total RNA was used for cDNA synthesis.  
 
3.2. FIRST STRAND cDNA SYNTHESIS 
 
The purified total RNAs were used in first strand cDNA synthesis. The integrity and 
amplification efficiency of the cDNA samples were determined by amplifying the 
samples with housekeeping gene specific primers for GADPH. The total RNAs 
isolated both from the primary tumor and the cell lines were synthesized with the 
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same efficiency and gave the expected 150bp amplification product in RT-PCR with 
GADPH primers. This result showed that the cDNAs were intact and can be used for 
further analysis (Figure 3.1). 
 
 
Figure 3.1: GADPH amplified cDNA samples. (A) Primary breast tumor tissue 
RNAs and (B) cell line RNAs were used for cDNA synthesis and amplified with 
GADPH gene specific primers. The DNA size marker is pUC8 and the product size 
is 150 bp. 
 
3.3. MELT CURVE ANALYSIS 
 
The real-time RT-PCR reaction uses SYBR Green I as a detection system. SYBR 
Green I is a DNA intercalating agent which binds to double stranded DNA during the 
product amplification at q-rt-RT-PCR.  
 
The melt curve analysis is an important step to show the specificity of the q-rt-RT-
PCR reaction.  In a typical melt curve result, we expect to see a single peak for each 
sample at the same dissociation temperature. Any extra peak means that nonspecific 
amplicons, or primer dimers occurred in the reaction.  Therefore, in each real-time 
RT-PCR reaction, melt curve analysis was carried out to ensure the specificity of the 
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reaction. Figure 3.2 A shows a typical melt curve result, and Figure 3.2 B shows a 
melt curve graph that contains non-specific amplicon and primer dimer in the 
reaction. 
 
In this study, the PCR conditions for each gene were optimized to give the desired 
melt curve with real-time RT-PCR. If the desired melt curve was not achieved, new 
primer pairs were designed for that gene. IHH gene specific primers were redesigned 
because the first set of primers gave non-specific amplicon (Figure 3.2.B).  
 
 
 
Figure 3.2: Melt curve graph: (A) Melt curve for q-rt-RT-PCR reaction of GLI1 
gene for breast carcinoma cell lines gave single peak for each sample at the same 
temperature. (B) Melt curve for the first set IHH primer pair gave nonspecific PCR 
product in q-rt-RT-PCR reaction for breast carcinoma cell lines.  
 
B 
 Nonspecific binding 
Primer dimer 
A 
Specific Binding 
 55
3.4. STANDARD CURVES AND AMPLIFICATION 
EFFICIENCIES 
 
Amplification efficiency calculation is an important step in the q-rt-RT-PCR 
analysis. In relative quantification measurements, it is used in the calculation of the 
comparative expressional level of the samples. If the amplification efficiency for 
both reference gene and the target gene was 100%, equation 1.2 (section 1.3.2.1) was 
used for the calculations. In other cases, equation 1.3 (section 1.3.2.1) was used.  
 
A cell line that shows the highest expression level for a particular gene was chosen to 
determine the amplification efficiency of the primers for that particular gene. 
Standard curves for each gene specific primer pairs were generated based on the data 
obtained by performing the q-rt-RT-PCR with a two-fold serial dilution of the 
cDNAs. Theoretically, a 100% efficient amplification of a PCR product equals one 
cycle of increase in each two-fold dilution series.  
 
GAPDH was used as a housekeeping gene for the carcinoma cell lines and ACTB, 
TBP, and SDHA were used for the primary breast tumor and normal samples. The 
amplification efficiencies for housekeeping genes were calculated previously by Bala 
Gur on a series of ten-fold dilution of cDNA (unpublished data). 100% efficient 
amplification equals to 3.33 cycle of increase in each ten-fold dilution series. Figure 
3.3 shows the results of the amplification efficiency standard curves of the genes 
used in the study. 
 
The slopes obtained from the dilution curves were used to calculate the amplification 
efficiency of the primers with the equation 1.4 (the equation was given in (section 
1.3.2.1). The amplification efficiency of the all the housekeeping gene primers were 
100 percent. Table 3.1 shows the summary of the amplification efficiencies of the 
primers used in this study. 
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Figure 3.3: The amplification efficiency graphs of the gene specific primers. The 
amplification efficiency was calculated from the 10-fold dilution series of cDNAs for 
housekeeping genes and 2-fold serial dilution series of cDNAs for the Hh pathway 
specific genes.  
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Table 3.1: Amplification efficiencies of the gene-specific primers 
Gene Slope Efficiency 
GAPDH -3.35 99 
ACTB -3.45 95 
SDHA -3.25 103 
TBP -3.44 95 
SHH 1.06 92 
IHH 1.14 84 
PTCH1 1.15 83 
SMO 1.05 94 
GLI1 1 100 
GLI2 0.93 112 
GLI3 0.88 120 
BCL2 1.025 97 
 
3.5. QUANTITATIVE REAL-TIME RT-PCR 
 
The Hh signaling pathway expression profile of the carcinoma cell lines of epithelial 
origin was determined by q-rt-RT-PCR analysis. In this study, human breast, 
hepatocellular, and colon carcinoma cell lines, and human primary breast tumor 
samples were used for the expression profiling of the target genes (Table 2.1, 2.2, 
2.3, and 2.4 respectively, in section 2.1). 
 
All the q-rt-RT-PCR reactions were run on a BioRad iCycler. The software displays 
an amplification graph, Ct values and the melt curve at the end of each amplification 
reaction. Figure 3.5 shows a typical q-rt-RT-PCR amplification and melt curve 
graphs for a target gene. All the reactions were target gene specific and displayed the 
expected single melt curve peak in the graphs. 
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Figure 3.4: q-rt-RT-PCR amplification graph and the melt curve. (A) The 
amplification graph of PTCH1 gene in breast carcinoma cell lines, and (B) melt 
curve graph of the same reaction. 
 
Q-rt-RT-PCR reaction for each gene was performed in duplicates, including positive 
and negative control samples. The duplicate PCR products were run on 2% agarose 
gel to observe the specific product size and confirm the melt curve analysis obtained 
with q-rt-RT-PCR reactions. 
 
A 
B 
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Figure 3.5: Selected q-rt-RT-PCR agarose gel electrophoresis photographs for 
GLI1. (A) PCR products of GLI1 gene in breast carcinoma cell lines, (B) 
hepatocellular carcinoma cell lines, (C) colon carcinoma cell lines, and (D) primary 
breast tumor samples. For each q-rt-RT-PCR reaction, negative control was used. 
The DNA size marker is pUC8 and the GLI1 product size is 154 bp. 
 
3.6. BREAST CARCINOMA CELL LINES 
 
Quantification of mRNA expression values of each gene is calculated by using the 
equations 1.2 and 1.3 that are given in section 1.3.2.1. The expression values that 
were obtained with these calculations were then transformed to log2 scale. Log2 
transformation makes upregulation and downregulation values more symmetrical.  
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Table 3.2: Fold expression values of the Hh pathway genes in breast carcinoma 
cell lines.  The value in bold may represent an outlier. 
 
GENE GLI1 GLI2 GLI3 SHH IHH PTCH1 SMO BCL2 
MDA MB157 -2.20 6.52 4.80 0.20 2.48 7.70 2.77 3.25 
MDA MB231 -1.75 4.51 0.05 0.92 -1.07 2.50 0.59 3.50 
MDA MB361 -2.55 -2.92 0.39 1.48 -2.46 3.97 0.23 2.30 
MDA MB453 -0.10 -20.59 4.54 -0.56 -1.56 3.98 0.66 1.70 
MDA MB468 -0.80 0.12 1.80 0.03 -0.72 5.17 2.49 3.60 
BT474 1.45 -5.43 0.08 1.41 4.80 1.43 4.31 5.70 
BT20 -3.15 -2.25 0.00 -0.07 0.31 4.32 1.66 0.80 
MCF7 -0.50 -5.57 2.89 -0.21 0.93 4.88 1.59 8.00 
MCF12A -2.15 3.19 2.41 -0.57 -3.96 2.99 2.12 0.30 
HCC1937 -3.70 6.98 1.26 -1.51 1.38 4.44 0.59 1.40 
CAMA1 1.70 -0.19 4.31 0.69 4.41 1.45 4.32 5.85 
SKBR3 -2.90 -3.66 -2.69 -0.18 -3.27 1.58 -0.55 -2.55 
ZR75.1 -3.35 -4.58 -0.85 -0.52 -1.67 1.96 -0.17 4.60 
T47D -0.80 -17.39 3.54 0.18 -0.29 1.92 4.02 -0.50 
HBL100 -0.30 3.19 -0.35 2.71 -2.17 2.38 -0.01 1.90 
 
3.6.1. Expression Status of Hh Pathway Target Genes  
 
The expression status of the Hh pathway target genes in breast carcinoma cell lines 
were determined by q-rt-RT-PCR.  Fifteen human breast carcinoma cell lines and an 
hTERT immortalized normal human mammary epithelial cell line, hTERT-HME1, 
were used to obtain the Ct values of each target gene. Each gene’s Ct value was 
normalized to that of the housekeeping gene GADPH for a given sample. Then, the 
normalized values compared to the normalized Ct value of the hTERT-HME1 cell 
line by using the equations 1.2 and 1.3 (section 1.3.2.1.). Figure 3.6 shows the 
expression levels of the breast carcinoma cell lines for Hh pathway target genes. 
Observed log fold differences ranged between 7.7 and -20.6; accordingly, a higher 
variability in gene expression has been observed for GLI2 whereas SHH and SMO 
exhibited the least amount of variation in terms of mRNA expression (Table 3.2; 
Figure 3. 6). 
  
The raw Ct values are given in Appendix XXX.  
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Figure 3.6: Expression profile of the Hedgehog pathway target genes in human 
breast carcinoma cell lines. Fold expressions were given in log2 scale. 
 
3.6.2. Hierarchical Cluster Analysis 
 
Cluster analysis makes grouping of the objects according to association between the 
objects. Hierarchical Cluster Analysis was carried out to observe possible grouping 
of the cell lines based on their gene expression profiles. 
 
Expression values of all the target genes in 15 human breast carcinoma cell lines 
were clustered by using the Cluster 2.11 program created by Eisen Lab 
[http://rana.lbl.gov/]. Average cluster analysis was performed both in a gene and 
array based manner and represented as a tree and dendrogram in Figure 3.7.  
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Figure 3.7: Two-dimensional Cluster Analysis of genes in human breast 
carcinoma cell lines. A dendogram obtained from hierarchical clustering, using 
expression data from 8 genes in 15 breast carcinoma cell lines. The red and the green 
colors indicate the high and the low expressions values respectively.  
 
3.6.3. Pearson Correlation Analysis 
 
Pearson correlation analysis was used to determine if there is a linear relationship 
between the two genes’ expression pattern in the cell lines studied. This analysis was 
applied to the data obtained from 15 human breast carcinoma cell lines by using 
statistical tools in Minitab Program. A correlation of +1 represents a perfect 
positive relationship with a p value less than 0.05, which means that the performed 
analysis is significant. This data shows that IHH, SMO and GLI1 gene expression 
profiles were found to be highly correlated with each other in all the breast 
carcinoma cell lines studied. Significant correlations included those between GLI1 
and IHH (r=0.521, p=0.047); SMO and GLI1 (r=0.637, p=0.011); and SMO and IHH 
(r=0.708, p=0.003). No multiple test correction has been made.  
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Table 3.3: Pearson Correlation for human breast carcinoma cell lines. The first 
value represents the Pearson correlation and the second value represents the p value 
for each pair of gene. 
 
 
 
3.6.4. Multidimensional Scaling (MDS) 
 
MDS, a data analysis tool to make the data much easier to comprehend, provides a 
visual representation of the pattern of proximity of a set of objects. The proximity is 
a number which indicates how similar or how different these objects from each other. 
MDS plots the objects in a map in which objects with high similarity are placed near 
each other. Interpoint distances correspond to experimental dissimilarities between 
the points. In this study the proximity calculation was performed by Pearson 
correlation as given in section 3.6.3.  
 
MDS was performed to 15 human breast carcinoma cell lines with an input matrix of 
Pearson correlation of genes, or cell lines in the Matlab program. This analysis was 
performed to examine the clustering among genes upon reduction of the data 
dimensions. All the Hh target gene expression values and the cell lines used in this 
                 GLI1     GLI2     GLI3      SHH      IHH     PTCH1     SMO   
GLI2   -0.316 
        0.251 
 
GLI3    0.417   -0.230 
        0.122    0.410 
 
SHH     0.472    0.109   -0.216 
        0.076    0.699    0.440 
 
IHH     0.521    0.088    0.382    0.073 
        0.047    0.756    0.160    0.795 
 
PTCH1  -0.301    0.268    0.444   -0.275    0.088 
        0.276    0.334    0.098    0.322    0.756 
 
SMO     0.637   -0.131    0.579    0.082    0.708   -0.028 
        0.011    0.643    0.024    0.771    0.003    0.921 
 
BCL2    0.496    0.108    0.281    0.177    0.599    0.126    0.323 
        0.060    0.703    0.310    0.528    0.018    0.655    0.240 
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study were taken into consideration for MDS analysis. The results of MDS analysis 
of the Hh target genes showed that there was not a strong grouping among the genes 
(Figure 3.8); yet when the same analysis was performed for the cell lines for their 
target genes’ expression profiles, the pattern of dissimilarity has led to the 
identification of mainly two major groupings. The most striking expression 
similarities between cell lines included those between MDA MB453 and T47D; 
MDA MB361, MDA MB468, MCF7, ZR75.1 and BT20 (Figure 3.9). In addition in 
the right part of the Figure 3.9, MDA MB157, MDA MB231, MCF12A, HCC1937, 
and HBL100 were clustered together which were also clustered in the Hierarchical 
Cluster analysis (Figure 3.7). 
 
 
 
Figure 3.8: Gene-based MDS Analysis for breast carcinoma cell lines. 
Correlation values between the expression levels of genes were used as the input 
data. Each point shown in the map by a number represents one gene. The numbering 
of genes used in the analysis from number 1 to 8 is GLI1, GLI2, GLI3, SHH, IHH, 
PTCH1, SMO, BCL2 respectively. 
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Figure 3.9 Cell line-based MDS Analysis for breast carcinoma cell lines. 
Correlation values between the expression levels of cell lines were used as the input 
data. Each point shown in the map by a number represents one cell line. The 
numbering of cell lines used in the analysis from number 1 to 15 is in the same order 
as given in Table 3.2. 
 
3.6.5. Discriminant Function Analysis (DFA) 
 
DFA differentiates the separate populations by combining a number of variables and 
maximizing the ratio of the differences. A prior knowledge of grouping of the 
samples is required. The grouping was carried out for the estrogen receptor (ER) 
status of the cell lines. The ER status of the cell lines were given in Table 2.1. 
 
Linear discriminant function analysis (DFA) was performed for 15 human breast 
carcinoma cell lines. There are 7 ER (-) and 8 ER (+) cell lines available for the 
study. When all the target gene expression values were taken into consideration for 
the DFA, the analysis predicted the ER status correctly in 93% of the cell lines 
(Table 3.4). Cross-validation has been performed to assess the variability in 
misclassification rate. Cross-validation of the DFA results indicated that the 
percentage of correct classification might vary depending on the selection of cell 
lines since the misclassification rate increased to 40% with cross-validation. 
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Table 3.4: DFA of human breast carcinoma cell lines based on their ER status. 
 
 
 
3.7. HEPATOCELLULAR CARCINOMA CELL LINES 
 
Quantification of mRNA expression values of each gene is calculated by using the 
equations 1.2 and 1.3 that are given in section 1.3.2.1. The expression values that 
were obtained with these calculations were then transformed to log2 scale.  
 
Classification 
 
Put into     ..True Group.. 
Group           ER-     ER+ 
Total N          8        7 
N Correct        7        7 
Proportion   0.875    1.000  
Proportion Correct= 0.933 
Classification with Cross-
validation 
 
Put into     ..True Group.. 
Group           ER-     ER+ 
Total N          8        7 
N Correct        5        4 
Proportion   0.625    0.571  
Proportion Correct = 0.600 
A B 
C Linear Discriminant Function for Group 
              ER-      ER+ 
Constant   -9.269  -20.673 
GLI1       -4.567   -8.801 
GLI2       -0.384   -0.628 
GLI3       -0.081    1.034 
SHH         2.971    4.693 
IHH        -1.573   -3.020 
PTCH1       0.099   -2.968 
SMO         4.444    8.143 
BCL2        2.027    4.431 
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Table 3.5: Fold expression values of the Hh pathway genes in HCC cell lines. 
The value in bold may represent an outlier. 
 
GENE GLI1 GLI2 GLI3 SHH IHH PTCH1 SMO BCL2 
SNU182 0.86 7.89 8.52 6.72 -8.84 3.16 5.34 4.61 
SNU387 2.46 7.55 6.52 4.00 -6.29 1.79 -10.76 -9.59 
SNU398 1.86 0.74 5.75 -0.72 -11.44 1.56 -15.91 -14.74 
SNU423 0.16 2.15 5.97 7.11 -0.87 -0.33 4.84 4.11 
SNU449 0.86 0.88 3.49 0.47 -1.04 -1.64 3.49 3.46 
SNU475 5.06 3.01 -14.84 8.93 6.72 1.26 2.04 10.76 
HEP3B -2.04 -6.22 -10.58 5.21 0.39 -1.05 3.44 -2.44 
HEP3B TR -0.94 -4.84 -12.88 5.41 2.93 -1.63 4.94 -1.44 
HEP40 -2.99 -6.98 1.12 -10.78 5.82 -0.73 3.39 1.36 
HEPG2 -2.79 -6.35 -5.16 2.07 2.33 -1.56 2.74 0.61 
SKHEP1 -3.79 0.42 2.38 -11.63 -2.64 -2.28 2.44 4.36 
HUH7 -1.24 -5.77 -8.49 8.01 6.85 0.44 5.74 -2.59 
PLC/PRL/5 1.36 -6.62 4.22 -10.58 1.77 -2.01 1.99 -6.29 
FOCUS 0.76 1.54 3.30 -3.26 -3.35 -0.39 -13.86 7.41 
MAHLAVU -1.49 0.91 4.12 -10.05 -4.84 -1.16 -18.36 4.31 
 
 
3.7.1. Expression status of Hh pathway target genes in Hepatocellular 
Carcinoma Cell Lines (HCC) 
 
The expression status of the Hh pathway target genes in hepatocellular carcinoma 
cell lines were determined by q-rt-RT-PCR.  Fifteen human HCC cell lines were 
used to obtain the Ct values of each target gene. Each genes Ct value was normalized 
to the Ct value of the housekeeping gene GADPH for a given sample. The Ct values 
from all the samples were used to calculate the geometrical mean of each target and 
GADPH genes. The geometric mean of the each target gene was normalized to 
geometric mean of GADPH gene. The first normalized values compared to the 
normalized geometric mean Ct value of the each gene for a given cell line by using 
the equations 1.2 and 1.3 (section 1.3.2.1.). Observed log fold differences ranged 
between 10.76 and -18.36; accordingly, almost all of Hh genes exhibited substantial 
variability in terms of mRNA expression while GLI1 and PTCH1 showed a relatively 
more stable expression level among HCC cell lines (Table 3.5; Figure 3. 10). 
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Figure 3.10: Expression profile of the Hedgehog pathway target genes in human 
HCC cell lines. The fold expressions were given in log2 scale. 
 
 
3.7.2. Hierarchical Cluster Analysis 
 
Expression values of all the target genes in 15 human HCC cell lines were clustered 
by using the Cluster 2.11 program created by Eisen Lab. Average cluster analysis 
was performed both in a gene and array based manner and represented as a tree and 
dendrogram in Figure 3.11.  
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Figure 3.11: Two-dimensional Cluster Analysis of genes in human HCC cell 
lines. A dendogram obtained from hierarchical clustering, using expression data 
from 8 genes in 15 HCC cell lines. The red and the green colors indicate the high and 
low expression values respectively.  
 
3.7.3. Pearson Correlation Analysis 
 
Pearson correlation analysis was applied to the data that was obtained from 15 
human HCC cell lines by using statistical tools in Minitab Program. Significant 
negative correlations were observed between IHH and GLI2 (r=-0.647, p=0.009) and 
GLI3 (r=-0.721, p=0.002) as shown in Table 3.6. High positive correlations were 
obtained for PTCH1 and GLI1 (r=0.586, p=0.022), and GLI2 (r=0.661, p=0.007). No 
multiple test correction has been made.  
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Table 3.6: Pearson Correlation for human HCC cell lines. The first value 
represents the Pearson correlation and the second value represents the p value. 
 
 
 
3.7.4. Multidimensional Scaling 
 
MDS was performed to 15 human HCC cell lines with an input matrix of Pearson 
correlation of genes (Table 3.6), and cell lines in the Matlab© program. This analysis 
was performed to examine the clustering among genes upon reduction of the data 
dimensions. 
 
All of the Hh pathway gene expression values and the 15 cell lines used in this study 
were taken into consideration for MDS analysis. When MDS was performed with 
respect to the Hh genes, the resulting graph showed that there was not a strong 
grouping among genes (Figure 3.12).  MDS analysis of the 15 HCC cell lines, on the 
other hand, revealed that there were several subgroups of cell lines (Figure 3.13).  
The most striking expression similarities between cell lines included those between  
 
                  GLI1    GLI2    GLI3      SHH      IHH     PTCH1      SMO 
GLI2    0.560 
        0.030 
 
GLI3    0.041   0.494 
        0.886   0.061 
 
SHH     0.417   0.253   -0.427 
        0.122   0.364    0.112 
 
IHH    -0.174  -0.647   -0.721    0.111 
        0.535   0.009    0.002    0.694 
 
PTCH1   0.586   0.661    0.199    0.533   -0.412 
        0.022   0.007    0.477    0.041    0.127 
 
SMO    -0.230  -0.353   -0.405    0.330    0.611   -0.187 
        0.409   0.196    0.134    0.230    0.015    0.505 
 
BCL2   -0.048   0.176   -0.191    0.034    0.340   -0.141    0.265 
        0.866   0.531    0.495    0.905    0.216    0.615    0.340 
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FOCUS and MAHLAVU; SNU387 and SNU398; and HEP3B, HEP3B TR, 
SKHEP1 and PLC/PRL/5.  
 
 
 
Figure 3.12: Gene-based MDS Analysis for HCC cell lines. Correlation values 
between the expression levels of genes were used as the input data. Each point shown 
in the map by a number represents one gene. The numbering of genes used in the 
analysis from number 1 to 8 is GLI1, GLI2, GLI3, SHH, IHH, PTCH1, SMO, BCL2 
respectively. 
 
 
Figure 3.13: Cell line-based MDS Analysis for HCC cell lines. Correlation values 
between the expression levels of cell lines were used as the input data. Each point 
shown in the map by a number represents one cell line. The numbering of cell lines 
used in the analysis from number 1 to 15 is in the same order as given in Table 3.5. 
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3.7.5. Discriminant Function Analysis  
 
Linear discriminant function analysis was performed for 15 human HCC cell lines. 
The grouping was performed for the differentiation status of the cell lines. There 
were 6 well differentiated and 9 poorly differentiated HCC cell lines (Table 2.2). 
When all the target gene expression values were taken into consideration for the 
DFA, it predicted the differentiation status of the cell lines perfectly (Table 3.7). 
Cross-validation of the DFA results indicated the percentage of correct classification 
might vary depending on the selection of cell lines since the misclassification rate 
increased to 27% with cross-validation. 
 
Table 3.7: DFA of human HCC cell lines based on their differentiation status 
 
 
 
Summary of Classification 
 
Put into     ..True Group.. 
Group          Poor      Well 
Total N          9        6 
N Correct        9        6 
Proportion   1.000    1.000  
Proportion Correct = 1.000 
 
 
Summary of Classification  
with Cross-validation 
 
Put into     ....True 
Group.... 
Group          Poor      Well 
Total N          9        6 
N Correct        6        5 
Proportion   0.667    0.833  
Proportion Correct = 0.733 
A B 
C Linear Discriminant Function for Group 
             Poor     Well 
Constant  -2.7461  -6.8274 
GLI1       0.5564  -0.4646 
GLI2       0.9089  -2.0837 
GLI3       0.0414  -0.0605 
SHH        0.0326   0.0955 
IHH       -0.4068   0.1212 
PTCH1     -1.2270   1.5965 
SMO       -0.1538   0.2074 
BCL2       0.3182  -0.2604 
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3.8. COLON CARCINOMA CELL LINES 
 
The list of colon carcinoma cell lines used in this study was given in Table 2.3. The 
fold expression values of the target genes were calculated and transformed to log 
scale (Table 3.8). 
 
Table 3.8: Fold expression values of the Hh pathway genes in colon carcinoma 
cell lines. The value in bold may represent an outlier. 
 
GENE GLI1 GLI2 GLI3 SHH IHH PTCH1 SMO BCL2 
SW620 -2.70 -6.36 2.44 -0.60 1.99 0.30 3.94 -0.03 
SW480 -2.05 4.29 9.91 -0.14 -2.45 -0.75 8.44 -4.08 
SW48 -0.70 4.47 14.12 -0.52 -2.95 1.77 -8.16 -0.68 
HCT8 -0.90 -0.42 -7.93 0.56 -2.84 0.09 -5.56 2.72 
HCT15 -1.65 3.58 -1.01 2.94 0.20 2.20 0.29 3.27 
HT29 3.80 -1.66 -6.78 4.06 0.91 0.20 -7.01 -2.03 
TC71 3.30 0.23 8.87 1.19 -3.00 -2.40 1.19 1.52 
T7 1.35 -2.80 -6.19 1.11 4.98 -0.13 0.84 1.27 
LOVO 1.65 1.77 5.48 2.23 3.68 -0.08 9.74 4.07 
LS411 1.15 0.12 -1.68 -0.27 1.77 0.08 -0.16 0.52 
COLO205 -3.05 -10.80 -6.61 -4.79 -4.21 1.09 -1.56 -2.38 
CL115 -1.45 2.66 -9.37 -2.74 -2.54 -2.15 0.54 -2.63 
W05 2.15 -0.16 -4.31 -3.75 0.48 0.85 -0.46 -2.13 
KM12 -1.95 2.13 -8.83 -0.11 2.29 -0.81 -7.61 -0.23 
 
3.8.1. Expression status of Hh pathway target genes 
 
The expression status of the Hh pathway target genes in colon carcinoma cell lines 
were determined by q-rt-RT-PCR.  Fourteen human colon carcinoma cell lines were 
used to obtain the Ct values of each target gene. Each genes Ct value was normalized 
to the Ct value of the housekeeping gene GADPH for a given sample. The Ct values 
from all the samples were used to calculate the geometrical mean of each target and 
GADPH genes. The geometric mean of the each target gene was normalized to 
geometric mean of GADPH gene. The first normalized values compared to the 
normalized geometric mean Ct value of the each gene for a given cell line by using 
the equations 1.2 and 1.3 (section 1.3.2.1.). Observed log fold differences ranged 
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between 14.12 and -10.80; accordingly, GLI1, SHH, PTCH1, and BCL2 showed 
relatively more stable expression levels among the cell lines whereas GLI3 gene 
expression showed high variability (Table 3.8; Figure 3. 14). 
 
Figure 3.14: Expression profile of the Hedgehog pathway target genes in human 
colon carcinoma cell lines. Fold expressions were given in log2 scale. 
 
3.8.2. Hierarchical Cluster Analysis 
 
Expression values of all the target genes in 14 human colon carcinoma cell lines 
were clustered by using the Cluster 2.11 program created by Eisen Lab. Average 
cluster analysis was performed both in a gene and array based manner and 
represented as a tree and dendrogram in Figure 3.15.  
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Figure 3.15: Two-dimensional Cluster Analysis of genes in human colon 
carcinoma cell lines. A dendogram obtained from hierarchical clustering, using 
expression data from 8 genes in 14 colon carcinoma cell lines. The red and the green 
colors indicate the high and the low expression values respectively. 
 
3.8.3. Pearson Correlation Analysis 
 
Pearson correlation analysis was applied to the data that was obtained from 14 
human colon carcinoma cell lines by using statistical tools in Minitab Program. 
Significant positive correlation was observed between SHH and BCL2 (r=0.547, 
p=0.043) (Table 3.9). No multiple test correction has been made.  
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Table 3.9: Pearson Correlation for human colon carcinoma cell lines. The first 
value represents the Pearson correlation and the second value represents the p value. 
 
 
 
3.8.4. Multidimensional Scaling 
 
MDS was performed to 14 human colon carcinoma cell lines with an input matrix of 
Pearson correlation of genes (Table 3.9), and cell lines in the Matlab© program. This 
analysis was performed to examine the clustering among genes upon reduction of the 
data dimensions. All of the Hh pathway gene expression values and the 14 cell lines 
used in this study were taken into consideration for MDS analysis. When MDS was 
performed with respect to the Hh genes, the resulting graph showed that there was 
not a strong grouping among genes (Figure 3.16).  MDS analysis of the cell lines, on 
the other hand, revealed mainly two subgroups of cell lines (Figure 3.17).  The most 
striking expression similarities between cell lines included those between HCT8, 
HT29 and KM12; T7, LS411, and W05.   
 
               GLI1     GLI2     GLI3     SHH      IHH     PTCH1      SMO 
GLI2   0.143 
       0.626 
 
GLI3   0.066    0.365 
       0.822    0.199 
 
SHH    0.441    0.371    0.181 
       0.114    0.191    0.535 
 
IHH    0.299   -0.005   -0.198    0.414 
       0.299    0.988    0.497    0.141 
 
PTCH1 -0.221   -0.131    0.074    0.018    0.070 
       0.447    0.654    0.802    0.952    0.812 
 
SMO   -0.037    0.019    0.359    0.014    0.214   -0.236 
       0.900    0.948    0.207    0.963    0.463    0.416 
 
BCL2   0.199    0.119    0.068    0.547    0.392    0.153    0.105 
       0.494    0.684    0.817    0.043    0.166    0.601    0.721 
 80
 
 
Figure 3.16: Gene-based MDS Analysis for colon cancer cell lines. Correlation 
values between the expression levels of genes were used as the input data. Each point 
shown in the map by a number represents one gene. The numbering of genes used in 
the analysis from number 1 to 8 is GLI1, GLI2, GLI3, SHH, IHH, PTCH1, SMO, 
BCL2 respectively. 
 
 
Figure 3.17: Cell line-based MDS Analysis for colon cancer cell lines. Correlation 
values between the expression levels of cell lines were used as the input data. Each 
point shown in the map by a number represents one cell line. The numbering of cell 
lines used in the analysis from number 1 to 14 is in the same order as given in Table 
3.8. 
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3.9. PRIMARY BREAST TUMOR SAMPLES 
  
The list of primary breast tumor samples used in this study was given in Table 2.4. 
The fold expression values of the target genes were calculated and transformed to log 
scale (Table 3.10). 
 
Table 3.10: Fold expression values of the Hh pathway genes in primary breast 
tumor samples. The value in bold may represent an outlier. N.D: not detected. +: 
fold expression could not be calculated due to lack of expression in normal sample 
pools. 
 
GENE GLI1 GLI2 GLI3 SHH IHH PTCH SMO BCL2 
MFT14 1.98 -0.69 -1.71 N.D. 1.19 -1.13 -3.21 1.96 
MFT16 0.83 3.54 2.05 N.D. -1.41 0.31 3.84 3.31 
MFT21 -1.42 2.51 2.05 N.D. -2.27 -1.98 -1.18 -3.10 
MFT25 -0.12 -2.88 -1.99 N.D. -0.53 -2.31 -6.36 1.16 
MFT40 3.73 -2.13 1.31 N.D. -3.61 -0.04 4.74 -1.04 
MFT41 -0.11 -3.85 -2.28 N.D. -3.62 -3.47 -9.87 -0.44 
MFT49 3.01 -3.50 -1.79 N.D. 1.57 -1.55 -5.60 2.98 
MFT78 -0.77 1.13 4.21 N.D. -5.10 -2.27 1.64 -0.29 
MFT79 0.38 -2.77 -3.41 N.D. -5.10 -3.49 -9.36 1.21 
MFT90 -1.07 -0.90 -1.14 N.D. -5.28 -3.14 -6.91 0.51 
MFT94 0.43 4.51 0.46 N.D. -1.23 2.35 3.84 -2.04 
MFT 95 4.97 -10.96 3.66 N.D. 1.26 -0.31 -7.79 5.14 
MFT97 -1.52 -3.74 -1.42 N.D. -2.46 -4.05 -7.01 -3.04 
MFT113 3.22 1.24 0.73 N.D. 3.10 0.07 -4.64 0.04 
MFT115 0.63 1.56 1.59 N.D. 1.41 2.14 4.59 1.21 
MFT116 1.13 -0.94 0.89 N.D. 0.78 0.66 -6.03 0.90 
MFT117 -2.57 -3.41 -3.81 N.D. -3.52 -5.01 -7.41 -5.79 
MFT127 -1.37 -1.49 -1.99 + -3.91 -3.62 -5.56 -3.39 
MFT120 2.22 0.51 2.42 N.D. 2.77 1.53 -2.94 -0.61 
MFT124 0.15 2.11 2.72 N.D. -1.64 2.95 -1.56 0.57 
MFT125 0.11 1.10 1.78 N.D. 0.30 -0.64 -0.25 0.33 
MFT129 0.82 2.35 1.53 N.D. -4.71 -0.15 0.41 -0.06 
MFT131 -1.67 -2.02 29.92 + -7.57 -5.97 -17.36 -3.04 
MFT132 -2.22 1.94 -1.19 N.D. -3.96 0.26 -1.41 -1.89 
MFT149 27.38 4.29 3.24 N.D. -3.21 1.44 2.49 2.61 
MFT154 -7.62 2.42 3.07 N.D. -4.71 0.26 -1.86 -10.09 
MFT155 -0.57 4.24 4.95 N.D. -2.29 2.88 2.74 2.56 
MFT173 -0.32 3.06 0.11 N.D. -2.95 -0.13 3.39 0.56 
MFT174 -1.17 -13.48 -1.65 N.D. -18.47 -5.45 -14.16 -4.84 
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3.9.1. Expression Status of Hh Pathway Target Genes 
 
The expression status of the Hh pathway target genes in primary breast tumor 
samples were determined by q-rt-RT-PCR.  Twenty nine primary breast tumor 
samples were used to obtain the Ct values of each target gene. Each genes Ct value 
was normalized to the geometric mean of Ct values of the housekeeping genes 
ACTB, SDHA, and TBP for a given sample. Then, the normalized values compared to 
the normalized Ct value of the normal tissue pools by using the equations 1.2 and 1.3 
(section 1.3.2.1.). Figure 3.18 shows the expression levels of the primary breast 
tumor tissues for Hh pathway target genes. Observed log fold differences ranged 
between 29.92 and -18.47; accordingly, SMO exhibited the least amount of variation 
in terms of mRNA expressions (Table 3.10; Figure 3. 18). 
 
 
Figure 3.18: Expression profile of the Hedgehog pathway target genes in 
primary breast tumor samples. Fold expressions were given in log2 scale. 
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3.9.2. Hierarchical Cluster Analysis 
 
Expression values of all the target genes in 29 human primary breast tissues were 
clustered by using the Cluster 2.11 program created by Eisen Lab. Average cluster 
analysis was performed both in a gene and array based manner and represented as a 
tree and dendrogram in Figure 3.19.  
 
Figure 3.19: Two-dimensional Cluster Analysis of genes in primary breast 
tumor tissues. A dendogram obtained from hierarchical clustering, using expression 
data from 8 genes in 29 primary tumor samples. The red and the green colors 
indicate the high and the low expression values respectively.  
 
3.9.3. Pearson Correlation Analysis 
 
Pearson correlation analysis was applied to the data that was obtained from 29 
primary breast tumor samples by using statistical tools in Minitab Program. High 
positive correlations were obtained for PTCH1 and SMO (r=0.772, p=0.000); PTCH1 
and GLI2 (r=0.725, p=0.000); SMO and GLI2 ( r=0.725, p=0.000) (Table 3.11). No 
multiple test correction has been made.  
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Table 3.11: Pearson Correlation for primary breast tumor tissues. The first value 
represents the Pearson correlation and the second value represents the p value. 
 
 
 
3.9.4. Multidimensional Scaling 
 
MDS was performed to 29 primary breast tumor tissues with an input matrix of 
Pearson correlation of genes (Table 3.11), and cell lines in the Matlab© program. 
This analysis was performed to examine the clustering among genes upon reduction 
of the data dimensions. All of the Hh pathway target gene expression values and the 
29 tumor samples used in this study were taken into consideration for MDS analysis. 
When MDS was performed with respect to the Hh genes, the resulting graph showed 
that there was not a strong grouping among genes except for the GLI2, PTCH1, and 
SMO (Figure 3.20).  MDS analysis of the 29 primary breast tumor tissues, on the 
other hand, revealed that there were several subgroups of samples (Figure 3.21).  The 
most striking expression similarities between samples included those between 
MFT14, MFT25, and MFT49; MFT16 and MFT173; MFT97, MFT113, MFT116, 
MFT117, and MFT120.  
                  GLI1     GLI2    GLI3      IHH      PTCH1    SMO 
GLI2    0.119 
        0.540 
 
GLI3    0.011    0.104 
        0.954    0.591 
 
IHH     0.170    0.400   -0.132 
        0.377    0.031    0.496 
 
PTCH    0.284    0.621   -0.093    0.554 
        0.135    0.000    0.631    0.002 
 
SMO     0.224    0.725   -0.231    0.396    0.772 
        0.242    0.000    0.227    0.033    0.000 
 
BCL2    0.497    0.056   -0.059    0.482    0.380    0.239 
        0.006    0.772    0.759    0.008    0.042    0.211 
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Figure 3.20 Gene-based MDS Analysis for primary breast tumor tissues. 
Correlation values between the expression levels of genes were used as the input 
data. Each point shown in the map by a number represents one gene. The numbering 
of genes used in the analysis from number 1 to 7 is GLI1, GLI2, GLI3, IHH, PTCH1, 
SMO, and BCL2 respectively. 
 
 
 
Figure 3.21: Sample-based MDS Analysis for primary breast tumor tissues. 
Correlation values between the expression levels of tumor samples were used as the 
input data. Each point shown in the map by a number represents one tumor sample. 
The numbering of tumor samples used in the analysis from number 1 to 29 is in the 
same order as given in Table 3.10. Two large clusters are apparent while highly 
similar sets of cell lines also could be detected within each cluster (shown by red 
circles).  
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3.9.5. Discriminant Function Analysis 
 
Linear DFA was performed for 29 primary breast tumor samples. The grouping was 
performed for the estrogen receptor (ER) status and grade status of the human breast 
cancer tumor samples (Table 2.4). There were 13 ER (-) and 10 ER (+) tumor 
samples (Table 2.4). When all the target gene expression values were taken into 
consideration for ER status, DFA predicted the ER status correctly in 87% of the 
samples (Table 3.12A). Cross-validation of the DFA results indicated the percentage 
of correct classification might vary depending on the selection of cell lines since the 
misclassification rate increased to 35% with cross-validation (Table 3.12B). DFA 
predicted the grade status correctly in 71% of the samples as shown in Table 3.13A. 
Correct prediction rate decreased to 57% after cross-validation test (Table 3.13B). 
 
Table 3.12: DFA of primary breast tumor tissues based on their ER status 
 
 
 
 
 
 
Summary of Classification 
 
Put into     ..True Group.. 
Group          ER-      ER+ 
Total N         13       10 
N Correct       11        9 
Proportion   0.846    0.900  
Proportion Correct= 0.870 
Summary of Classification  
with Cross-validation 
 
Put into     ..True Group.. 
Group          ER-      ER+ 
Total N         13       10 
N Correct        8        7 
Proportion   0.615    0.700  
Proportion Correct= 0.652 
Linear Discriminant Function for Group 
              ER-      ER+ 
Constant  -2.0837  -0.6783 
GLI1       0.8247   0.3559 
GLI2       0.6961   0.3972 
GLI3      -0.1445  -0.0775 
IHH       -0.4129  -0.2446 
PTCH       0.1301   0.0424 
SMO       -0.5633  -0.2981 
BCL2      -0.6052   0.1753 
A B 
C 
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Table 3.13: DFA of primary breast tumor tissues based on their grade status 
 
 
 
 
3.9.6. Mann-Whitney U Test 
 
Mann-Whitney U test was performed to primary breast tumor samples with known 
ER status in Minitab. The grouping was performed for the estrogen receptor (ER) 
status (Table 2.4). There were 13 ER- and 10 ER+ tumor samples (Table 2.4). For 
each gene Mann-Whitney U test was performed in 95% confidence interval. 
 
Table 3.14: Mann-Whitney test for primary breast tumor tissues based on their 
ER status. Bold p value represents the significant results. 
 
GENE ER (-) Median ER (+) Median W Value P Value 
GLI1 -1.17 0.49 120 0.0277 
GLI2 -0.94 0.22 152 0.8282 
GLI3 0.46 0.42 145 0.5149 
IHH -3.91 -0.97 124.5 0.0545 
PTCH1 -1.98 0.72 139 0.3062 
SMO -5.56 -3.925 142.5 0.4201 
BCL2 -2.04 0.865 105 0.0017 
 
 
 
Summary of Classification 
 
Put into     ..True Group.. 
Group            1        2        3 
Total N          4       11       13 
N Correct        4       10        6 
Proportion   1.000    0.909    0.462  
Proportion Correct= 0.714 
Summary of Classification 
with Cross-validation 
 
Put into     ..True Group.. 
Group            1        2        3 
Total N          4       11       13 
N Correct        1       10        5 
Proportion   0.250    0.909    0.385  
Proportion Correct= 0.571 
Linear Discriminant Function for Group 
                1        2        3 
Constant  -2.3198  -1.3272  -0.5479 
GLI1       0.1414  -0.0132   0.0766 
GLI2       0.0113   0.3809   0.1174 
GLI3      -0.1326   0.0039  -0.0349 
IHH       -0.2477  -0.0873  -0.2644 
PTCH1      1.4716  -0.9646   0.6211 
SMO       -0.6777  -0.0726  -0.2235 
BCL2      -0.2657   0.2707  -0.0329 
A B 
C 
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CHAPTER 4 
 
 
DISCUSSION 
 
Signaling pathways with a role in development are known to interact with each other 
and disturbance in one pathway can influence the regulation of others. It is therefore 
important to study these signaling pathways in cancer. 
 
Dysregulation of Hh pathway has been implicated in the formation of different types 
of cancer. The research describing the role of Hh pathway in cancer mainly focus on 
particular genes of the pathway, namely SHH, PTCH1, and GLI1. The observed 
phenotypes of this pathway in different types of cancers are the mutations in the 
PTCH1 gene and/or overexpression of the other genes in this pathway. However 
misregulation of the remaining genes having role in this pathway may disturb the 
homeostasis of the pathway.  
 
In this study, the expression profiles of seven genes, SHH, IHH, SMO, PTCH1, 
GLI1, GLI2 and GLI3, that play major roles in the Hh pathway, and a downstream 
target of Hh pathway which has an important role in cancer progression, BCL2, were 
analyzed in three different types of human epithelial cancer cell lines and primary 
breast tumor samples by quantitative real-time RT-PCR technique. Fifteen breast, 14 
colon, and 15 hepatocellular carcinoma (HCC) cell lines were used in this study. To 
the best of our knowledge, this is the first comprehensive study that shows the 
expression profiles of the main target genes of the Hh pathway in cancer cell lines 
that have an epithelial cell origin.  
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An association between the Hh pathway activation and the initiation of human 
tumors have been shown [Magliano et al., 2003], but not effectively studied in breast 
cancer.  In addition to the cell lines, the expression profiles of the genes named in 
this study were analyzed in 29 primary breast tumor samples and three matched 
normal tissue sample pools by quantitative real-time RT-PCR. Evidences indicate 
that aberrant Hh pathway signaling may be acting in a ligand-dependent or ligand-
independent manner depending on the type of cancer [Regl et al., 2004]. Our results 
showed that each target gene analyzed in this study was differentially co-regulated in 
different types of carcinoma cell lines. Hierarchical cluster and Pearson correlation 
analyses results indicated that different components of the pathway may be 
responsible for activating this pathway in each cancer type.  
 
4.1. EXPRESSION ANALYSIS IN BREAST CARCINOMA CELL 
LINES  
 
One type of epithelial cancer cell line used in this study was the human breast 
carcinoma cell lines (Table 2.1, Section 2.1). Fifteen cell lines were used for 
quantitative real-time RT-PCR and the results were analyzed by using different 
statistical analysis. Expression of GLI3, PTCH1, SMO and BCL2 were increased in 
all of the cell lines analyzed except for SKBR3 as shown in Figure 3.6 and 3.7. In 
SKBR3 cell line, BCL2, SMO and GLI3 expressions were found to be low. Kubo 
et.al. (2004) showed increased expression of SHH, PTCH1, and GLI1 in BT474, 
SKBR3, MDA-MB231, and MCF7 cell lines by immunostaining. The authors also 
observed clear nuclear staining of GLI1 in three cell lines except MDA-MB231. 
However, increase in the mRNA level of SHH and GLI1 were not observed in our 
study for SKBR3 and MCF7 cell lines. In MDA MB231 cell line, one-fold increase 
was detected in SHH expression whereas GLI1 expression was low. PTCH1 was 
upregulated in all the cell lines, and all these genes were upregulated in BT474. This 
finding may be explained by the basal level of mRNA expression may be enough for 
the detected protein expressions or proteins accumulate in these cells. 
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GLI2 mRNA expression showed high variability in breast carcinoma cell lines. In 
MDA MB453 and T47D cell lines, expression was decreased over 15-fold. 
Explanation for these findings may come from the studies on the inhibitors of the Gli 
transcription factors such as protein kinase A and analysis of epigenetic changes in 
the GLI2 promoter region in these cell lines [Magliano et al., 2003]. SHH and IHH 
gene expressions, which are the ligands of the Hh pathway, were not observed in 
most of the cell lines; this finding suggests that if there is any pathway activity it is 
likely to be through a ligand-independent manner in these cell lines or basal level 
expression of the ligands are sufficient for an aberrant pathway activity. Ligand-
independent signaling has been shown to be the result of either the loss of function 
mutations of PTCH1 or the gain of function mutations of SMO [Regl et al., 2004]. 
 
In most cases of the cancer types where Hh pathway is a cause for the disease, 
expression of the GLI1, PTCH1, and SMO have been found to be upregulated 
[Toftgard, 2000]. SMO and GLI1 are thought to be oncogenes responsible for the 
aberrant pathway activity. The receptor PTCH1 is also a downstream target of the 
pathway and its increased transcription indicates an active pathway. In the breast 
carcinoma cell lines, high GLI1 expression was not detected in most of the cell lines, 
only in CAMA1 and BT474 cell lines had increased expression of GLI1. If the Hh 
pathway is active, it should be through other transcription factors of the pathway, 
such as GLI2. GLI2 was found to be highly expressed in five cell lines, MDA 
MB157, MDA MB231, MCF12A, HCC1937, and HBL100, and other cell lines had 
low GLI2 expression. Gli-independent Hh signaling has also been implicated in some 
developmental processes [Kato et al., 2001], which may be responsible for the active 
pathway in the breast carcinoma cell lines.  
 
Expression values of all the target genes for 15 human breast carcinoma cell lines 
were clustered by using two dimensional Hierarchical cluster analyses. Clustering 
resulted in two major groups as shown in Figure 3.7. In the small cluster formed by 
MCF12A, HBL100, MDA MB231, HCC1937, and MDA MB157 target genes had 
upregulated expression profile except for IHH and GLI1. GLI2 expression seems to 
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be the most definitive factor in the groping of the cell lines. When GLI2 expression 
was not included clustering changes completely. However when PTCH1 or GLI1 
expressions were not included there was no change in the two major clusters, but 
only minor changes in small subgroups. This finding was also confirmed by stepwise 
regression analysis (data not shown).  This data shows that at least in some breast 
cell lines aberrant Hh pathway activity is present and induction of target gene 
expression might occur through the GLI2 transcription factor. It was indicated that 
GLI1 and GLI2 regulate a similar set of target genes during mouse embryogenesis. 
But later in development, new gain-of-function defects can emerge, suggesting that 
context-dependent regulation of biological activities of GLI factors [Bai et al., 2001]. 
Whether GLI1 or GLI2 or a combination of both factors is required for Hh-induced 
tumorigenesis is not clear yet.  
 
Pearson correlation analysis was used to determine if there is a linear relationship 
between the two genes’ expression patterns in the breast carcinoma cell lines studied. 
The analysis showed that IHH, SMO and GLI1 gene expression profiles were found 
to be highly correlated with each other in all the breast carcinoma cell lines studied.  
There was a strong positive correlation between SMO and GLI1 (r=0.637, p=0.011) 
and SMO and IHH (r=0.708, p=0.003) and weak correlation between GLI1 and IHH 
(r=0.521, p=0.047) (Table 3.3).  Although there was a correlation among these genes, 
not all of them were clustered together in the Hierarchical cluster analysis (Figure 
3.7). In the cell lines where IHH and GLI1 were increased, SMO expression was also 
high. But since SMO was increased in all the cell lines they did not cluster together in 
the Hierarchical cluster analysis. Hierarchical cluster analysis not only includes the 
Pearson correlation values, but also expression levels of the cell lines. That is why it 
is meaningful that these genes did not cluster together in the hierarchical clustering. 
GLI1 is the downstream target of the Hh pathway. So when there is a high IHH 
expression it is expected to have an upregulated GLI1 expression. SMO upregulation 
thus should correlate with GLI1 expression as well since SMO is the receptor that 
mediates the downstream signaling when the ligand is bound.  
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To identify the distance between the genes and the distance between the cell lines, 
Multidimensional Scaling (MDS) was performed. The correlated genes IHH, SMO, 
and GLI1 did not cluster together in the gene based MDS analysis although they 
were closer to each other than they were to other genes based on their correlation 
coefficients (Figure 3.8). The small group formed in Hierarchical cluster analysis 
was also formed in the cell line based MDS analysis as shown in Figure 3.9. There 
were two small groupings as well which were formed in Hierarchical cluster 
analysis. MDS analysis confirmed the Hierarchical cluster and Pearson correlation 
analysis. 
 
ER status is an important parameter in the prognosis of the breast cancer which helps 
in determination of treatment strategy for breast cancer patients. Patients with high 
ER level respond to hormone therapy better than the others. Recent studies showed 
that spatiotemporal expression of SHH can be regulated by steroid hormones in the 
development of several organs [Pu et al., 2004]. Estrogen exposure can suppress the 
Shh expression in the developing rat prostate [Pu et al., 2004]. Genes can be 
differentially expressed during the progression from estrogen dependent state to 
estrogen independent state. To investigate the presence of a potential role of Hh 
pathway target gene expressions with respect to ER status of the cell lines, linear 
Discriminant Function Analysis was performed. Expression profiles of the target 
genes predicted the ER status correctly in 93% of the cell lines studied (Figure 3.4A) 
although cross-validation seemed to have decreased prediction power to 60%. GLI1, 
SMO, and BCL2 expression patterns affected the ER status the most (Figure 3.4B). 
BCL2 expression was upregulated two fold in the ER (-) cell lines while induced 
four-fold in the ER (+) cell lines. Similarly, SMO expression showed a four-fold and 
eight-fold increase in ER (-) and ER (+) cell lines, respectively. Generally these 
results show that, Hh pathway target genes might exhibit higher expression in ER (+) 
cell lines. ER positivity is frequently associated with well-differentiated tumors, 
while more poorly differentiated cancers, and cancers with significant lymphocytic 
infiltration, are more likely to be ER (-) [Stanford et al., 1986]. In Sorlie’s 
microarray study higher SMO expression has been observed in non-metastatic tumor 
samples than metastatic ones (t=2.937; p=0.012) [Sorlie et al., 2003], which 
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correlates with our study since ER (+) tumor samples have been thought to be less 
metastatic than ER (-) tumor samples. 
In conclusion, human breast carcinoma cell lines have different levels of target gene 
expression in the Hh pathway, such that this pathway is activated only in some of the 
breast carcinoma cell lines possibly through a ligand-independent pathway. It is 
difficult, however, to draw a definite conclusion from the results obtained in this 
study based on the breast cancer cell lines that a specific gene or a set of genes of the 
Hh pathway is the main cause of the breast cancer formation. One way to obtain 
more insight to this question can be to use primary tumor samples, which were also 
included in this study.   
 
4.2. EXPRESSION ANALYSIS IN HEPATOCELLULAR      
CARCINOMA CELL LINES 
 
In this study 15 human hepatocellular carcinoma cell lines were used to analyze the 
expression level of the defined target genes with q-rt-RT PCR. In SNU182, SNU423, 
and SNU449 cell lines, all the genes were upregulated as shown in Figure 3.11. This 
may indicate the active Hh pathway in these cell lines. GLI1 is thought to be main 
transcription factor which shows the aberrant pathway activity [Toftgard, 2000; 
Wetmore 2003]. In our study, GLI expression was high in 40% of the HCC cell lines 
and low in 47% of the cell lines, and did not change in the remaining 13% (Figure 
3.10). In the cell lines where GLI1 expression was low, the expression level of other 
transcription factors were also low in general. The cell lines that express high GLI1 
and GLI2 were SNU182, SNU387, SNU423, and SNU475. SHH and PTCH1 
expressions were also found to be increased in these cell lines. This indicates that the 
ligand dependent pathway might be a more likely route in these HCC cell lines. GLI3 
mRNA expression varied between the cell lines extensively, and it is almost 
downregulated in the four well differentiated HCC cell lines and SNU475. 
Microarray study performed by Chen et al. (2002) has showed that GLI2, PTCH1, 
and BCL2 expressions were decreased in HCC tumor tissues as compared to non-
tumor tissues while the expression of SMO increased. We found correlated results 
with Chen’s microarray study: PTCH1 expression decreased in 60% of the cell lines, 
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however expression of GLI2 and BCL2 were decreased only in 40% of the cell lines. 
SMO expression was increased in 73% of the HCC cell lines in our study. Increased 
SMO expression may lead to constitutive activation of the Gli transcription factors 
although their expressional levels were low. 
 
Mature hepatocytes lack Hh pathway activity despite the liver’s requirement for Hh 
signaling during embryogenesis [Sicklick et al., 2006]. Previous studies have shown 
that GLI1 and SMO expressions were higher in HCC tumor samples compared to 
paired-normal tissues whereas SHH, IHH, and PTCH1 expressions did not change 
between the tumor-normal pairs [Patil et al., 2006]. Wang et al., (2006) showed 
GLI1 and PTCH1 expression in 50% of the hepatocellular carcinoma samples by in 
situ hybridization. In another study, SHH, IHH, PTCH, SMO, and GLI1 expression 
were upregulated in HEP3B and HEPG2 cell lines [Sicklick et al., 2006]. Our 
findings were correlated with Sicklick et al., for the SHH, IHH, and SMO genes 
expression profiles. However upregulation of PTCH1 and GLI1 in HEP3B and 
HEPG2 were not observed in our study. 
 
Hierarchical cluster analysis differentiated the cell lines into four subgroups based on 
their expression profile. In the small group at the right part of the Figure 3.11 all the 
target genes analyzed except for IHH had increased expression. These cell lines had 
elevated Hh pathway activity through increased SHH expression. The group formed 
by HEPG2, HUH7, HEP3B TR, HEP3B, and SNU 475 had decreased transcription 
factor expression. In the aggressive tumors, GLI3 expression may be lost to induce 
Hh target gene expression since in the cell lines where GLI3 expression is 
downregulated target gene induction occurs through the derepression of the promoter 
region [Ruiz I Altaba, 1999]. The third subgroup was formed by SNU398, SNU387, 
MAHLAVU, and FOCUS. These cell lines showed elevated expression of 
transcription factors GLI2 and GLI3 whereas reduced expression of SMO and IHH. 
The fourth group was formed by PLC, HEP40, and SKHEP1 of which PTCH1 and 
SHH expressions were reduced. 
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Pearson correlation analysis was performed to find out the linear relationship 
between the expression patterns of the genes. There was a strong positive correlation 
between PTCH1 and GLI1 (r=0.586, p=0.022) and PTCH1 and GLI2 (r=0.661, 
p=0.007) (Table 3.6).  These genes clustered together in the Hierarchical cluster 
analysis (Figure 3.11). GLI1 and PTCH1 are the downstream targets of the Hh 
pathway, and hence increased GLI2 can bind to their promoter region and induce 
their expressions. Significant negative correlation between IHH and GLI2 (r=-0.647, 
p=0.009) and IHH and GLI3 (r=-0.721, p=0.002) genes were identified in the HCC 
cell lines studied and as expected these genes did not cluster together in the 
Hierarchical cluster analysis. Having a negative correlation between the expressional 
regulation of ligands and transcription factors is not an expected finding. Instead, an 
increased ligand expression should have led to increased transcription factor 
expression not to the decreased one unless there is an alternative pathway in which 
the ligand is used to activate other downstream targets while default transcription 
factors are repressed.  
 
Multidimensional Scaling (MDS) was performed to determine the distance between 
the genes and the distance between the cell lines based on the correlation between 
their expression profiles. The correlated genes PTCH1, GLI1, and GLI2 clustered 
together in the gene based MDS analysis (Figure 3.12). Three small clusters were 
formed in the cell line based MDS analysis as shown in Figure 3.13. Two of the 
clusters were also formed in the Hierarchical cluster analysis. However, the group 
formed by HEP3B, HEP3B TR, SKHEP1, and PLC/PRL/5 did not clustered in the 
Hierarchical clustering (Figure 3.11), but belong to two different clusters. SKHEP1 
and PLC/PRL/5 clustered with HEP40 in the Figure 3.11 although HEP40 was far 
from these cell lines in the MDS analysis. These findings confirmed the Hierarchical 
cluster analysis in most respect. 
 
The hepatocellular carcinoma cell lines can be defined as two groups based on their 
differentiation status. HEP3B, HEP3B TR, HEP40, HEPG2, HUH7, and PLC/PRL/5 
are well differentiated cell lines while others, SNU 182, SNU 387, SNU 398, SNU 
423, SNU 449, SNU 475, SKHEP1, FOCUS, and MAHLAVU, are poorly 
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differentiated (Table 2.2). While GLI2 gene had decreased expression in all well 
differentiated cell lines, SMO and IHH genes were highly expressed. These 
expression patterns differentiate the well differentiated cell lines from poorly 
differentiated ones in DFA analysis (Table 3.7). High SMO and IHH expressions 
have been found to be markers for aberrant Hh pathway activity in the well 
differentiated cell lines. However, due to reduced transcription factor expression Gli-
independent signaling pathway may be responsible for the active pathway in the well 
differentiated HCC cell lines. In view of the fact that these expression patterns 
differentiate the poorly differentiated cell lines from well differentiated ones in DFA 
analysis perfectly (Table 3.7), this finding may help to identify differentiation status 
of the HCC samples, and treatment of the disease with further experiments. In the 
microarray study performed by Okada et al., (2003) HCC grade 1 tumors have been 
found to have decreased IHH expression than grade 3 (r=0.35; p=0.006). Since grade 
3 tumors are more undifferentiated than grade 1 tumors this finding does not in 
accordance with our results. Because carcinoma cell lines may not reflect the real 
tumor environment, having a different phenotype is not surprising. 
 
To conclude, human HCC cell lines are thought to have Hh pathway target gene 
expressions, but that does not mean that Hh pathway is a cause for the hepatocellular 
carcinoma formation. To further investigate the role of Hh pathway in HCC, same 
study should be carried out in the tumor samples, and also functional protein 
detection should be performed for the pathway components. 
 
4.3. EXPRESSION ANALYSIS IN COLON CARCINOMA CELL 
LINES 
 
Human colon carcinoma cell lines were the third type of epithelial cell lines used in 
this study. In the adult human colon, SHH mRNA expression was determined in the 
epithelial cells at the base of normal intestinal crypts, which suggest a role for Hh 
signaling in the stem cell maintenance of colon [Qualthrough et al., 2004] similar to 
Wnt pathway. Dysregulated Wnt pathway is a cause for the colon carcinoma. The Hh 
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pathway may have a role in colon carcinoma. There are contrary findings on the role 
of the Hh signaling in colon carcinoma. One study suggests an inhibitory role for 
GLI1 in the progression of the colon cancer through inhibition of Wnt signaling 
[Akiyoshi et al., 2006]. The opponents propose an autocrine Hh pathway signaling 
that can increase cell survival in the colorectal tumor cells [Qualthrough et al., 2004]. 
Qualthrough et.al. showed expression of SHH, IHH, PTCH1, SMO and GLI1 in the 
carcinoma-derived cell lines HT29 and SW480 in both mRNA and protein level by 
RT-PCR and western blotting respectively. Qualthrough et.al. also proposed that 
there is a change in the role of the signaling during progression to invasive 
carcinoma because adenoma-derived cell lines had more IHH expression than 
carcinoma-derived ones.  
 
Our findings do not correlate with the study of Qualthrough et al., (2004). In SW480 
colon carcinoma cell line, only for SMO gene increased expression was observed: 
SHH, IHH, PTCH1, and GLI1 expressions were decreased. In HT29 cell line, SHH, 
IHH, and GLI1 showed increased expression while PTCH1 and SMO expressions 
were much lower (Table 3.8). This contradiction between the two studies may partly 
be explained by the experimental strategy followed. By performing RT-PCR, only 
the presence or absence of the mRNA can be identified. To determine the 
upregulation or downregulation as compared to normal tissue, quantitative real time 
RT-PCR should be performed. Qualthrough et al., (2004) carried out RT-PCR 
reactions for 35 cycles, which is above the Ct values we obtained for these genes in 
our q-rt-RT-PCR reactions in these cell lines except for the SMO expression in HT29 
(Appendix XX). In our study no SMO expression was detected in HT29 cell line at 
all, which was also determined by Zhu et al., (2003) by RT-PCR. They showed that 
SMO is fully methylated in the HT29 and HCT15 cell lines, and partially methylated 
in the LOVO cell line. In our study we did not detect SMO expression in HCT15 as 
well, but 10-fold increased expression was determined in LOVO as shown in Table 
3.8. SW480 was almost completely unmethylated, and showed 8-fold increased SMO 
expression in our study. 
 
 98
To further evaluate our findings, microarray studies for Hh pathway expression were 
analyzed. Only three studies with significant results were obtained. GLI1 and BCL2 
expressions have been shown to be decreased in the adenocarcinoma samples as 
compared to normal colon tissues in Alon’s (1999) and Notterman’s (2001) 
microarray studies respectively. In addition, Scherf’s (2000) cell line microarray 
study has showed that SMO expression was lower in colon carcinoma cell lines as 
compared to other carcinoma cell lines (t=-4.754; p=3.1E-4). Only in four cell lines 
we observed increased SMO expression, in others it was decreased or not changed in 
our q-rt-RT-PCR assays. GLI1 and BCL2 expressions were decreased in 50% and 
43% of the cell lines respectively in our study while in 43% of the cell lines GLI1 
expression was high, and in 36% of the cell lines BCL2 had increased expression.  
 
Human colon carcinoma cell lines showed deregulated expression profile among the 
genes. Two dimensional Hierarchical cluster analyses were performed to colon 
carcinoma cell lines to observe the data obtained from the q-rt-RT PCR reactions 
easier. Clustering resulted in two major groups as shown in Figure 3.15. In the 
cluster formed in the right part of the figure by SW620, TC71, SW48, LOVO, 
SW480 and HCT15, SMO and GLI3 genes had upregulated expression profile. GLI3 
expression seems to be the most definitive factor in the grouping of the cell lines. In 
general, Hh pathway components studied in this research did not show significant 
upregulation except for LS411, LOVO, and HCT15 cell lines. Aberrant pathway 
activity was observed only in these cell lines. 
 
Pearson correlation analysis was performed to human colon carcinoma cell lines and 
a significant positive correlation only between BCL2 and SHH (r=0.547, p=0.043) 
(Table 3.9) was observed.  These genes clustered together in the Hierarchical cluster 
analysis (Figure 3.15) as well. There was no significant negative correlation between 
any genes in the colon carcinoma cell lines studied, which may mean that in the 
colon carcinoma cell lines, Hh pathway genes may act independently from each 
other. 
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Multidimensional Scaling (MDS) was performed to determine the distance between 
the genes and the distance between the colon carcinoma cell lines. In this study, 
Pearson correlation was used as the input matrix for the distance. The correlated 
genes SHH and BCL2 clustered together in the gene based MDS analysis although 
IHH was also the same distance to them (Figure 3.16) which were clustered together 
in Hierarchical cluster analysis, too. The cluster formed in the right part of the 
Hierarchical cluster analysis was also formed in the cell line based MDS analysis as 
shown in Figure 3.17. There were two small groupings as well which were formed in 
Hierarchical cluster analysis. The cell lines clustered together in the MDS analysis 
were also clustered together in the Hierarchical cluster analysis. However for the 
group formed by T7, LS411, CL115, and W05, hierarchical clustering separated 
these cell lines into two different groups. Since it was based on expression profile of 
the cell lines along with the correlation coefficients it is reasonable to have different 
grouping there. 
 
To sum up, human colon carcinoma cell lines do not seem to have aberrant Hh 
pathway target gene expression, however we can not drawn a conclusion from the 
cell lines’ study whether Hh pathway is active or inactive in the colon carcinoma 
Cell line studies generally do not reflect what happens in vivo in most cases. Hence, 
the same study should be performed in the tumor samples, and also functional 
protein detection should be performed for the pathway components along with 
mutation analysis. 
 
4.5. EXPRESSION ANALYSIS IN PRIMARY BREAST TUMOR 
TISSUES 
 
Pathways with a role in cancer formation have been shown mostly by studies done in 
tumor samples, which is the most reliable way to identify causes of cancer. 
Observing the increased Hh pathway component expression in human breast 
carcinoma cell lines prompted us to further evaluate the pathway in the primary 
breast tumor tissues. For this purpose q-rt-RT-PCR analysis was performed on 29 
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primary breast tumor samples with known clinical properties. All the tumor samples 
were chosen from invasive ductal carcinoma patients because the Hh pathway has 
been implicated in the development of mouse mammary ductal histoarchitecture 
[Lewis et al., 2004].  
 
Kubo et.al. (2004) showed the constitutive activation of the Hh pathway in human 
breast carcinoma for the first time by performing immunohistochemistry to 52 tumor 
samples. Carcinoma tissues overexpressed SHH, PTCH1, and GLI1 proteins in all 
the samples studied whereas no protein was detected in normal tissues. In our study, 
we did not detect any SHH mRNA expression in either in tumor samples or in 
normal sample pools as shown in Table 3.10. Besides, PTCH1 and GLI1 mRNA 
expressions were highly increased in only 6 and 8 of the samples respectively. 
Accumulated protein levels may be responsible for the finding of Kubo et al., (2004) 
or since tumor samples used are different this contradictory findings are reasonable. 
Since we did not detect any SHH expression in tumor samples and normal sample 
pools we studied, we searched for possible alternative transcripts of the SHH in the 
literature and ENSEMBL database, which may not be recognized by our primers. 
The primers we used for SHH corresponds to exon 1 and exon 2 of the SHH gene. 
We did not found any alternative transcripts of the gene. However, SHH gene has a 
high CpG island content which may be responsible for hypermethylation of the gene 
in the primary breast tumor samples we studied which should be checked with 
methylation specific PCR. 
 
GLI1 and GLI2 are the transcriptional activators in the Hh pathway. When we look 
at individual tumor samples, in 69% of the samples at least one of the genes had 
increased expression. Hence, in 69% of the tumor samples Hh target gene induction 
may occur. Only in 28% expressions of both transcription factors were low. There 
may be functional redundancy between these genes in breast cancer, and lack of 
increased expression of one gene may result from the epigenetic changes in the 
promoter region of the genes. 
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Expression values of all the target genes for primary breast tumor samples were 
clustered by using two dimensional Hierarchical cluster analyses. Clustering resulted 
in three major groups as shown in Figure 3.19. The cluster formed in the left side of 
the figure had elevated expressions of the target genes except for the IHH. There is a 
small subgroup in the cluster at the right part of the figure, in which all the genes’ 
expressions were downregulated. There was no significant pathological property that 
differentiates these groups from each other. Hierarchical cluster analysis shows that 
in most of the tumor samples Hh pathway target gene expression was decreased. 
Gene based clustering showed that GLI2 expression was correlated with receptor 
expressions in primary breast tumor tissues and BCL2 was correlated with GLI1. 
GLI1 may be the transcription factor inducing BCL2 expression in these tumor 
samples. 
 
Pearson correlation analysis was performed for primary breast tumor samples to 
determine the linear relationship between the expression patterns of the genes, and to 
confirm the data obtained from the Hierarchical cluster analysis. Strong positive 
relationships were found between PTCH1, SMO, and GLI2 expressions (Table 3.11), 
which were clustered together in the Hierarchical cluster as well. This finding may 
be explained by sequential induction of the genes. If the SMO expression is 
increased, GLI2 transcription factor will be active and induce the expression of 
PTCH1, which is a downstream target of the Hh pathway. GLI2 may be the major 
transcription factor inducing Hh target gene induction in the samples where SMO and 
PTCH1 expressions were increased. IHH had a correlation with these genes as well, 
but this correlation was not highly significant as shown in Table 3.11. Correlation 
between the BCL2 and GLI1 was confirmed by Pearson correlation analysis, too. 
BCL2 had a correlation with IHH and PTCH1 as well, but these values were not 
highly significant although had a significant p value. There was no significant 
negative correlation between any genes in the tumor samples used in this study 
which shows that genes do not act opposite to each other. 
 
MDS was performed to Hh pathway expression profile in a sample- and gene-based 
manner to visualize the distance between the samples, and between the genes. In the 
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gene-based MDS analysis, the correlation between the PTCH1, SMO and GLI2 was 
confirmed as shown in Figure 3.20. Other genes were at very distant from this cluster 
based on their expression profile. GLI3 was the outlier of the genes, which was also 
placed at a distance from the other genes in the Hierarchical cluster. Since GLI3 is 
thought to have a repressor activity when the pathway is active, it is expected to have 
adverse expression profile with the other genes studied.  
 
Sample-based MDS analysis gave several small clusters of the samples based on the 
correlation between their expression profiles. The most striking clusters were those 
between MFT16 and MFT173; MFT14, MFT25, and MFT49; and MFT97, MFT113, 
MFT116, MFT117, and MFT120. These clusters did not correspond to the 
Hierarchical cluster analysis. Besides, the most obvious clusters formed in the 
Hierarchical clustering were spread in the MDS distance map, and mixed with other 
samples. MDS was not sufficient to differentiate the groups clearly. The large sample 
size may be responsible for this outcome. 
 
Knowledge of the steroid receptor levels of human breast cancer is important for 
diagnosis and for deciding the appropriate treatment for breast cancer In a study, a 
positive correlation between percentage of nuclear staining of GLI1 and ER status 
was found by performing Mann-Whitney U test [Kubo et al., 2004]. This 
corresponds to our finding with the GLI1 gene and ER (+) status in our tumor 
samples which showed a positive correlation with Mann-Whitney test (W=120, 
p=0.0277). In addition, a positive correlation was found for BCL2 and ER (+) with 
the same statistical test (W=105, p=0.0017) (Table 3.14). To determine if the 
expression profiling of Hh pathway genes discriminate the ER status of the tumor 
samples Discriminant Function analysis was performed. Gene expression profiles of 
the samples predicted the ER status correctly in 87% of the tumor samples studied 
(Figure 3.12A). Although the cross-validation test decreased prediction power to 
65%, there was still a very strong prediction for ER status of the samples with the 
expression of the genes included in this study.  
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PTCH1 and BCL2 expression patterns seem to have an effect for the ER status 
(Figure 3.12B) since their slopes are opposite to each other. Their expression values 
still did not discriminate too much between ER (+) and ER (-) tumor samples. This 
finding does not fully correlate with the cell lines’ DFA analysis. In the cell lines, 
PTCH1 expression was not affected in ER (-) cells whereas in the tumor samples it 
was increased in ER (-) tumors relative to the ER (+) cells which was also shown in 
Sorlie’s microarray study [Sorlie et al., 2003]. BCL2 expression was decreased in ER 
(-) tumor samples, while it did not change in ER (+) ones. However, in the breast 
carcinoma cell lines, BCL2 expression was increased 4-fold in ER (+) cell lines, and 
2-fold in ER (-) cell lines. Indeed, almost all the genes studied seemed to have basal 
level expression in ER (+) samples.  Accordingly, it is possible that tumor samples 
exhibit larger variability with respect to the link between Hh signaling and ER status 
as suggested by the cell line study; this might be because multiple signaling 
pathways might carry out the downstream effect of ER status.  Moreover, it is well 
known that cell line studies cannot fully explain real cancer cases due to factors such 
as divergence in the microenvironments tumors encounter.  
 
There are lots of microarray studies that aim to identify expression profiles specific 
to grade of the tumor samples. With knowledge of the genes that differentiates the 
grade; it will be easier to treat the disease by targeting these genes specifically. 
Microarray studies performed by Zhao et al., (2004) and Van’t Veer et al., (2002) 
have showed that expression of GLI1, GLI2, and BCL2 are higher in grade 1 tumors 
than in grade 3 tumors. Hence, DFA was performed for the grade status of the 
samples to find out whether Hh pathway had any predictive effect. DFA predicted 
the grade status correctly in 71% of the samples as shown in Table 3.13A, which 
decreased to 57% after cross-validation test (Table 3.13B). 71% is a high percentage 
to predict the grade status yet its power may be increased by including other genes’ 
expression profiles. PTCH1 gene expression profile was the most predictive value in 
the discrimination of the grade status (Table 3.13C). In the grade 1 tumors, its 
expression was 1.5 fold increased and 1 fold decreased in the grade 2 tumors. Since 
the invasiveness of the disease increase with higher grade, loss of PTCH1 expression 
in grade 2 tumors may be explained by early role of hedgehog signaling in the cancer 
 104 
progression. In the grade 3 tumors there was still 0.6 fold increased PTCH1 
expression but this was not significant. Since we did not detect increased expression 
profile for Hh pathway target genes, these predictions may not reflect the grade 
status perfectly. 
 
In conclusion, primary breast tumor samples did not have aberrant Hh pathway gene 
expressions although in a small group there were elevated expressions, but that does 
not mean that Hh pathway is not active in these samples. To make such conclusion 
functional protein detection should be performed for the pathway components and 
possible mutation analysis should be carried out. In the tumor samples where 
expression of pathway components was high, there was no SHH expression and IHH 
expression was decreased. Thus, ligand-independent pathway activity may exist in 
these samples due to mutations in the pathway components, which was also found in 
the breast carcinoma cell lines. One other possibility is elevated expression of DHH, 
which has a very restricted expression profile in embryonic development [Bale, 
2002]. 
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CHAPTER 5 
 
 
FUTURE PERSPECTIVES 
 
Signaling pathways generally reactivated in cancer due to increased expression of the 
ligands and/or mutations in the pathway genes. Gain of function genetic events in 
oncogenes by DNA mutations, rearrangements or amplifications, and loss-of-
function mutations in tumor suppressor genes are the molecular events leading to 
aberrant pathway activity. In the Hh signaling, SMO, SHH, IHH, GLI1, and GLI2 are 
known oncogenes and PTCH1 and SUFU can function as tumor suppressors 
[Magliano et al., 2003; Wetmore, 2003]. There have been studies showing PTCH1 
mutation in two of seven human breast cancers [Xie et al., 1997], and linking the 
polymorphism in the 3’end of the PTCH1 to increased breast cancer risk associated 
with oral contraceptive use [Chang-Claude et al., 2003]. In addition, mice showing 
hyperplastic defects in the mammary gland of ∆Ptch1 + and ∆Gli1 mutants suffer 
from breast cancer [Lewis et al., 2004]. In the cell lines and tumor samples studied, 
possible mutations of Hh signaling should be checked to investigate the contribution 
of mutations to the expression profiles of the genes and to cancer formation. Such a 
study will show the mechanism by which Hh pathway is activated in the epithelial 
cell lines and tumor samples studied. 
 
Furthermore, epigenetic changes in the Hh pathway may be responsible for the 
aberrant pathway activity. There have been studies showing that SMO is fully 
methylated in the HT29 and HCT15 colon carcinoma cell lines, and partially 
methylated in the LOVO cell line [Zhu et al., 2003]. Besides, SUFU expression may 
be downregulated through promoter methylation [Sheng et al., 2004]. Analysis of 
these epigenetic changes in the epithelial cell lines studied may help in understanding 
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of the observed gene expression profiles. Especially SKBR3 is a good candidate cell 
line for this study since all the genes shown to have low expression in this cell line. 
 
BCL2 expression was not correlated with GLI2 expression in all the cell lines and 
tumor samples studied, which was unexpected since activation of the BCL2 
expression in response to Hh signaling occurs through the binding of GLI2 to the 
promoter of BCL2 [Regl et al., 2004]. There should a positive correlation between 
expression values of these two genes if the BCL2 is activated in response to Hh 
signaling. There is also a study showing that BCL2 expression can be induced by 
GLI1 in mouse keratinocytes [Bigelow et al., 2004]. However, there was no positive 
correlation between expressional levels of these two genes in our analysis. Hence we 
think that BCL2 may not be regulated through Hh pathway but regulated by other 
pathways in the cancer formation in these cell lines and tumor tissues. Although 
there was no significant correlation, regulation of the BCL2 promoter by GLI 
transcription factors should be checked with knock down and cotransfection studies 
to the cell lines where BCL2 and transcription factor expressions were high. 
Bioinformatics analysis of the coexpressed genes based on their promoter sequences 
also may provide insight into the shared regulatory regions/modules by which Hh 
signaling is synchronized or sequentially regulated.   
 
Hh signaling has a role in cell proliferation by directly activating the expression of 
genes that have a role in cell cycle control [Magliano et al., 2003]. In the cell lines 
where pathway thought to be active expression of several of these target genes 
should be checked such as MYC, cyclin D, cyclin E, and cyclin B expressions to 
show the Hh pathway is responsible for the cancer progression through induction of 
cell proliferation. Cyclin D1 is downstream target of the SHH signaling in 
developing CNS [Lobjois et al., 2004] although SHH expression does not have any 
effect on the expression profile of cyclin D1 in ductal development in virgin mice 
[Michno et al., 2003]. Expression of c-MYC, l-MYC, and n-MYC have found to be 
decreased in medulloblastomas by cyclopamine treatment [Berman et al., 2002]. The 
same study should be performed to the cell lines we studied with elevated 
expressions of the target genes.  
 107 
Blocking the pathway with cyclopamine treatment is a way of determining the role of 
the Hh signaling in the cell lines studied. There are several inhibitors of the Hh 
pathway acting at different levels for the components of the pathway [Magliano et 
al., 2003]. For example anti-SHH antibody blocks SHH and inhibits the cell 
proliferation in vivo. These inhibitors can be used to study the effect of Hh signaling 
in the epithelial cell lines in which pathway thought to be active such as MDA 
MB157, BT474, CAMA1 breast carcinoma cell lines. For HCC, SNU 182 and SNU 
475 and for colon carcinoma TC71 and LOVO are best candidate cell lines suitable 
for this analysis. Inhibition of the Hh pathway by inhibitors would suppress the cell 
proliferation and cell invasiveness. Thus, cell invasion and apoptosis assays should 
be performed. LOVO is an aggressive cell line and it can be a good candidate cell 
line to identify the role of Hh pathway in the metastasis by performing cell migration 
assays. 
 
For the primary breast tumor samples, there were three clusters formed in the 
hierarchical cluster analysis, which could not differentiated based on their known 
pathological properties. Determination of subtype of each sample used in this 
analysis may help in understanding of these clusters better. Since breast cancer is a 
heterogeneous disease each subtype has its own stable phenotype. Furthermore, the 
study should be performed in primary hepatocellular carcinoma and colon carcinoma 
samples to find out gene expression profile of Hh pathway in the real tumor 
environment for these carcinomas, which has been shown previously by in situ 
hybridization in liver cancer and by q-rt-RT PCR in colon cancer for some members 
of the pathway as shown in Table 1.5 in section 1.2.4 [Huang et al., 2006; Manzo et 
al., 2006]. 
 
Having an increased gene expression profile does not mean functional protein 
expression is found in most of the cases. Gene expression profiling should be 
supported by protein expression profiling. The best way of showing the protein 
expression profile is to perform western blot and/or immunohistochemistry studies. 
By showing protein expression, the role of Hh pathway can be identified more 
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clearly. Increased expression of GLI1, PTCH1, SHH, and HIP indicate the activation 
of the Hh pathway. 
 
In conclusion, the Hh signaling pathway is activated in some epithelial carcinomas 
and that the components of the Hh pathway can be potential therapeutic targets, 
making it possible to develop new treatment strategies against epithelial cancers.  
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APPENDICES 
 
APPENDIX A 
 
Quantitative Real Time RT-PCR Ct Values for Breast Carcinoma Cell Lines 
 
Cell Line GLI1 GLI2 GLI3 SHH IHH PTCH1 SMO BCL2 GAPDH-1 GAPDH-2 
MDA157 27.4-27.4 25.9-26.7 20.3-22 29.4-30.8 28.3-27.7 20.3-20.8 27.1-26.9 25-25.3 14.9-14.2 15.4-15.6 
MDA231 27.1-27.2 26.5-26.6 25.2-25.8 29.3-29.8 30.2-29.9 26.4-25.7 43-42.4 25.1-25.1 14.3-15.2 13.2-14.3 
MDA361 25.6-25.4 32.8-32.5 23.1-23 26.3-26.4 30.4-30.8 22.4-22.1 24.9-24.4 24.2-23.5 12.4-12 13-12.7 
MDA453 25.2-25.1 NA 21.1-21.4 30.8-30.7 30.4-30.8 24.5-24.8 39-39.7 26.7-26.4 14-14.8 13.5-14 
MDA468 26.6-26 32-32 24.1-24 30.3-30.9 31.3-31.3 23.8-23.8 26-26.5 25.1-25.2 14.7-15 15.1-15.3 
BT474 25.7-25.9 38.9-39.3 27.7-26.5 30.6-31.4 27.2-27.5 29.8-30.4 32.3-33.5 24.6-24.9 16.5-16.7 17.2-17.3 
BT20 28.5-28.5 34.3-33.1 25.4-25.6 30.3-30.8 30-29 24.2-23.4 34.5-34.8 28.1-27.4 14.6-14.8 14.6-14.7 
MCF7 25.5-24.7 36.2-37.5 22.4-22.2 30.1-29.7 28.7-29 23.2-23 44.4-39.7 19.9-19.7 14.5-13.4 15-14.4 
MCF12A 27.1-26.8 29-28.8 22.8-23 30.9-30.1 35.3-34.1 25.8-25.2 29.7-29.3 27.6-27.8 14.5-13.8 14.7-15.2 
HCC1937 27-26.8 23.9-24.4 22.9-22.1 29.6-31 27.1-27.2 21.3-22.7 37.7-37.4 25.1-24.9 12.6-12.5 13.7-13.6 
CAMA1 25.7-25.1 34.2-34.3 23.4-23.1 31.3-31.9 28-27.7 30.6-29.2 34.7-33.9 24.3-24.6 16.6-16.3 17.2-17.4 
SKBR3 27.6-28.3 33.5-32.9 27.2-28 30.4-30.3 31-31.7 27.8-27 48-48.4 31.3-30.3 14.7-14.1 12.9-12.5 
ZR75.1 28.8-27.7 34.1-34 25.7-26 31.1-30 29.3-30 26.8-26.8 33-34.7 23.5-23.5 14.2-14.3 12.6-13 
T47D 26.7-26.2 NA 23-22.3 31.2-30 32.7-32.9 27.4-28 32.7-32.4 28.9-29.8 16.1-15.9 17-16.9 
HBL100 28.2-28.2 26.8-26.8 29.2-28.9 30.2-30.4 30-30.2 29.4-30.1 26.3-26.6 28.8-29.6 17.7-16.8 13.1-12.3 
HME1 25.1-24.8 30.9-30.9 25.2-25.1 29.9-30.2 31.3-31.9 29.3-28.9 31.7-31.3 27.9-28.4 14.4-14.2 14.2-13.6 
 
NA: no amplification 
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APPENDIX B 
 
Quantitative Real Time RT-PCR Ct Values for Hepatocellular Carcinoma Cell Lines 
 
Cell Line GLI1 GLI2 GLI3 SHH IHH PTCH1 SMO BCL2 GAPDH 
SNU182 25.3-25.2 22.6-22.1 21.2-21.9 28.7-29.3 NA 21.1-22 25.8-26.9 28.1-28.4 16.7-16.9 
SNU387 26.7-26.2 24.7-25.4 25.9-25.2 35.2-34 NA 25.9-26.2 NA NA 19.3-19.4 
SNU398 20-22.8 26.5-26.7 21.7-21.7 33.1-35.2 NA 20.6-20.2 NA NA 14.2-14.2 
SNU423 24.8-24.9 26.8-26.1 22.7-22.5 27.1-27.2 29-29.8 24.3-23.7 25.7-25.3 27.5-27.3 15.6-15.3 
SNU449 22.6-22.2 26.3-25.7 23.4-23.1 32.3-32.4 27.6-27.6 23.8-23.2 24.8-25.4 26.3-26.3 13.5-13.9 
SNU475 24.7-24.3 30.1-29.7 47.7-44.9 29.9-30.2 26-25.9 27.5-27.3 32.8-32.9 24.8-25.8 19.8-20.2 
HEP3B 26-25.7 32.7-33.6 37.1-36.1 28.2-27.6 26.6-26.6 23.4-23.5 25.4-26 32.2-33.3 14.2-14.3 
HEP3B TR 25-24.9 32.8-31.3 36.4-38.5 28-27.8 24.2-23.7 24.6-24.1 24.7-24.4 32.3-31.6 14.414.5 
HEP40 26.9-26.9 33.8-34.1 25.9-25.9 NA 20.8-20.3 23.7-22.7 26.3-25.4 28.9-29.2 14.4-14.3 
HEPG2 27.7-27.7 34.7-33.9 31.7-32.9 31.7-33.1 25.4-25.9 25.3-25.3 28-27 31-30.6 15.3-15.4 
SKHEP1 26.6-27.1 26.4-26.1 24.5-23.6 NA 29.5-28.9 24-24 26.4-25.5 25.6-24.8 13.9-13.1 
SAOS2 22.6-22.6 21.1-21.2 21.6-21.4 46.5-45.4 22.6-23 18.3-18.4 25.9-25.7 25.7-25.7 14.3-14.1 
HUH7 24.6-24.9 32.3-32.6 35-35 24.6-24.6 19.6-19.6 21.2-21.6 23.3-24.1 32.7-33.7 14.4-14.7 
PLC 22.5-23 33.5-34.1 34-34 NA 24.7-24.7 24.7-25.1 27-26.7 36.1-36.5 13.9-14 
FOCUS 23.1-23 26-25.8 23.1-23.6 36.9-36.9 31.1-31.3 23.1-22.3 43.3-46.7 22.8-23.6 14.8-14.3 
MAHLAVU 25.4-24.8 26.4-26.2 23.9-23.9 NA-43.9 32.5-32.6 23.2-23.5 47.5-48 25.9-26.1 14.4-14.1 
 
NA: no amplification 
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APPENDIX C 
 
Quantitative Real Time RT-PCR Ct Values for Colon Carcinoma Cell Lines 
 
Cell Line GLI1 GLI2 GLI3 SHH IHH PTCH1 SMO BCL2 GAPDH-1 GAPDH-2 
SW 620 28.9-29.3 36-37.7 31-30.6 29.4-29.8 25.9-26.3 23.6-23.4 33.3-33 28.1-29.7 14.8-15.1 12.9-12.7 
SW 480 27.3-26.8 26.8-26.7 22.8-23.2 30-29.8 29.1-30 23.7-22.5 29.2-29.6 31.6-31.5 13.5-13.6 13.8-13.3 
SW 48 27.2-27.5 25.7-25.6 21-20.5 29.1-29.4 32.4-31.6 22.2-22 NA 29.7-29.9 15.6-14.8 12.5-12.6 
HCT8 27.6-27.2 33.4-33.2 NA 32.5-30.7 31.4-32 24.4-23.3 NA-45.7 26.2-26.3 15.3-14.8 15.7-16 
HCT15 30.5-29.4 27.6-27.7 NA 27.5-26.3 30.8-29.8 23.3-23.7 37.9-37.7 27.3-27.7 16.8-16.9 13.6-14 
HT29 23.9-23.8 31.8-33.1 NA 25.4-25.8 29.1-28.4 25.2-24.9 NA 32.3-32 16.6-15.8 14.2-13.2 
TC 71 21.9-21.7 27.9-28.8 24.2-23.8 25.8-26.2 30.7-29.9 25.2-25 34.3-34.3 25.8-26.3 14.3-13 11.4-11 
T7 25.8-25.7 33.3-32.8 39.5-38.5 31-29.3 23.6-23.4 25.2-24.4 37.3-36 28.5-28.1 15.8-15.5 13.3-13.1 
LOVO 24.1-24.2 28.3-27.3 27.9-27.3 25.8-26 23.5-23.5 23.5-23 26.8-26.6 25.5-24.9 14.4-14.3 12.1-12.2 
LS411 24.5-24.6 29.6-30.3 47.2-33.8 29.2-29.3 25.3-25.8 22.7-23 36.7-37.8 27.9-27.4 14.4-14.1 12.9-12.7 
COLO205 30.2-29.5 40.2-43.1 39-39.1 33.6-34.7 33.3-33.9 23.2-22.9 39.4-38 32.1-31.2 15.6-15.1 13-12.7 
CL115 26.3-26.5 26.5-26.6 39.8-40 30.3-31.1 29.4-29.8 24.4-24.9 35.4-35.5 29.6-30.5 13.8-13.2 11.6-11.8 
W 05 24.1-24.1 30.1-30.6 36.6-36.6 24.7-24.4 27.6-27.7 22.8-22.6 37.5-37.9 30.8-30.9 14.9-14.7 12.8-13.1 
KM 12 27.7-27.4 28.9-27.9 NA 29.8-29 24.8-24.9 23.9-23.8 NA 28.5-28.1 14.2-14.1 13.2-13 
 
NA: no amplification 
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APPENDIX D 
 
Quantitative Real Time RT-PCR Ct Values for Primary Breast Tumor Samples 
 
Tumor Sample GLI1 GLI2 GLI3 SHH IHH PTCH1 SMO BCL2 ACTB TBP SDHA 
MFT14 25.1-25.7 32.3-33.6 28.2-27.4 NA 27.6-27.7 29.9-29.8 33.6-34.1 22.7-23.2 21.4-22.7 20.7-20.1 23.5-24 
MFT16  26.6-26.5 29.2-28.8 24.5-24.5 NA 30.8-30.4 27.9-28.5 27.2-26.4 21.7-21.5 16.1-16 21.1-21.1 19.2-19.1 
MFT21 27.1-28 30-29.3 23.1-23.3 35.1-45 28.9-29.2 27.4-27.7 27.3-27.6 25-26.4 14-13.7 19.7-20.2 19.4-20.1 
MFT25 27.5-27.5 45.5-35 28.7-27.4 NA 29.6-33.8 30.9-31.5 36.1-37.9 24-23.5 26.4-26 23.9-23.8 27.4-27.7 
MFT40 23.8-23.5 34.3-47.6 25.5-24.8 35.7 33.1-43.3 28.6-28.4 26-25.8 26.2-25.7 15.6-14.2 20.2-19.9 19.3-18.9 
MFT41 28.3-28.7 34.2-35.2 28.6-29.4 NA 33.4-32.9 31.5-32.2 38-38.8 26-25.5 15.7-15.4 22.2-22.4 22.7-22.8 
MFT49 25.3-25.2 34.7-33.8 28.6-28.3 NA 27.1-27.1 29.4-29.6 33.9-34.1 22.5-21.9 16.1-16 20.7-20.8 22.9-23.6 
MFT78 28.2-28.1 31.4-31.1 22.4-22.8 NA 36.9-34.8 31.1-31.2 29-29 25.7-24.7 17.1-15.7 22.7-22.4 20.8-20.3 
MFT79 27.2-26.8 NA 29.6-29 NA 32.2-34.8 32.5-32.6 42.5-40 23.6-23.8 25.3-25.5 23-22.9 26.8-27.4 
MFT90 28.2-28.7 34-32.3 27.2-27.4 NA 35-33.2 31.4-32.9 38.4-36.7 24.7-24.1 21.6-20.5 21.7-21.8 23.2-22.8 
MFT94 26.9-27 27.8-28.4 26-25.8 36 30.2-30.6 25.7-26 26.8-26.8 27-26.9 14.8-15.6 21.2-21.5 20.3-19.8 
MFT95 26.8-26.8 44.50 26.5-26.9 NA 31.5-31.4 31.9-32.3 39.7-43.6 23.5-23.6 20.2-19.9 23.6-23.8 26.7-26.5 
MFT97 28.8-29 35.6-36 27.5-27.6 NA 32.6-31 33.2 37.1-38.2 27.9-28 24.4-23.7 25.1-25 27.7-28.1 
MFT113 27.2-26.9 32.3-31.1 28-28 NA 27.6-27.7 30.1-29.8 35.7-34.4 27.3-27 16.8-16.6 23.2-23.5 26.8-26.3 
MFT115 26.9-26.6 31-30.7 25-24.8 NA 27.7-27.1 26.1-26.1 26-26.1 24.1-23.3 17-15.2 20.8-20.7 20.2-20.1 
MFT116 30.9-30.3 35.3-34.9 29.4-28.9 NA 31.8-32.1 31.2-30.7 37.9-40.4 27.4-28.1 18.9-19 25-25.2 27.1-27 
MFT117 29.9-30 35.5 30.1-29.2 NA 33.2-32.8 34.3 38.2-37.9 31.6-29.9 24.7-23.5 26.6-26.8 27.4-27.3 
MFT120 29.1-28.1 33.1-32.7 26.7-27.3 NA 28.5-28.8 29.2-28.6 34.1-33.7 28.4-28.3 18.2-17.9 23.9-24.1 26-25.5 
MFT124 30.1-29.1 31.6-29.2 25.7-25.9 NA 32-32.9 26.3-25.8 31.7-31.2 26.4-25.8 17.5-17.3 22.4-22.5 24.8-24.5 
MFT125 27.5-27.4 29.2-29.4 24.8-24.6 32.8-32.7 27.8-27.7 27.7-27.6 28-27.9 24.1-24.2 14.6-14.6 21.3-21.2 22.9-21.9 
MFT127 28.5-29 NA 28.2-27.9 33.6-35.1 33.2-33.7 32.9-32.5 43.9-36.2 28.1-28.5 24.7-24.9 24.8-24.6 27.1-27.6 
MFT129 27.3-27.5 28.7-28.8 25.2-25.8 NA 33.6-34.8 27.7-28 28-27.9 25.3-25.1 15-15.2 22.1-21.9 23-23.3 
MFT131 29.3-28.8 34.2-39.1 29.4-26.8 33.7-34.6 37.3-37.9 35.3-35.7 NA 28.3-27.6 24-24.2 24.1-23.9 26.1-25.3 
MFT132 29.4-29.8 30.5-30.5 27.4-27.3 34.8 34.8-33.5 28.5-28 32.5-31.6 26.8-26.8 17.6-16.8 23.2-23.7 22.3-22.2 
 127 
MFT149 31.2-28.7 28.9-27.7 22.8-24.1 NA 32.5-32.8 27-26.8 28.1-28.1 22.6-22 16.5-15.1 20.8-20.6 21.3-20.7 
MFT154 NA 31.2-30.9 23.3-23.9 48.6 34.2-34.5 28.3-28.2 32.8-32.2 NA NA 24.1-24 28-27.3 
MFT155 27.9-28 28.4-28.3 21.8-22.1 NA 33-31.6 25.1-25.4 28-27.8 22.4-22.3 16.7-16.3 21.8-21.7 21-20.9 
MFT173 27.8-27.6 29.7-29.2 26.8-25.8 NA 32.6-32.1 28.7-28.7 27.6-26.8 24.8-23.9 16.7-16.9 22.7-22.1 21.1-20.7 
MFT174 28.5-28.6 48.1-44.9 27.5-28 NA 50-50 34.8 44.8 29.5-30 27.5-27.3 25-25.2 26.8-27.5 
MFN P1-1 28.2-27.4 31.9-30.2 26.7-26.3 NA 28.1-27.4 27.1-26.1 29-28.2 24.9-24 16.3-15.9 21.9-21.4 22.1-21.1 
MFNP1 27.2-27.3 32.9-32.5 26.1-25.2 NA 28.4-28 27.6-27.2 29.7-29.7 24-23.7 18.2-17 22.7-22.8 22-21.8 
MFN P2-1 27.8-27.3 31.3-32.1 27.9-28.5 NA 28.6-28.4 29.4-28.4 29.1-29.4 26.4-26.5 15.1-15.2 21.9-21.3 23-20.6 
MFNP2 27.3-27.4 34-34.4 27.7-27.8 NA 31.8-29.1 31.7-30.3 32.7-32.6 27.1-26.6 17.8-16.3 23.4-22.7 22.9-22 
MFN P3-1 28.1-28.2 29.2-28.9 24.9-25 32.6-30.9 28.9-29 26.3-26.3 25.8-26.5 23.2-23.7 15.8-15.8 21.3-21.4 22-22.5 
MFNP3 27.6-27.5 30.7-29.6 25.6-25.5 NA 30.2-29.3 27.3-27.5 29.5-29.8 24-24.3 16.7-18.2 22.5-22.2 21.6-21.6 
 
NA: no amplification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
